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ABSTRACT 
Hepatocellular carcinoma (HCC) is a neglected major public health problem worldwide. In SubSaharan 
Africa (SSA), most HCC cases are diagnosed with advanced disease, well past the timing of possible 
treatment. Most HCC cases worldwide are caused by chronic infection with hepatitis B virus (HBV). 
Although the bulk of the burden of HBV is in SSA, there are no screening programmes implemented in 
the general African population so only 0.8% of HBV-infected individuals are diagnosed. Most research 
on HBV-related HCC has been conducted in Asia, where HBV is also endemic, but where there are 
differences in disease progression and presentation. The present study investigated HBV and HCC from 
an African perspective and tackled these public health issues by incorporating three key components 
for early diagnosis of HBV-related HCC: HBV screening, HCC biomarkers, and HBV-related HCC 
genomics.  
The HBV screening study found the prevalence of HBV in a South African community-based cohort 
using a validated point-of-care test to be 2.2% (95% CI: 1.4%–3.3%). The test performed well in the 
field and had a sensitivity, specificity, negative and positive predictive values of 100%. The test was 
also accepted by the community (93% uptake) and health care providers. The results of the present 
study support the case for the implementation of HBV screening in South Africa by demonstrating the 
magnitude of the HBV health problem in South Africa and new evidence that the POCT test performs 
well in the field, is accepted by the community and health care providers, and that patients diagnosed 
with the test can be successfully linked to treatment and long-term follow-up. 
The HCC biomarker study found significant differences in methylation expression levels in CpG islands 
in the promoter region of the tumour suppressor gene RASSF1A between HCC cases and normal liver 
tissue controls as well as a significant association between HBV genotype A and HCC. Although the 
sample size was small, it showed that there are biomarkers that may be used to identify HCC, paving 
the way for future studies looking into developing HCC risk scores for early diagnosis of HCC.  
Using whole-exome sequencing, the HBV-related HCC genomics study identified two novel germline 
variants in the SMARCA1 and RAB19 genes that in the absence of other risk factors besides HBV 
infection, could have contributed to early-onset HBV-related HCC in their respective hosts.  
Overall, these data provide evidence that early diagnosis of HBV-related HCC in an African setting is 
possible especially if a multi-targeted approach is taken. The simplest approach to minimise the 
incidence of HCC in SSA would be to implement HBV screening, at the very least in pregnant women, 
to break the transmission cycle of HBV. Moreover, the biomarkers of interest identified in the present 
study should be investigated further in larger cohorts and non-invasive patient samples to determine 
their utility in stratifying HCC risk. Lastly, the WES study showed that there are germline variants that 
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could predispose carriers to HCC although these results need to be further investigated in in-silico and 
proteomic studies. 
OPSOMMING 
Hepatosellulêre karsinoom (HCC) is ‘n omvangryke maar verontagsame publieke gesondheid probleem 
wêreldwyd. In sub-Sahara Afrika (SSA) word meeste HCC gevalle eers gediagnoseer met reeds-
gevorderde siekte, lank nadat moontlike behandeling toegepas kon word. Meeste HCC gevalle word 
deur kroniese hepatitis B virus (HBV) infeksie veroorsaak. Alhoewel die grootste HBV las op SSA is, 
bestaan daar geen siftingsprogramme vir die algemene populasie in Afrika nie, wat veroorsaak dat slegs 
0.8% van HBV positiewe individuele gediagnoseer word. Meeste HBV verwante HCC navorsing is tot 
dusvêr in Asië uitgevoer waar HBV ook endemies is, maar daar is verskille in siekte ontwikkeling en 
voordoening. Hierdie studie het HBV en HCC uit ‘n Akrika perspektief benader en die publieke 
gesondheid kwessies ondersoek deur drie sleutelkomponente in ag te neem om HBV verwante HCC 
vroeg te identifiseer, naamlik: HBV sifting, HCC biomerkers en HBV verwante HCC genomika. 
In die HBV sifting studie, het ‘n geverifieërde punt-van-sorg toets gevind dat die voorkoms van HBV 
in ‘n Suid Afrikaanse gemeenskap gebaseerde kohort 2.2% (95% CI: 1.4%–3.3%) is. Die toets was 
suksesvol uitgevoer en het sensitiwiteit, spesifisiteit, negatiewe en positiewe voorspellende waardes van 
100% behaal. Die toets is ook deur die gemeenskap (93% opname) en gesondheidsorgverskaffers 
aanvaar. Die bevindings van die huidige studie ondersteun die implementering van HBV sifting in Suid 
Afrika deur die omvang van HBV as ‘n meenigte gesondheids probleem te bevestug is en deur nuwe 
bevindings dat the punt-van-sorg toets gebruiklik in die veld is en aanvaar word deur die gemeenskap 
en gesondheidsorgverskaffers. Pasiënte gediagnoseer met die toets kan ook behandeling en langtermyn 
nasorg ontvang. 
Die HCC biomerker studie het bekenisvolle verskille in metilering uitdrukking-vlakke in CpG eilande 
in die promotor area van die tumor onderdrukking geen RASSFIA tussen HCC gevalle en normale 
lewer weefsel kontroles gevind, asook ‘n betekenisvolle verwantskap tussen HBV genotype A en HCC. 
Alhoewel die steekproefgrootte klein was, het dit daartoe aanduiding gegee dat sekere biomerkers 
gebruik kan word vir die identifikasie van HCC, wat die pad voorberei vir verdere studies om HCC 
risiko-gradering te gebruik om HCC vroegtydig te diagnoseer. 
Met die gebruik van heel-eksoom nukleïensuurvolgordebepaling het die HBV-verwante HCC 
genomika studie twee nuwe kiemlyn variante in die SMARCA1 en RAB19 gene geïdentifiseer, wat 
onafhanklik van ander risiko faktore, HBV uitgesluit, kon bydra tot vroeë HBV-verwante HCC aanvang 
in hulle onderskeie gashere. 
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In samevatting, verskaf hierdie data bewyse dat vroeë diagnose van HBV-verwante HCC in ‘n Afrika-
omgewing moontlik is, veral wanneer ‘n multi-geteikende benadering geneem word. Die eenvoudigste 
benadering tot die vermindering van HCC in SSA is om HBV-sifting te implementer, minstens in 
swanger vroue om die oordragsiklus te verhoed. Verder moet die biomerkers wat in hierdie studie 
geïdentifiseer is, in meer omvattende studies ondersoek met gebruik van nie-indringende pasiënt 
monsters. Laastens het die WES studie aangedui dat daar sekere kiemlyn variante is wat draers kan 
vatbaar maak aan HCC, hoewel hierdie resultate verder ondersoek moet word in ‘in-silico’ en 
proteomiese studies. 
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1. INTRODUCTION 
1.1 Background 
Primary liver cancer is a neglected major public health problem (O’Hara, McNaughton, Maponga, Jooste, 
Ocama, et al., 2017). Worldwide, it is the fifth most common cancer in men and the ninth most common cancer 
in women. In SubSaharan Africa (SSA), however, it is the second most common cause of cancer in men and 
the third most common cause of cancer in women (Ervik, Lam, Ferlay, Mery, Soerjomataram, et al., 2016). 
Annually, 39 000 new liver cancer cases are diagnosed in SSA (Ervik et al., 2016) with an age-standardized 
incidence of as high as 25.8/100 000 persons/year reported in Gambia (Ervik et al., 2016). Although primary 
liver cancers include hepatocellular carcinoma (HCC), cholangiocarcinoma, and angiosarcoma, the most 
common type of primary liver cancer worldwide and in SSA remains HCC (Wong, Jiang, Goggins, Liang, 
Fang, et al., 2017). Therefore, reported incidence of primary liver cancer is often considered to reflect 
incidence of HCC. HCC has a high case fatality rate so that its prevalence reflects incidence (Ervik et al., 
2016) and in SSA most HCC cases are diagnosed with advanced disease, well past the timing of possible 
curative therapy (Kew, 2013). In South Africa, liver cancer is the fifth most common cause of cancer mortality 
in men and the age-standardized annual incidence is estimated to be 4.8/100 000 persons (Ervik et al., 2016). 
Most HCC cases worldwide are caused by chronic infection with viral hepatitis, namely hepatitis B virus 
(HBV) and hepatitis C virus (HCV). However, while HCV is the main cause of HCC in developed countries, 
in contrast, in resource-limited settings, the main etiology of HCC remains HBV  (Baecker, Liu, La Vecchia 
& Zhang, 2018; Maucort-Boulch, de Martel, Franceschi & Plummer, 2018). Baecker et al. 2018 reported a 
similar trend in SSA where a higher proportion of HCC cases are caused by HBV, ranging from 58% (95% CI 
52%–65%) in East Africa to 69% (64%–74%) in West Africa. These proportions vary from country to country 
although neighbouring countries usually have similar prevalences. For example, a South African study showed 
that 68.2% (95% CI 54.3%-73.2%) of HCC cases were positive for hepatitis B surface antigen (HBsAg), 
indicating active HBV infection (Maponga, 2016). Similarly, in Zambia, the fraction of HBV-related HCC 
was reported to be 46.3% (95% CI 15.5%-73.2%) (Maucort-Boulch et al., 2018). 
Chronic hepatitis B virus infection (CHB) affects 257 million people worldwide, the majority of whom are in 
SSA and Asia. However, only 9% of affected individuals are aware of their status as CHB is usually 
asymptomatic (World Health Organization, 2017a). Moreover, although the bulk of the burden of HBV is in 
SSA, there are currently no HBV screening programmes implemented in the general population of SSA so 
only 0.8% of CHB cases get diagnosed. In contrast, although high-income countries have a lower HBV burden, 
18% of their HBV cases get diagnosed (World Health Organization, 2017b). Current evidence suggests that 
SSA has a prevalence of CHB of 2.5% to 22.4% (Schweitzer, Horn, Mikolajczyk, Krause & Ott, 2015). 
These data demonstrate that HBV-related HCC is a major health issue in SSA, although it is likely that these 
numbers are underestimations as HBV screening is not routinely practised, even after HCC diagnosis. 
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Moreover, HCC is underdiagnosed and underreported, especially since most SSA countries have registries that 
require histological diagnosis for an HCC case to be included within the registry and often lack recent data 
(Kew, 2013). Despite the high burden of disease observed in SSA, few studies to date have been conducted to 
establish whether targeted health approaches could be implemented in an African setting to enable early 
timeous diagnosis of HBV-related HCC, reflecting the need for more research in SSA on Africans to better 
understand the disease from an African perspective. 
1.2 Study Rationale 
Most research on early diagnosis of HBV-related HCC has been conducted in Asia, where HBV is also 
endemic but where there are differences in disease progression and presentation (Kew, 2013; de Martel, 
Maucort-Boulch, Plummer & Franceschi, 2015; Yang, Altekruse, Nguyen, Gores & Roberts, 2017). HBV-
related HCC in SSA presents earlier, at a mean age of 38.9 years, compared to 54.5 years in Eastern Asia (de 
Martel et al., 2015) and it is estimated that 40% of HBV-related HCC cases occur before the age of 40 (Yang, 
Gyedu, Afihene, Duduyemi, Micah, et al., 2015). Moreover, the main genotypes in circulation in SSA are 
genotypes A, D, and E (Kramvis & Kew, 2007a) compared to genotypes B and C in Asia (Kao & Chen, 2006), 
which show differences in clinical disease progression (Lin & Kao, 2017). Therefore, although risk factors of 
HBV-related HCC have been identified and HCC risk prediction scores have been developed for Asian 
populations (Lee & Ahn, 2016; Wong, Chan, Mo, Chan, Loong, et al., 2010; Yang, Yuen, Chan, Han, Chen, 
et al., 2011; Yuen, Tanaka, Fong, Fung, Wong, et al., 2009), they have not been validated elsewhere and may 
not be applicable to an African setting. The present study therefore does not only seek to understand the 
epidemiology and risk factors of HBV-related HCC but also apply the basic scientific results obtained through 
laboratory testing as part of a screening strategy to try to solve a public health issue. 
1.3 Research statement 
How can HBV point-of-care test (POCT) screening, biomarker testing, and genetic testing be utilised to 
contribute to the early diagnosis of HBV-related HCC in a South African population from the Western Cape? 
1.4 Study Aims 
The overarching goal of the study was to contribute to the body of knowledge on the epidemiology of HBV 
and HBV-related HCC in the South African population and to explore screening, biomarker, and genetic testing 
strategies that could be further utilised to contribute to early detection of HBV-related HCC in South Africans. 
Toward this main aim, three separate sub-studies were developed, each with its respective sub-aim. 
Sub-aim 1: To assess the need for and feasibility of implementing HBV POC testing in a community setting 
in the Western Cape, South Africa. 
Sub-aim 2: To identify biomarkers that can potentially be utilised clinically to discriminate between HCC and 
non-HCC cases. 
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Sub-aim 3: To identify genetic variants that can possibly predispose South African men to developing early-
onset HBV-related HCC 
1.5 Hypotheses 
A separate hypothesis was developed for each study, corresponding to their respective sub-aim. 
STUDY I: HEPATITIS B VIRUS POINT-OF-CARE TESTING STUDY 
There is a need for implementing HBV POC testing in a community setting in the Western Cape, South Africa, 
and its implementation is feasible. 
Null hypothesis: The implementation of HBV POC testing is not needed and/or is not feasible in a community 
setting of the Western Cape, South Africa 
STUDY II: HCC BIOMARKER STUDY 
Clinical biomarkers can be identified that may potentially be used to discriminate between HCC and non-HCC 
patients in the population of the Western Cape, South Africa. 
Null hypothesis: There are no clinical biomarkers that can potentially be used to screen patients for HCC in 
the population of the Western Cape, South Africa 
STUDY III: WHOLE EXOME SEQUENCING STUDY 
Certain germline driver mutations potentially predispose South African men from the Western Cape to 
developing early-onset HBV-related HCC. 
Null hypothesis: There are no germline driver mutations contributing to the development of early-onset HBV-
related HCC in South African men from the Western Cape. 
1.6 Study Objectives 
STUDY I: THE HEPATITIS B VIRUS POINT-OF-CARE TESTING STUDY 
1. To determine the prevalence of active HBV infection in a community-based South African population from 
the Western Cape using a validated HBsAg POCT. 
2. To test the performance of the HBsAg POCT in terms of sensitivity, specificity, positive and negative 
predictive values. 
3. To assess the perception of the tested population toward the HBV POCT and the reasons for 
accepting/refusing the test. 
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4. To assess the perception of the nursing staff toward the HBV POCT and the barriers encountered in 
administering the HBV POCT. 
STUDY II: THE BIOMARKER STUDY 
1. To determine the proportion of HCC caused by HBV in two tertiary hospitals in the Western Cape, South 
Africa. 
2. To determine and compare HBV genotypes between HCC and non-HCC cases. 
3. To compare the occurrence of aflatoxin exposure between HCC and non-HCC cases. 
4. To determine the differences in methylation levels in tumour suppressor genes between HCC and non-
HCC cases. 
5. To determine the proportion of human immunodeficiency virus (HIV)-positive HCC patients. 
6. To determine the proportion of HCC cases with cirrhosis 
7. To evaluate the potential of the above-listed biomarkers to discriminate between HCC and non-HCC 
patients in terms of sensitivity, specificity, positive and negative predictive values.  
STUDY III: THE WHOLE EXOME SEQUENCING STUDY 
1. To use whole exome sequencing to identify novel rare germline variants predisposing young HBV-infected 
South African men to developing HBV-related HCC and confirm the presence of the identified variants by 
Sanger sequencing 
2. To validate the identified potential genetic variants using Sanger sequencing in a retrospective cohort of 
HBV-infected patients without HCC 
1.7 Chapter Overview 
Chapter two is a literature review, whilst chapter three, four, and five detail the research design and 
methodology, results, and discussion for sub-studies one, two, and three, respectively. Each sub-study will 
have a conclusion in which the summary of research findings, recommendations, as well as suggestions for 
future research, will be provided. This dissertation will have a final conclusion in chapter six summarising the 
main findings of the overall research project.  
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2. LITERATURE REVIEW 
2.1 Hepatitis B virus 
Hepatitis B virus is a virus belonging to the family Hepadnaviridae (Gust, Burrell, Coulepis, Robinson & 
Zuckerman, 1985), with the genera Orthohepadnavirus and Avihepadnavirus. The former genus includes 
hepatitis B viruses that have been isolated from mammals, such as humans (HBV), non-human primates such 
as woolly monkeys (WMHBV; Lanford, Chavez, Brasky, Burns & Rico-Hesse, 1998), woodchucks (WHV; 
Summers, Smolec & Snyder, 1978), and bats (BtHV; Drexler, Geipel, Konig, Corman, van Riel, Leijten, 
Bremer, Rasche, Cottontail, Maganga, Schlegel, Muller, Adam, Klose, Borges Carneiro, Stocker, Franke, 
Gloza-Rausch, Geyer, Annan, Adu-Sarkodie, Oppong, Binger, Vallo, Tschapka, Ulrich, Gerlich, Leroy, 
Kuiken, Glebe & Drosten, 2013). The latter genus includes hepatitis B viruses that have been isolated from 
birds such as the Pekin duck (DHBV; Mason, Seal & Summers, 1980) and herons (HHBV; Sprengel, Kaleta 
& Will, 1988). A hepadnavirus was recently isolated from a white sucker (Catostomus commersonii), making 
it the first isolate to be identified in fish (Hahn, Iwanowicz, Cornman, Conway, Winton, et al., 2015) and has 
been tentatively named a parahepadnavirus. Subsequently, other hepadnaviruses have been isolated from fish 
and amphibians and tentatively grouped as metahepadnaviruses and herpetohepadnaviruses, respectively (Dill, 
Camus, Leary, Di Giallonardo, Holmes, et al., 2016). 
 Structure 
Hepatitis B virus was first discovered in 1967 by Blumberg and was initially called the Australia antigen 
(Blumberg, Gerstley, Hungerford, London & Sutnick, 1967). Three distinct types of viral particles can be 
identified in the blood of an individual infected with HBV. The first one is the Dane particle, a mature spherical 
virion, 42 nm in diameter (Dane, Cameron & Briggs, 1970). The Dane particle is composed of two layers, an 
outer envelope composed of hepatitis B surface antigen proteins and an inner nucleocapsid made up of hepatitis 
B core antigens that can exhibit either a T3 or T4 symmetry, depending on the number of core proteins, which 
can result in core particles of 32 nm or 36 nm (Crowther, Kiselev, Böttcher, Berriman, Borisova, et al., 1994). 
Within the nucleocapsid are the HBV genome and endogenous deoxyribonucleic acid (DNA) polymerase. 
Two sub-viral proteins are secreted and non-infectious and composed of hepatitis B surface proteins; one is 
spherical in shape and 17–25 nm in diameter and the other is filamentous and 20 nm in diameter and varying 
lengths. Their function is still unknown although it is speculated that they may act as immune decoys.  
Hepatitis B virus has several peculiarities. Firstly, unlike most DNA viruses, it uses the enzyme reverse 
transcriptase for its replication (Seeger, Ganem & Varmus, 1986). Secondly, it has a partially-double stranded 
relaxed circular genome, with an incomplete plus strand to which the viral DNA polymerase is bound and a 
complete minus strand (Delius, Gough, Cameron & Murray, 1983). Thirdly, it is the smallest DNA virus to be 
identified to date, with a genome that varies in length, from 3181 to 3248 bases, according to the genotype, 
but whose length is also restricted because viral replication occurs within the nucleocapsid (Chirico, Vianelli 
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& Belshaw, 2010). Fourthly, to compensate for this restriction in genomic length, the minus strand encodes 
the entire viral genome as four overlapping open reading frames (ORF) (Nassal & Schaller, 1993). The longest 
ORF codes for the viral polymerase, the precore/core ORF code for the hepatitis B envelope antigen (HBeAg) 
and hepatitis B core proteins, the X ORF codes for the hepatitis B x antigen (HBx), and the surface ORF codes 
for the Pre-S1, Pre-S2, and S proteins. 
 Life cycle and replication  
The host cells of HBV are human hepatocytes (Seeger, Mason, Seeger & Mason, 2000) although viral DNA 
has been found in peripheral blood mononuclear cells (PBMCs) (Bouffard, Lamelin, Zoulim, Pichoud & 
Trepo, 1990) and the human ovary (Yu, Gu, Xia, Wang, Kan, et al., 2012). In 2012, the entry mechanism for 
HBV was elucidated and the sodium taurocholate cotransporting polypeptide (NTCP), a multiple 
transmembrane transporter predominantly expressed in the liver, was identified as the cellular receptor for the 
HBV pre-S1 receptor-binding region (Yan, Zhong, Xu, He, Jing, et al., 2012). 
After entering the hepatocytes, the nucleocapsids are transported to the nucleus where the enclosed relaxed 
circular genome is released and using host cell enzymes is converted to covalently closed circular (ccc) DNA 
resulting in a minichromosome (Bock, Schranz, Schröder & Zentgraf, 1994). The minichromosome acts as a 
template for transcription of all genomic and subgenomic messenger RNAs (mRNAs) using host polymerase 
(Bock et al., 1994) and is also responsible for viral persistence. The genomic transcripts code for the viral 
polymerase and core proteins, as well as for the pre-core protein, which is subsequently modified to form 
HBeAg. The subgenomic transcripts are involved in the production of the X and surface proteins.  
One of the genomic length mRNA transcripts, called the pregenomic RNA is packaged with viral polymerase 
forming core particles, in which reverse transcription occurs to form the partially double-stranded DNA. The 
viral envelope consisting of surface proteins is assembled independently of the nucleocapsids in the 
endoplasmic reticulum. Nucleocapsids with completed minus strand are preferentially enveloped with surface 
proteins and hijack the endosomal sorting complex required for transport (ESCRT) for release into the 
extracellular space. A proportion of nucleocapsids do not get enveloped and are instead transported to the 
nucleus using an intracellular conversion pathway thereby maintaining the number of cccDNA molecules in 
the hepatocytes (Wong & Locarnini, 2018). Viral DNA integration with host genome occurs randomly and 
although it is not a prerequisite for viral replication, it is an important hepatocarcinogenic pathway (Seeger & 
Mason, 2015). 
2.2 Prevalence of HBV  
 Globally 
A report by Schweitzer et al, 2015, where the authors performed mathematical calculations on worldwide 
HBsAg prevalence on a country-by-country basis, estimated that in 2010, 248 million people were living with 
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CHB, accounting for 3.61% of the global population (Schweitzer et al., 2015). Although HBsAg prevalence 
varies across continents and between countries and regions, it is apparent that it is more prevalent in resource-
limited areas, with the highest prevalence documented in Africa (8.83%; 95% CI: 8.82%–8.83%), followed by 
the Western Pacific region (5.26%; 95% CI: 5.26%-5.26%), where the highest prevalence observed in any 
country was 22.7% in the Kiribati (Schweitzer et al., 2015).  
Certain countries such as China have had significant success in controlling HBV by implementing health 
measures such as the administration of the birth-dose HBV vaccine. As a result, the prevalence of HBV in the 
Chinese general population has dramatically dropped from 13.99% (13.76%-14.23%) in the period 1957-1989 
to 5.41% (5.40%-5.43%) in the period 1990-2013 (Schweitzer et al., 2015). Another recent study modelled 
that the prevalence of HBsAg in China has decreased by 11% annually from the year 2000 onward (Ott, Horn, 
Krause & Mikolajczyk, 2017). 
High-income countries tend to have a lower prevalence of HBV. Hence, in Europe, the overall prevalence of 
HBV observed is relatively low (Ott, Stevens, Groeger & Wiersma, 2012) although it varies across countries, 
from as low as 0.01% in the United Kingdom to 10.3% in Kyrgyzstan (Schweitzer et al., 2015). In the North 
American mainland, the prevalence observed is less than 1% in Canada, the USA, and Mexico. Haiti, on the 
other hand, has the highest prevalence of HBsAg in the Americas region at 13.6%. Overall, the World Health 
Organization (WHO) Eastern Mediterranean Region has a low-intermediate prevalence of HBsAg, which 
varies from a low of 0.7% in the United Arab Emirates to a high of 14.8% in Somalia. 
However, these overall prevalences do not provide an accurate picture of the HBV burden, because even within 
countries, certain groups, for example, refugees and immigrants, can be at higher risk of infection and 
transmission than the general population. For example, in Italy, while the countrywide HBsAg prevalence is 
2.52% (95% CI: 2.49%–2.54%), a study found the HBsAg prevalence in undocumented refugees and 
immigrants to be 9.6% (Coppola, Alessio, Gualdieri, Pisaturo, Sagnelli, et al., 2017). A good understanding 
of the epidemiology of HBV infection is required so that targeted public health policies can be implemented 
to prevent further transmission in high-risk groups. 
 
 Africa 
It is estimated that more than 75 million Africans are currently living with CHB, making up approximately 
8.83% of the African continent’s population (Schweitzer et al., 2015). It must be acknowledged that this 
number is likely an underestimation of the actual prevalence of CHB because it is based on either incomplete 
or unavailable data for some African countries. For example, half of the SubSaharan African countries included 
in the modelling calculations of Schweitzer et al. 2015 had less than five relevant studies that could be utilised. 
In contrast, Nigeria had 85 studies available, making it more likely that the overall calculated prevalence would 
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be more accurate. Furthermore, there are intra-country variations in HBsAg prevalence that could have 
influenced the reported prevalence. 
Unlike the annual decrease in HBsAg prevalence observed in Asian countries endemic for HBV, several 
African countries, including Senegal, South Africa, Nigeria, and Uganda, had an annual increase in HBsAg 
prevalence of 1%, 2%, 2%, and 5%, respectively (Ott et al., 2017). These data reflect the fact that the HBV 
epidemic in Africa is largely underestimated as a public health issue and is largely unknown to the public due 
to the fact that CHBs are usually asymptomatic and usually only manifest when they have progressed to end-
stage liver disease. HBV is considered to be a disease on the decline because of the availability of a safe and 
effective vaccine that should prevent most horizontal transmissions of the virus. Horizontal transmission 
during childhood has long been assumed to be the principal transmission route in Africa, based on studies pre-
dating the HIV epidemic. In Africa, the HIV and HBV epidemics form a potent combination and make mother-
to-child-transmission (MTCT) a bigger problem than previously described. A meta-analysis of HBV MTCT 
studies in SSA showed that 367 250 newborns are infected at birth every year, which is twice the number of 
infants infected by HIV annually (Keane, Funk & Shimakawa, 2016). Unfortunately, research funding in much 
of SSA is geared toward research on malaria, tuberculosis, and HIV making HBV a neglected tropical disease 
(O’Hara et al., 2017). 
 South Africa 
South Africa is considered to be endemic for HBV and while the predominant mode of HBV transmission in 
South Africa was initially thought to be horizontal transmission (Botha, Dusheiko, Ritchie, Mouton & Kew, 
1984; Prozesky, Szmuness, Stevens, Kew, Harley, et al., 1983), vertical transmission from mother to child 
may have been underestimated as shown in a study by Vardas et al. 1999, before the HBV vaccine was 
introduced to the South African Expanded Programme on Immunization, where 8.1% of unvaccinated infants 
between the ages of 0 and 6 months were positive for HBsAg.  
Certainly, recent studies from the different South African provinces have reported HBV MTCT and HBsAg 
prevalences of 0.4%, 7%, and 13% in HIV-exposed infants from the Western Cape (Chotun, Nel, Cotton, 
Preiser & Andersson, 2015), Gauteng (Hoffmann, Mashabela, Cohn, Hoffmann, Lala, et al., 2014), and 
KwaZulu Natal (Mdlalose, Parboosing & Moodley, 2016), respectively. HIV-unexposed infants from 
KwaZulu Natal had a lower prevalence of HBsAg of 7.5% than HIV-exposed infants (Mdlalose et al., 2016). 
These differences in HBsAg distribution also clearly demonstrate the variability in distribution of the disease 
which has previously been reported between South African provinces (Dusheiko, Conradie, Brink, Marimuthu 
& Sher, 1989; Ive, MacLeod, Mkumla, Orrell, Jentsch, et al., 2013; Kew, 1996).  
A pitfall of the numerous epidemiological studies conducted on HBV in South Africa is that they targeted 
pregnant women, blood donors, healthcare workers, and HIV-infected cohorts. These groups, although 
important to study, are not representative of the general South African population. Blood donors tend to be 
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healthy members of the population and the questionnaires administered to potential donors already weed out 
those considered at high risk of carrying blood-transmissible diseases. Moreover, like in developed countries, 
in South Africa, blood donations are voluntary and unpaid. In South Africa, pregnant women are used as 
proxies to determine the prevalence of the HIV-1 epidemic and antenatal surveys are conducted yearly to 
monitor the evolution of the epidemic. However, in the context of HBV infections, pregnant women are not a 
reliable proxy for the general prevalence of HBV and testing them will likely underestimate the extent of the 
silent epidemic. Healthcare workers are often used in studies as proxies for the general population but are often 
at higher risk of acquiring infections (nosocomially) than the general population (Fritzsche, Becker, Hemmer, 
Riebold, Klammt, et al., 2013). Finally, unlike immunocompetent individuals, HIV-infected individuals are 
immunocompromised and more likely to develop CHB if exposed to HBV in adulthood and are also more 
likely to have HBV infections despite being HBsAg-negative which would necessitate more expensive 
molecular techniques for their detection (Lukhwareni, Burnett, Selabe, Mzileni & Mphahlele, 2009). As HIV 
and HBV share the same modes of transmission, HBV co-infection is usually more prevalent in HIV-1 infected 
individuals as has been shown previously (Andersson, Maponga, Ijaz, Barnes, Theron, et al., 2013). 
 Distribution of genotypes and their clinical significance  
There are ten genotypes of HBV, named A to J, that have been described worldwide and that are at least 8% 
genetically different (Arauz-Ruiz, Norder, Robertson & Magnius, 2002; Huy, Ngoc & Abe, 2008; Norder, 
Couroucé & Magnius, 1994; Olinger, Jutavijittum, Hübschen, Yousukh, Samountry, et al., 2008; Stuyver, De 
Gendt, Van Geyt, Zoulim, Fried, et al., 2000; Tatematsu, Tanaka, Kurbanov, Sugauchi, Mano, et al., 2009). 
However, genotype I is contested by experts in the field as being a potential recombinant (Kurbanov, Tanaka, 
Kramvis, Simmonds & Mizokami, 2008) and genotype J has been identified in only one patient thus far 
(Tatematsu et al., 2009). These genotypes can be further categorised into sub-genotypes differing genetically 
by between 4% and 8%. HBV genotypes and sub-genotypes tend to group in distinct geographical areas 
(Norder, Couroucé, Coursaget, Echevarria, Lee, et al., 2004).  
In SSA, genotypes are A, D, and E are the most common. Subgenotype A1 is the most commonly found in 
SSA, especially Eastern and Southern Africa, including South Africa (Kramvis & Kew, 2007b), while 
genotype D is the most prevalent in North Africa and the Mediterranean basin (Kramvis, Kew & François, 
2005). Genotype D has also been described in South Africa (Chotun, Preiser, van Rensburg, Fernandez, 
Theron, et al., 2017; Chotun, Strobele, Maponga, Andersson & Etienne De La Ray, in press; Maponga, 2016) 
and is considered to be the second most prevalent genotype in South Africa (Kimbi, Kramvis & Kew, 2004). 
Genotype E is found in Central and West Africa (Kramvis & Kew, 2007a) although some isolates have been 
identified in South Africa, originating from West African immigrants (Maponga, 2016).  
These different genotypes can influence the management of affected individuals as they have been shown to 
be different in terms of disease progression (Lin & Kao, 2017) and susceptibility to antiviral therapy (Lin & 
Kao, 2013). Unfortunately, there is limited data on the influence of HBV genotypes on clinical outcomes in 
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SSA as most research on the topic has been conducted in Asia where the most prevalent genotypes are B and 
C. Research on genotype A1 in South Africa has shown that it was associated with a higher risk of HCC 
compared to genotype D (Kew, Kramvis, Yu, Arakawa & Hodkinson, 2005). In The Gambia, a significant 
association was also found between genotype A and increased risk of liver fibrosis although the study sample 
size was very small (Shimakawa, Lemoine, Njai, Bottomley, Ndow, et al., 2016). 
2.3 Natural history of HBV infection 
 Acute hepatitis 
About 70% of individuals infected with HBV will have a self-limiting sub-clinical manifestation of the disease 
while the remaining 30% will develop clinical symptoms such as jaundice, termed icteric hepatitis (Oliphant, 
1944). A severe form of acute hepatitis, termed fulminant hepatitis, is rare and will occur in about 1% to 2% 
of patients with acute HBV infection (Chu & Liaw, 1990). In patients with acute hepatitis, the liver enzymes 
alanine aminotransferase (ALT) and aspartate transaminase (AST) levels will initially be high and normalise 
within six months.  
Persistently elevated ALT levels may be an indication that the acute infection is becoming chronic in nature. 
The risk of progression from acute to chronic infection is linked to age at exposure to HBV; perinatal exposure 
has a 90% risk of developing into a chronic infection (Beasley, Hwang, Lin, Leu, Stevens, et al., 1982; Beasley, 
Trepo, Stevens & Szmuness, 1977), exposure between the ages of one and five years has a 20% – 50% risk 
(McMahon, Alward, Hall, Heyward, Bender, et al., 1985), and exposure as an adult carries a less than 5% risk 
(Tassopoulos, Papaevangelou, Sjogren, Roumeliotou-karayannis, Gerin, et al., 1987). There is no 
recommended treatment for acute hepatitis B and a Cochrane review showed no clear benefits of nucleos(t)ide 
treatment during acute infection (Mantzoukis, Rodriguez-Peralvarez, Buzzetti, Thorburn, Davidson, et al., 
2017). Mantzoukis et al. 2017 also reported that treatment did not appear to be efficacious in cases of fulminant 
hepatitis B although studies on infantile fulminant hepatitis B have shown that administering treatment does 
not worsen disease prognosis (Chotun et al., in press; Laubscher, Gehri, Roulet, Wirth & Gerner, 2005). 
 Chronic hepatitis 
Chronic hepatitis B virus infection is defined as persistent positivity for HBsAg for more than six months 
(Terrault, Lok, McMahon, Chang, Hwang, et al., 2018). Many patients with CHB are asymptomatic or may 
present with nonspecific symptoms, such as fatigue (Song, 2005). Their liver enzyme levels (ALT and AST) 
may be normal to slightly elevated although patients may experience flares sporadically. 
2.3.2.1 Phases of chronic hepatitis B virus infection 
The natural course of CHB is host- and virus-dependent and its progression is affected by factors such as age 
at acquisition, sex, alcohol consumption, and comorbidities (such as HIV co-infection). HBV is never truly 
cleared from the host’s body even when HBsAg seroconversion is achieved and viral loads are undetectable 
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in the sera (Kuhns, McNamara, Mason, Campbell & Perrillo, 1992) and HCC can still develop years after 
HBsAg clearance (Simonetti, Bulkow, McMahon, Homan, Snowball, et al., 2010). This is because HBV can 
still persist as cccDNA in hepatocyte reservoirs leading to low transcriptional levels and replication despite 
HBsAg seroconversion (Yuen, Wong, Fung, Ip, But, et al., 2008). 
2.3.2.1.1 Immune tolerance 
Patients who have acquired HBV perinatally initially present with an immune tolerance phase that is generally 
asymptomatic. Clinically, this phase is characterised by high levels of HBV DNA and HBeAg in the blood, 
but no evidence of liver damage or immune response to the viral infection. Hence, patients may present with 
normal liver enzyme levels and minimal fibrosis (Fattovich, Bortolotti & Donato, 2008). The immune tolerance 
phase can last for 10–30 years with a low annual rate of clearance of HBeAg in adolescence and early 
adulthood (Lok, Lai, Wu, Leung & Lam, 1987). This phenomenon can lead to an increased risk of mother-to-
child transmission, thus maintaining the cycle of viral transmission. 
2.3.2.1.2 Immune-active, HBeAg positive 
During this phase, patients undergo spontaneous HBeAg clearance, often accompanied by flares in levels of 
ALT and inflammation (Liaw, Pao, Chu, Sheen & Huang, 1983). This clearance seems to be preceded by an 
increase in viral activity (Liaw, Pao, Chu, Sheen & Huang, 1987), although how and why those changes occur 
are unknown. Clinically, patients in this phase rarely present with symptoms and will be diagnosed during 
routine follow-ups. However, patients with previously unknown HBV status may be mistakenly diagnosed 
with acute HBV when in this phase as it may be accompanied by antibody to the HBV core antigen (anti-HBc) 
IgM positivity (Chu, Liaw, Pao & Huang, 1989), which is often used as a marker of acute HBV infection. This 
phase may lead to HBeAg seroconversion and HBV DNA clearance from the blood, with a reported annual 
clearance rate of 10% to 20% (Alward, McMahon, Hall, Heyward, Francis, et al., 1985; Lok et al., 1987). In 
certain patients, however, viral clearance from the blood is not achieved and the flares may become recurrent 
(Liaw et al., 1987), increasing their risk of cirrhosis and HCC as they age (Chen, Chu & Liaw, 2010). 
2.3.2.1.3 Inactive chronic HBV 
Subsequent to HBeAg clearance from the blood and seroconversion, patients enter the inactive CHB phase, 
where they are HBeAg negative and positive for antibodies to the envelope antigen (anti-HBe). These patients 
tend to have a low level or undetectable levels of HBV DNA in the blood and normal ALT levels, indicating 
that the liver disease is in remission. However, reports suggest that three consecutive normal ALT levels and 
HB viral loads below 2000 IU/ml over a one-year period are required to confirm that patients are truly in this 
phase of CHB (Lampertico, Agarwal, Berg, Buti, Janssen, et al., 2017; Sarin, Kumar, Lau, Abbas, Chan, et 
al., 2016; Terrault et al., 2018). Histologically, patients may still present with liver inflammation and fibrosis 
although a meta-analysis has suggested that this was a rare occurrence in patients with repeatedly normal levels 
of ALT and low HB viral loads (Papatheodoridis, Manolakopoulos, Liaw & Lok, 2012). 
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2.3.2.1.4 Immune-active, HBeAg negative 
Some patients, while having achieved HBeAg seroconversion, may be infected with HBV variants that cannot 
produce HBeAg due to viral precore (PC) or basal core promoter (BCP) mutations (Carman, Jacyna, 
Hadziyannis, Karayiannis, McGarvey, et al., 1989). These patients still have active liver disease and will 
present clinically with increased ALT levels and moderate HB viral loads (Lok, Hadziyannis, Weller, 
Karvountzis, Monjardino, et al., 1984). These patients are said to have HBeAg-negative chronic hepatitis and 
tend to be older, with more advanced liver disease, repeated peaks in ALT levels (Kumar, Chauhan, Gupta, 
Hissar, Sakhuja, et al., 2009) and viral loads and are at risk of developing HCC (Hsu, Chien, Yeh, Sheen, 
Chiou, et al., 2002). 
2.3.2.1.5 Occult hepatitis B infection 
Some individuals may test negative for HBsAg but still have other detectable markers of HBV infection such 
as anti-HBc, a low serum viral load (< 200 IU/ml), and detectable intrahepatic DNA which are indicative of 
an “occult” (hidden) HBV infection (Raimondo, Allain, Brunetto, Buendia, Chen, et al., 2008). These 
individuals account for a small proportion of all CHBs (The Gambia – 4%; Shimakawa et al., 2016) and are 
still at risk of HCC (Kew, Welschinger & Viana, 2008; Wong, Huang, Lai, Poon, Seto, et al., 2011). Occult 
HBV infection seems to occur in higher proportions in HIV-infected individuals (Mayaphi, Rossouw, 
Masemola, Olorunju, Mphahlele, et al., 2012) but this could be caused by atypical HBV serological 
presentations observed in HBV/HIV co-infected individuals due to their inherent immunosuppression, as 
demonstrated in previous South African studies where the authors reported HB viral loads above 200 IU/ml 
and up to 108 IU/ml in HBsAg negative and anti-HBc positive HBV/HIV co-infected patients (Lukhwareni et 
al., 2009; Mphahlele, Lukhwareni, Burnett, Moropeng & Ngobeni, 2006). 
2.3.2.1.6 Resolution of chronic hepatitis B virus infection 
Some patients may spontaneously undergo HBsAg-to-antibody to the hepatitis B surface antigen (HBsAg) 
[HBsAg-to-anti-HBs] seroconversion, although this is a process that is as yet unclear and happens in 0.5%–
2% of affected patients (Alward et al., 1985; Liaw, Sheen, Chen, Chu & Pao, 1991; Liu, Yang, Lee, Lu, Jen, 
et al., 2010; Simonetti et al., 2010). This seroconversion may be preceded by a decrease in HBV DNA and 
HBsAg levels (Liu et al., 2010). Lower DNA levels at baseline are associated with higher seroconversion rates 
(Liu et al., 2010). Although these patients tend to have a better prognosis than those who are positive for 
HBsAg, they are still at risk of HCC, especially if the seroconversion occurred after the age of 50 (Simonetti 
et al., 2010; Yuen et al., 2008). Many patients may still test positive for HBV DNA years after HBsAg 
seroconversion as they may still have low levels of replicating HBV in their hepatocytes (Yuen et al., 2008), 
or be infected with pre-S1 HBV variants that have suppressed HBsAg production (Cabrerizo, Bartolomé, 
Caramelo, Barril & Carreño, 2000), or they may have a reactivated infection due to immunosuppression 
(Shouval & Shibolet, 2013). 
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2.3.2.1.7 Reactivation of HBV 
Patients with a resolved HBV infection (anti-HBc and anti-HBs positive) are at risk of HBV reactivation if 
they undergo immunosuppressive therapy (such as chemotherapy) (Shouval & Shibolet, 2013) due to the 
persistence of cccDNA in hepatocytes and other tissues despite seroconversion (Yuen et al., 2008). This 
reactivation may either be asymptomatic and accompanied by a reversal of HBsAg seroconversion or may 
have severe consequences such as fulminant hepatitis leading to death (Gupta, Govindarajan, Fong & Redeker, 
1990). Moreover, a transplanted liver from an anti-HBc and anti-HBs positive donor can cause de novo HBV 
infection in a recipient (even in an anti-HBs positive recipient) (Bortoluzzi, Gambato, Albertoni, Mescoli, 
Pacenti, et al., 2013; Cholongitas, Papatheodoridis & Burroughs, 2010). Meta-analyses have shown that the 
administration of HBV antiviral therapy such as lamivudine and entecavir can reduce the risk of HBV 
reactivation (Huang, Hsiao, Hong, Chiou, Yu, et al., 2013; Paul, Saxena, Terrin, Viveiros, Balk, et al., 2016). 
2.3.2.2 Long-term consequences of CHB 
Patients with CHB may have different outcomes, from remaining clinically healthy inactive HBV carriers to 
developing cirrhosis and/or HCC. Chronic HBV infection is the cause of more than 75% of all HCC cases in 
SubSaharan Africa (SSA) and Asia (Baecker et al., 2018; Di Bisceglie, 2009; Ferenci, Fried, Labrecque, Bruix, 
Sherman, et al., 2010; Maucort-Boulch et al., 2018).  
In untreated CHB patients, the five-year progression rate from CHB to cirrhosis is estimated to be 8%–20%, 
from compensated cirrhosis to hepatic decompensation 20%–23%, and from compensated cirrhosis to HCC 
6%–15% (Fattovich, 2003; Hadziyannis & Papatheodoridis, 2006; McMahon, 2009). However, these are 
estimates from studies conducted in Caucasian and Asian population groups, making them unreliable for 
African patients. 
 Management of chronic HBV infection 
There are several guidelines published by major organisations worldwide available for the management of 
patients with CHB (Lampertico et al., 2017; Sarin et al., 2016; Terrault et al., 2018; World Health 
Organization, 2015). South Africa has also published guidelines for the management of CHB patients but these 
have not been updated since their first publication (Spearman, Sonderup, Botha, Van der Merwe, Song, et al., 
2013). 
At time of diagnosis, standard baseline evaluation including a thorough medical history and physical 
examination to evaluate the possibility of comorbidities, laboratory testing for platelet count, AST, ALT, total 
and conjugated bilirubin, albumin, viral markers of HBV infection (HBeAg, anti-HBe, and HBV DNA), and 
HIV coinfection, and if possible screening for fibrosis and cirrhosis using non-invasive tests and for space-
occupying lesions using ultrasound is recommended for CHB patients. Liver biopsies are only indicated for 
patients older than 40 years with persistently elevated viral loads. 
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In HBV monoinfected patients, lifelong treatment with nucleos(t)ide analogues with a high barrier to drug 
resistance, such as tenofovir and entecavir, is recommended in those with clinical evidence of cirrhosis 
irrespective of viral load and ALT levels and in individuals without cirrhosis who have persistently elevated 
ALT levels and viral loads of > 20 000 IU/ml (World Health Organization, 2015). However, in SSA, assessing 
the eligibility of HBV-infected patients for treatment using these criteria, especially HB viral loads and 
cirrhosis status, remain expensive and limited due to lack of trained personnel (Lemoine, Eholié & Lacombe, 
2015).  
Non-invasive fibrosis tests have not been well-studied in SSA where there are different comorbidities 
compared to developed countries. The aspartate transaminase-to-platelet ratio index (APRI) score is 
recommended by the WHO (World Health Organization, 2015) but its validation for use in SSA remains 
limited (Spearman, Afihene, Ally, Apica, Awuku, et al., 2017). A study from The Gambia has shown that 
gamma-glutamyl transpeptidase (GGT)-to-platelet ratio (GPR) was a more accurate test for significant fibrosis 
compared to the APRI and FIB-4 tests in HBV mono-infected patients (Lemoine, Shimakawa, Nayagam, 
Khalil, Suso, et al., 2016). However, their cohort did not include individuals showing excessive alcohol 
consumption and may therefore not be appropriate for use in a South African setting where GGT levels are 
frequently elevated in patients, including non-drinkers (Pisa, Vorster, Kruger, Margetts & Loots, 2015). More 
recently, an algorithm to determine who qualifies for HBV antiviral therapy based on ALT levels and HBeAg 
was published (Shimakawa, Njie, Ndow, Vray, Mbaye, et al., 2018), and could potentially be of better clinical 
value than the other tests once validated in this setting. 
In those HBV monoinfected patients who do not qualify for treatment, continued follow-ups are required to 
monitor disease progression. HBV/HIV co-infected patients should be initiated on antiretroviral therapy (ART) 
containing tenofovir irrespective of CD4 count (Terrault et al., 2018). In South Africa, all newly diagnosed 
HIV-infected individuals are immediately eligible for ART irrespective of CD4 count. First-line ART for 
patients with normal renal function in South Africa includes tenofovir thus inadvertently treating HBV 
infection in newly diagnosed HBV/HIV co-infected patients (Meintjes, Moorhouse, Carmona, Davies, 
Dlamini, et al., 2017).  
In both HBV monoinfected and HBV/HIV co-infected patients receiving treatment, baseline and annual renal 
function tests should be performed to monitor them for drug toxicity. Annual testing should also be conducted 
on both HBV monoinfected and HBV/HIV co-infected individuals for ALT, AST, HBsAg, HBeAg, and HBV 
DNA levels (Spearman et al., 2013; Terrault et al., 2018; World Health Organization, 2015). Annual non-
invasive fibrosis tests should also be conducted to determine the presence of cirrhosis (World Health 
Organization, 2015). More frequent follow-ups may be advisable in patients with more advanced disease 
(World Health Organization, 2015). 
2.4 HBV Diagnosis 
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 Gold standard 
Currently, the gold standard for the diagnosis of active HBV infection remains serological testing and 
confirmation by enzyme immunoassays (EIAs). Testing for HBsAg in the patient’s blood is a reliable marker 
of active HBV infection as it is produced in large quantities during most HBV infections and secreted in the 
bloodstream from infected hepatocytes. Once the presence of active HBV infection is determined, other 
markers can be tested to give a better clinical picture of the stage of infection and to better monitor disease 
progression.  
Acute HBV infection is diagnosed by positive HBsAg and anti-HBc IgM tests. It will resolve within six months 
and a patient receiving a repeat test after that timeframe will be negative for HBsAg, positive for anti-HBc 
IgG, which is a marker of past exposure to HBV, and positive for anti-HBs, which is a marker of immunity. 
The presence of anti-HBs alone (in the absence of anti-HBc) usually indicates artificial immunity, either 
actively acquired through vaccination or passively acquired through the administration of protective anti-HBV 
antibodies, commonly called HBV immune globulin (HBIG).  
A person positive for HBsAg for more than six months is said to have a chronic HBV infection. In this person, 
serum HBeAg provides an indication that the virus is actively replicating and that the infected person is highly 
infectious. Antibodies to the HBV core antigen indicate whether the patient has an acute infection (positive for 
IgM antibodies) or past exposure which could have resolved or become chronic (positive for IgG antibodies), 
although some CHB patients may present with flares of anti-HBc IgM antibodies. Antibodies to the envelope 
antigen usually develop in the later phase of CHB and are associated with lower levels of viral replication, 
although some anti-HBe positive patients may be infected with HBV mutant strains that are highly replicative 
(Jammeh, Tavner, Watson, Thomas & Karayiannis, 2008; Tong, Li, Vitvitski & Trépo, 1990). In addition to 
serological testing, molecular testing can also be used to monitor patients by testing for the serum HB viral 
load using quantitative real-time PCR.  
While these tests are reliable and robust, they are not widely available in SSA, partly because of the level of 
technical expertise that is required to conduct such tests and also because of the prohibitive cost of performing 
such tests. In many SubSaharan African countries, centres with such facilities are limited to cities and the tests 
may not be routinely performed or may not be accessible to all (Andriamandimby, Olive, Shimakawa, 
Rakotomanana, Razanajatovo, et al., 2017). Therefore, to increase diagnosis of CHB cases in this endemic 
setting, the utilisation of point-of-care tests that can be used as screening tools is highly desirable. 
 Hepatitis B surface antigen POC testing 
Point-of-care testing refers to the use of a test that will provide a result quickly so that a diagnosis can be 
provided to the patient being tested during the same session or on the same day. The field of POCT has rapidly 
progressed in the past forty years as research has focused on translational medicine, from the laboratory to the 
bedside and beyond, especially in resource-limited countries.  
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The ASSURED (Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and 
Deliverable) criteria were developed by the WHO to evaluate POCTs (Peeling, Holmes, Mabey & Ronald, 
2006). According to the ASSURED criteria, the ideal point-of-care test needs to have a short turnaround time 
(typically less than 30 minutes) so that the patient can be linked to care immediately if required and therefore 
follow-up losses minimised (rapid). It also needs to be stable at room temperature and not need refrigerated 
storage for at least one year (robust). This is especially relevant to SSA, where ambient temperatures in certain 
countries can be around 30°C all year round. The test itself needs to be sensitive so that the number of false 
negatives and, therefore, the number of undiagnosed infected patients, is minimised and specific so as to 
minimise the number of false positives and so that the results can be confidently communicated to the patient. 
The tests should also require minimal training so that they may easily be performed by non-technical staff and 
therefore be accessible to a larger number of end users (user-friendly). Moreover, the POCT should be simple 
enough to be used in resource-limited settings and therefore be portable/hand-held (deliverable) and not require 
any complex equipment at any stage of its use, especially to read the result. This is an important requirement 
especially in SSA where some countries have a poor health infrastructure and access to electricity is unreliable 
(equipment-free). Lastly, even if a test meets all the above requirements, it still needs to be affordable so that 
it can be widely used in resource-limited settings where the need for such tests is the greatest. 
These requirements often seem onerous, if not impossible, to achieve for a POCT. However, while some of 
the test requirements are non-negotiable, others may be more flexible. A survey of health care providers on 
the use of POCTs for sexually transmitted infections revealed that the majority of healthcare providers reported 
their ideal POCT needed to have at least a sensitivity of above 90%, low cost, and short turnaround time (Hsieh, 
Gaydos, Hogan, Uy, Jackman, et al., 2011).  
In the context of HBV POC testing, although several commercial tests are currently available for some of the 
HBV markers listed in section 2.4.1, few have been validated for use in SSA. For example, a test for HBeAg 
detection has been shown to have poor sensitivity when tested on West Africans, limiting its use in SSA (Seck, 
Ndiaye, Maylin, Ndiaye, Simon, et al., in press). A loop-mediated isothermal amplification assay (LAMP) 
assay has also been described for the semi-quantification of HBV DNA across genotypes A–F and had 
sensitivity and specificity of 75.7% and 92.0%, respectively, for viral loads of 2,000 IU/ml and sensitivity and 
specificity of 98.0% and 92.6%, respectively, for viral loads of 200,000 IU/ml but still needs to be validated 
in the field (Vanhomwegen, Kwasiborski, Sauvage, Boizeau, Hoinard, et al., 2018). 
For HBV screening purposes, however, HBsAg testing remains sufficient. There are several commercial tests 
available, although the Determine™ HBsAg test remains the best-studied one and appears to fulfil most of the 
ASSURED criteria. It provides a result after 20 minutes of incubation, has a shelf-life of 18 months and can 
be stored at 2–30°C (rapid and robust). It is inexpensive (< $2), does not require sophisticated equipment to be 
operated, is portable, and user-friendly (World Health Organization, 2001). Moreover, a meta-analysis of 
different POCTs for HBsAg reported that the Determine™ HBsAg test had a very high sensitivity (97.6 % 
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(95% Crl: 96.3–98.6 %) and specificity 99.7 % (95% CrI: 99.2–99.9 %) (Shivkumar, Peeling, Jafari, Joseph 
& Pai, 2012). In contrast, in the same study, the authors found that the other HBsAg POCTs assessed 
(Dainascreen, Serodia, Hybritech, DRW, Virucheck, Hexagon, Cypress, Hepacard, Genedia, Daewoong, SD, 
Asan, One Check, Accurate, Acon, Atlas, Intec, Blue Cross, DIMA, and Cortez) had a lower pooled sensitivity 
(94.8%, 95% CrI: 90.1–98.2) and specificity (99.5%, 95% CrI: 99.1–99.9), making them less attractive options 
for HBV screening. The Determine™ HBsAg test retains its high sensitivity with samples containing HBV 
variants with mutations that usually make their detection difficult (Hirzel, Pfister, Gorgievski-Hrisoho, 
Wandeler & Zuercher, 2015). However, its sensitivity has been found to be lower in field trials in The Gambia 
(88.5%, 95% CI; 80.7–93.9%) (Njai, Shimakawa, Sanneh, Ferguson, Ndow, et al., 2015) and Zambia (87.9%, 
95% CI; 77.5–94.6) (Chisenga, Musukuma, Chilengi, Zürcher, Munamunungu, et al., 2018), although the false 
negatives were all patients with low HBsAg titres and low HB viral loads, respectively. These findings can be 
further explained by the limit of detection of the Determine™ HBsAg test, which is between 1 and 2 IU/ml 
(Servant-Delmas, Duong, Hamon, Houdah & Laperche, 2015) compared to the limit of detection of the EIA 
gold standard which is 0.05 IU/ml. 
It should be mentioned that the WHO procurement eligibility for HBsAg POCTs requires that such tests have 
a sensitivity of ≥ 99% and specificity of ≥ 98%. With regard to analytical sensitivity, tests submitted to WHO 
prequalification (PQ) for use as screening tests in asymptomatic and symptomatic individuals require an 
analytical sensitivity of at least 4 IU/ml using the WHO 1st International Reference Preparation for HBsAg as 
a measure of HBsAg concentration. Those tests that pass this first PQ round are then tested on the WHO 
HBsAg specimen reference panel, HBsAg positive lot-to-lot variation panel, HBsAg seroconversion panel, 
HBsAg low titre performance panel, HBsAg mutants panel (World Health Organization, 2010). If an HBsAg 
test meets those laboratory requirements, the WHO recommends its use for screening of symptomatic and non-
symptomatic individuals if it satisfies other bureaucratic requirements. In South Africa, the Determine™ 
HBsAg test has been validated for use in a laboratory setting (Kariem, Chotun, Preiser & Andersson, 2015) at 
the Division of Medical Virology, Stellenbosch University, which is currently accredited as a WHO PQ 
evaluation laboratory (World Health Organization, 2018) but its performance in the field has not been fully 
investigated. 
In addition to conforming to the ASSURED criteria, it is also imperative to investigate the barriers to testing 
before a POCT is introduced so that they may be addressed prior to or at the time of implementation. A survey 
conducted on healthcare providers suggests that the biggest barriers to implementation of a POCT are time 
constraints, interruption of workflow, and reluctance of some patients to getting a finger prick (Hsieh, Hogan, 
Barnes, Jett-Goheen, Huppert, et al., 2010). However, the majority of respondents in that survey belonged to 
high-income countries where the perceived barriers may be different from the ones seen in low-and-middle 
income countries such as South Africa (Pai, Vadnais, Denkinger, Engel & Pai, 2012). It is therefore important 
for such surveys to be conducted in this setting to evaluate the feasibility of implementing HBV POC testing. 
Stellenbosch University  https://scholar.sun.ac.za
 18 
 
2.4.2.1 Implementation 
Before a screening test is implemented, it also needs to conform to certain criteria, known as the Wilson-
Jungner principles, devised in 1968 (Wilson, Jungner & World Health Organization, 1968). These principles 
are: 
2.4.2.1.1 The health problem needs to be an important issue 
The importance of a health problem can be measured in terms of its prevalence in the community where the 
screening test is to be implemented as well as its long-term consequences for the affected individual. However, 
even if the disease in question has a low prevalence but has severe consequences for the affected individual, it 
is still regarded as a relevant and important public health problem. 
Hepatitis B virus in South Africa fits both these descriptions. HBV is endemic to South Africa although its 
prevalence differs between the different provinces (Dusheiko et al., 1989; Ive et al., 2013; Kew, 1996). In 
addition, it can have severe consequences if not detected early as described in section 2.3.2.2 (Long-term 
consequences of CHB). 
2.4.2.1.2 Screening needs to improve the prognosis of those diagnosed 
This second criterion looks at whether treatment of those patients in whom the disease is detected at an earlier 
stage will result in a better prognosis (alters the outcome of the disease) compared to waiting for the patients 
to come forward of their own accord once they experience signs and symptoms of the disease. If early detection 
and management do not lead to an improved prognosis, then the test is of little use. 
In the case of HBV, it must be noted that the screening test could detect the presence of active infection at the 
pre-symptomatic stage before it progresses to cirrhosis or HCC. What should also be considered is that HBV 
is a largely asymptomatic disease and that symptoms only manifest when disease progression is under way. 
Even then, the symptoms tend to be so non-specific that HCC is rarely diagnosed in the early neoplastic stages, 
especially in resource-limited settings such as South Africa. In fact, the incidence of HCC mirrors mortality 
(Ervik et al., 2016) as most cases are diagnosed too late for any curative therapy (Kew, 2012). Even if HCC is 
diagnosed in the early stages and treated, more than half of patients undergoing liver resection will suffer from 
a recurrence within two years of surgery (Tabrizian, Jibara, Shrager, Schwartz & Roayaie, 2015) and five-year 
survival rates can be as low as 32% (Fong, Sun, Jarnagin & Blumgart, 1999). Therefore, testing for HBV 
becomes particularly important in the light of those observations and the POCT has a high prognostic value if 
used on a population where HBV is known to be endemic. 
2.4.2.1.3 There should be appropriate facilities for diagnosis and treatment of the disease 
This criterion is critical to the success of a screening programme. Once a patient is found to be positive on a 
screening test, there must be appropriate healthcare facilities where patients can be followed-up and receive 
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treatment once their diagnosis is confirmed. In the context of HBV in South Africa, EIA testing is available to 
confirm the HBV POCT results serologically and HB viral load testing is also available to help the clinical 
evaluation of the patient and to monitor disease progression (Chotun et al., 2017). The treatment for CHB is 
lifelong and consists of 300 mg tenofovir tablet daily. This treatment is also available to South Africans with 
CHB at the same healthcare facilities where they are followed-up (Chotun et al., 2017). 
The management of CHB patients in South Africa is undertaken by gastroenterologists at tertiary healthcare 
facilities countrywide to monitor CHB patients using implemented treatment protocols (Chotun et al., 2017). 
However, access to such specialists is limited in much of SSA and restricted to specific centralised health 
centres, raising the concern that there may be insufficient personnel to properly manage all newly diagnosed 
CHB patients if HBV POC testing is implemented (Andriamandimby et al., 2017). A potential solution to this 
problem would be the development of guidelines for management of CHB patients at primary health care 
(PHC) level by registered nurses or general practitioners, as has been successfully demonstrated for HIV in 
South Africa (World Health Organization & Médecins Sans Frontières South Africa, 2003) and SSA (Kredo, 
Adeniyi, Bateganya & Pienaar, 2014; Kredo, Ford, Adeniyi & Garner, 2013). In Australia, CHB management 
guidelines have been developed and successfully implemented as part of a larger programme for HBV 
education and CHB screening and monitoring at PHC level. However, this programme is guided by a 
stratification algorithm that allows primary PHC providers to determine the HCC risk of their CHB patients 
(Robotin, Kansil, Porwal, Penman & George, 2014). Before such guidelines can be developed for SSA, a better 
understanding of the risk factors of HCC in this setting is therefore required. 
2.4.2.1.4 The disease should be detectable at an asymptomatic stage 
There must be a latent period during which the disease can be identified and successfully managed or treated. 
In the case of chronic diseases, there will be a phase during the early stages of the disease where it is 
asymptomatic but can still be detected. This is the golden opportunity phase where the disease can be detected 
early enough so that it can be managed and treated before the appearance of symptoms and further disease 
progression. 
HBV has an asymptomatic stage during which the virus produces large quantities of HBsAg that can be 
detected using a POCT. In fact, this latent period can last for many decades without significant liver damage 
or disease progression (Chang, Hwang, Hsu, Lee & Beasley, 1988; Hui, Leung, Yuen, Zhang, Leung, et al., 
2007; Lok & Lai, 1988). A test screening for active HBV infection can therefore help in the detection of the 
disease decades before it progresses to cirrhosis and HCC. 
2.4.2.1.5 There should be a suitable test available to detect the disease 
There is indeed, as has been described in detail under section 2.4.2 (HBsAg POC testing). 
2.4.2.1.6 The test should be acceptable to the population 
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The test available for screening should be acceptable to the population both in terms of what it is testing for 
and the way in which it is performed. A Gambian study has shown that the test was accepted and uptaken by 
68.9% (95% CI, 65.0%–72.4%) of approached community members (Lemoine, Shimakawa, Njie, Taal, Ndow, 
et al., 2016). Although no such studies have been carried out in South Africa, a study of HIV-1 POC testing 
offered to community members attending the emergency department showed that 72.8% of approached 
individuals accepted to be tested (Hansoti, Stead, Parrish, Reynolds, Redd, et al., 2018), suggesting that if a 
similar test, such as an HBV POCT, was offered, it would be readily accepted. However, since HBV is 
generally unknown in an African setting (Malungu Ngaira, Kimotho, Mirigi, Osman, Ng’ang’a, et al., 2016), 
informational and educational campaigns would be required prior to the introduction of any HBV POCT as 
well as appropriate training programmes for the nursing staff and other healthcare providers who will provide 
the test so that they may provide adequate counselling to their patients. 
2.4.2.1.7 There should be an accepted and effective treatment for those diagnosed  
There is currently no cure for CHB but there is effective lifelong therapy available for treatment of patients 
with CHB. Nucleos(t)ide inhibitors such as lamivudine, tenofovir, and entecavir are accepted treatments for 
HBV (Lok, McMahon, Brown, Wong, Ahmed, et al., 2016). Antiviral treatment has been shown to reverse 
cirrhosis and to improve the lifespan of CHB sufferers (Marcellin, Gane, Buti, Afdhal, Sievert, et al., 2013). 
2.4.2.1.8 The natural history of the disease should be understood 
The natural history of HBV infection is well understood (section 2.3) although there are still gaps in the 
knowledge. However, based on current knowledge, patient monitoring and management are feasible and 
justifiable (section 2.3.3). 
2.4.2.1.9 There should be a policy on whom to treat as patients 
There are several guidelines available from international organisations such as the WHO (World Health 
Organization, 2015), the European Association for the Study of the Liver (EASL) (Lampertico et al., 2017), 
the American Association for the Study of Liver Diseases (AASLD) (Terrault et al., 2018), and The Asian 
Pacific Association for the Study of the Liver (APASL) (Sarin et al., 2016) describing standard of care of 
treatment and the criteria of those who qualify for treatment as has been described in detail in section 2.3.3
 (Management of chronic HBV infection). 
2.4.2.1.10 The screening programme should be cost-effective 
Economic evaluation studies comparing the costs of implementation with the health benefits (short- and long-
term) to the tested population are able to give an approximation of the cost-effectiveness of a screening 
programme. This information can then be used to compare different possible health interventions to determine 
which ones should be implemented. However, carrying out cost-effectiveness studies in countries with limited 
resources can be tricky as every cost needs to be researched and calculated individually at the location of 
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implementation since these data are rarely available online (as is the case in more developed countries). In the 
case of HBV screening, the costs would involve the rapid test, the additional resources required to implement 
testing (although these can be mitigated by merging HIV and HBV testing, hence existing resources including 
the nurses can be used as both HIV and HBV POCTs follow the same testing principles), the cost of follow-
up testing every six months if found positive, the cost of lifelong treatment if qualifying for treatment, and the 
initial information campaigns needed to inform the public about hepatitis B and its long-term consequences. 
The benefits can be measured in terms of disability-adjusted life years (DALYs) and quality-adjusted life years 
(QALYs). In The Gambia, a cost-effectiveness study, where the HBsAg prevalence is 8.8%, showed an adult 
screen-and-treat programme had an incremental cost-effectiveness ratio (ICER) of $540 per DALY averted, 
$645 per life-year saved, and $511 per QALY gained, compared with current practice, which was considered 
to be cost-effective as it was within one times the country’s gross domestic product (GDP) per capita ($487) 
per DALY averted (Nayagam, Conteh, Sicuri, Shimakawa, Suso, et al., 2016). A recent South African study 
has shown that the implementation of a Hepatitis Action Plan that includes HBV POC testing within its 
framework had an overall ICER of $3310 per DALY averted, which was considered acceptable value-for-
money as it was below the more stringent benchmark of half GDP per capita ($3810) per DALY averted. 
Moreover, the screen-and-treat HBV intervention for pregnant women alone within this action plan had an 
ICER of $5021 per additional DALY averted which was still within one times of South Africa’s GDP per 
capita ($7620) and therefore, still cost-effective (Hecht, Hiebert, Spearman, Sonderup, Guthrie, et al., 2018). 
2.4.2.1.11 Screening should be an ongoing process and not a one-off event 
The screening test should not be offered as part of a one-off drive or campaign. Case finding should be 
introduced in such a way that it becomes part of normal health care services offered to the public. 
WHO guidelines recommend integrating viral hepatitis testing with existing infrastructure (World Health 
Organization, 2017c). In South Africa, HBV POC testing could easily be integrated with HIV testing services 
already in place. Importantly, it can also be integrated with HIV PMTCT programmes to identify pregnant 
women at risk of transmitting HBV to their children. Counsellors already performing HIV testing could be 
trained to conduct HBV POC testing and the associated pre- and post-test counselling, as has previously been 
done in India, where counsellors with experience in HIV testing were also successfully trained to provide HCV 
pre- and post-test counselling and testing (World Health Organization, 2017c). Long-term, to be more cost-
effective, it is also possible to envisage using multiplex POCTs combining testing for both HIV and HBV 
(Robin, Mboumba Bouassa, Nodjikouambaye, Charmant, Matta, et al., 2018). 
2.5 HBV-related HCC 
Hepatocellular carcinoma is the most common form of primary liver cancer that arises from liver diseases such 
as cirrhosis and chronic viral hepatitis (B and C). It is a major cause of morbidity and mortality worldwide–it 
is the seventh most common cause of cancer and the second leading cause of cancer deaths (Ferlay, 
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Soerjomataram, Dikshit, Eser, Mathers, et al., 2015). It accounts for 5.6% (782 500/14 090100) of all new 
human cancers (excluding non-melanoma skin cancer) with an estimated 782 500 incident cases annually 
(Ferlay et al., 2015). HCC cases are often diagnosed during the terminal stages of diseases, such that incidence 
reflects mortality rates (Ervik et al., 2016). However, these values largely underestimate the real incidence of 
this particular cancer in SSA because of the lack of data from most African countries but also the quality of 
data utilised for those estimates. Cancer registries for example, only record histologically diagnosed cases of 
HCC (Kew, 2012). As a result, HCC is underreported because it is often diagnosed too late to necessitate a 
biopsy for confirmation of the diagnosis. 
 Epidemiology of HBV-related HCC 
2.5.1.1 Globally 
The global incidence of HBV-related HCC varies geographically. For example, in the developed world, HBV-
related HCC is overshadowed by lifestyle risk factors contributing to HCC, such as excessive alcohol 
consumption, obesity, and diabetes. However, in the developing world, HBV-related HCC plays a far more 
important role and accounts for more than 75% of all HCC cases (Baecker et al., 2018; Di Bisceglie, 2009; 
Ferenci et al., 2010; Maucort-Boulch et al., 2018).  
In Europe, a discordant trend is observed, and in countries such as Italy and Spain, chronic HCV infection is 
the main cause of HCC, whereas in countries such as Germany and Austria non-viral hepatitis causes of HCC 
lead, while Greece has a high prevalence of HBV-related HCC (Baecker et al., 2018; Maucort-Boulch et al., 
2018). 
In Asia, the incidence of HBV-related HCC seems to be higher in countries such as China, Taiwan, and South 
Korea but in contrast, HCV appears to be the primary aetiology of HCC in Japan (Baecker et al., 2018; 
Maucort-Boulch et al., 2018). Taiwan has experienced a remarkable reduction in HCC rates ever since the 
introduction of HBV vaccination in 1984. A nationwide study in Taiwan conclusively showed a significant 
decrease in annual incidence of HCC in children aged 6–14 years who were immunised against HBV at birth, 
from 0.70/100 000 prior to the introduction of the HBV vaccine to 0.36/100 000 10 years after its introduction 
(Chang, Chen, Lai, Hsu, Wu, et al., 1997). This success story demonstrates that the implementation of 
appropriate health measures to prevent HBV infection in areas where it is endemic will lead to a significant 
reduction in incidence of HCC. 
2.5.1.2 Africa 
In SSA, the data suggest that the highest burden of HCC is in West Africa, with an annual age-standardised 
incidence of 12.1/100 000, and the lowest in Eastern Africa, with an annual age-standardised incidence of 
4.0/100 000 (Ervik et al., 2016). In West Africa, The Gambia seemed to have the highest age-standardised 
incidence rate (25.8/100 000), although this could be an artefact caused by “over-reporting” in comparison to 
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other neighbouring West African countries. Studies on HBV have been carried out in The Gambia since 1973 
and the Prevention of Liver Fibrosis and Liver Cancer in Africa consortium has been present in The Gambia 
since 2011 (Howell, Ladep, Nayagam, Lemoine, Garside, et al., 2016), suggesting they have better diagnostic 
and reporting mechanisms for HCC than other African countries. 
2.5.1.3 South Africa 
Countrywide data on HCC in South Africa are sparse and incomplete as only histologically diagnosed liver 
cancer cases are recorded. In fact, a study from the Western Cape, South Africa, showed that only 30% of 
HCC cases were diagnosed histologically (Maponga, 2016). 
Moreover, the South African cancer registry provides annual incidence of liver cancer combined with bile duct 
cancer. In 2014, 248 cases of liver and bile duct cancers were histologically diagnosed in South African males 
and 165 in South African females. Of those, 148 were diagnosed in Black males, 22 in black Coloured males, 
63 in Caucasian males. In Black males, the highest frequency was observed in the 45-49 years age group and 
in Caucasian males, the 75-79 years age group (South African National Cancer Registry, 2014). 
 Diagnosis of HCC 
HCC is often diagnosed in the late stages because the lack of characteristic signs and symptoms makes its 
diagnosis difficult (Kew, Dos Santos & Sherlock, 1971). Consequently, patients tend to present at a late stage 
where only palliative treatment can be offered (Kew, 2012). The median survival time following diagnosis is 
6–20 months (The Cancer of the Liver Italian Program (CLIP) Investigators, 1998). Methods of HCC diagnosis 
depend on the size of the liver lesion at time of diagnosis and whether imaging modalities are sufficient for 
diagnosis or need to be confirmed histologically by performing a biopsy of the lesion. 
 
2.5.2.1 Clinical features 
Patients with HCC commonly present with symptoms indicative of their underlying chronic liver disease, for 
example, splenomegaly, ascites, jaundice, variceal bleeding. Some patients may present with mild abdominal 
pain, weight loss, feeling full after eating a few bites, or a palpable mass in the abdomen (Barghini, Donnini, 
Uzzau & Soardo, 2013). 
Laboratory testing for HCC is often non-specific although abnormal liver function test results will be observed. 
Some patients present with low serum albumin levels, high bilirubin levels, high aminotransferase, alkaline 
phosphatase, and gamma-glutamyl transpeptidase levels, but not consistently (Lopez, Balasegaram, 
Thambyrajah & Timor, 1996). The benefit of these tests is to monitor disease progression over time once a 
diagnosis has been made. 
2.5.2.2 Imaging methods for HCC diagnosis 
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In SSA, including South Africa, where HCC patients present at a late stage, HCC is usually diagnosed using 
imaging techniques. The imaging tests most commonly used in HCC diagnosis are ultrasounds and computed 
tomography (CT) scans (Kew, 2012). 
Ultrasonography is not considered a sensitive method of diagnosis as it cannot differentiate between HCC and 
other solid liver tumours. However, it is widely available in an African setting, non-invasive, and less 
expensive than other imaging modalities. Suspicious lesions observed on an ultrasound still need to be 
confirmed by other radiologic methods. A computed tomography (CT) scan of the liver is usually performed 
to confirm the nature of suspicious lesions observed on ultrasound. A meta-analysis has shown that the 
sensitivity and specificity of CT scans in the diagnosis of HCC were 83% (95% CI 46%-90%) and 91% (95% 
CI 86%-96%), respectively (Chou, Cuevas, Fu, Devine, Wasson, et al., 2015). 
Magnetic resonance imaging (MRI) can be used in the diagnosis of HCC and provides high-resolution images 
of the liver without the use of contrast agents or ionizing radiation. However, its use in an African setting 
remains limited due to its high cost.  
2.5.2.3 Serological markers of diagnosis 
The most commonly used marker in HCC diagnosis is alpha-fetoprotein (AFP). AFP is a glycoprotein normally 
produced during gestation by the foetal liver and yolk sac and its serum concentration is often elevated in HCC 
patients. However, elevated levels of AFP in adults are not specific to HCC. Elevated AFP levels are also 
observed in pregnant women and in patients with chronic liver disease. AFP is also not produced by all HCCs 
(Chen, Sung, Shed, Lai, How, et al., 1984). Although AFP has been largely considered to be an unreliable 
marker of HCC elsewhere (Forner, Reig & Bruix, 2009; Sherman, 2001), in SSA, where most HCC cases are 
caused by HBV, it remains an important non-invasive marker (Kew, van Staden & Bellingan, 1995). Moreover, 
if used in conjunction with ultrasound, the diagnostic sensitivity is increased from 71% to 79% (Sherman, 
Peltekian & Lee, 1995). The ability of AFP to predict the presence of HCC therefore depends on the population 
being tested and appropriate cut-off values have to be developed according to the population at risk of HCC 
development and the underlying cause of HCC. 
Other non-invasive markers are currently being investigated although none are recommended for diagnostic 
use or surveillance. MicroRNAs have shown some promise with a panel of six microRNAs (miR-122, miR192, 
miR-21, miR-223, miR-26a, and miR-801) accurately identifying HCC patients with a sensitivity of 82% and 
specificity of 84% and capable of distinguishing patients with HCC from those who were healthy, had CHB, 
or had cirrhosis (Zhou, Yu, Gao, Hu, Wang, et al., 2011). Other promising serological markers include Lens 
culinaris agglutinin-reactive AFP (AFP-L3), an AFP isoform and des-gamma-carboxy prothrombin (Carr, 
Kanke, Wise & Satomura, 2007). Des-gamma-carboxy prothrombin was shown to have a sensitivity of 74% 
and specificity of 86% in detecting early-stage HCC. When combined with AFP, its diagnostic sensitivity 
increased to 91% but the specificity decreased to 74% (Lok, Sterling, Everhart, Wright, Hoefs, et al., 2010). 
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These markers need to be externally validated in different populations so their diagnostic potential can be fully 
elucidated.  
2.5.2.4 Histological diagnosis 
Biopsies are not usually recommended unless the imaging results are inconclusive and non-invasive methods 
of assessing fibrosis are unavailable (Russo, Imondi, Lynch & Farinati, 2018; Terrault et al., 2018). There are 
risks associated with performing biopsies such as bleeding and seeding of tumour cells along the biopsy tract 
although this is considered minimal (Durand, Regimbeau, Belghiti, Sauvanet, Vilgrain, et al., 2001).  
Core biopsies are considered to be more useful than fine-needle biopsies because of the increased amount of 
tissue and the potential of obtaining non-neoplastic liver tissue to aid diagnosis. The histologic appearance of 
HCC can range from well-differentiated with minimal cytologic atypia to undifferentiated with spindle or 
round-shaped cells (Martins-Filho, Paiva, Azevedo & Alves, 2017). In cases where lesions cannot be 
characterized by haematoxylin and eosin (H&E) staining and microscopy alone, tumour markers such as 
CD34, CK7, glypican 3, Hsp70, and glutamine synthetase can help with the diagnosis (Zimmermann, 2017). 
2.5.2.5 HCC surveillance and models of early diagnosis 
Whilst the HBV vaccine was introduced to the South African EPI in 1995, its long-term benefits, namely HCC 
prevention, will not be seen for at least another ten to twenty years when the first generation of vaccinated 
children reaches the at-risk age group of 30 years and older. Meanwhile, men who did not have access to the 
HBV vaccine and who have CHB are at high risk of developing HCC.  
As HCC patients can be asymptomatic or present with non-specific symptoms until they reach an advanced 
stage of disease, screening for HBV infection and enrolling those who are HBV-positive in an HCC 
surveillance program could potentially identify those at high risk of HCC development and help to diagnose 
the cancer at an early stage. A previous randomized controlled trial found a 37% reduction in mortality rate 
after HCC surveillance with ultrasound and AFP over a five-year follow-up period in patients with CHB 
compared to patients with no surveillance. Moreover, 60.5% of HCC cases were diagnosed at the sub-clinical 
stage in the HCC surveillance group versus 0% in the non-surveillance group (Zhang, Yang & Tang, 2004). 
Such surveillance programmes would be of particular importance in SSA where HCC presents mainly in 
African men early in life (Kew & Macerollo, 1988; Yang et al., 2017; Yang & Roberts, 2010) and more than 
40% of HCC patients will be diagnosed before the age of 40 (Yang et al., 2015). This is in contrast to Asia, 
where the risk of HCC increases with age and is more prevalent in men in their fifties and above (Beasley, 
Hwang, Lin & Chien, 1981; Yang et al., 2017). Developing cancer in mid-adulthood puts a drain on health 
care resources as well as income in low- and middle-income families, further adding to the importance of better 
understanding this malignancy and setting up screening procedures for HBV and HCC surveillance in high-
risk groups. 
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Ideally, an individualised approach to assess a patient’s HCC risk is desired. If HCC risk could be accurately 
predicted in HBV-positive patients, the surveillance procedures could be adapted to fit that particular patient’s 
profile. In Asia, algorithms have been developed to predict risk of HCC within a 3-year, 5-year and 10-year 
period and have been validated in Asian populations (Hsu, Yip, Ho, Wong, Huang, et al., 2018; Wong et al., 
2010; Yang et al., 2011; Yuen et al., 2009). These simple models use patient demographics (age, sex), disease 
factors (ALT levels) and virological factors (presence of core mutations, hepatitis B viral loads) that can be 
obtained through laboratory testing to predict risk of HCC. However, these models have not been externally 
validated and have been shown to have limited use in a non-Asian population (Arends, Sonneveld, Zoutendijk, 
Carey, Brown, et al., 2015) as certain factors (such as older age and genotype B/C) that are considered major 
predictors of HCC development in Asian populations are not risk factors elsewhere. 
As there is currently no such risk score available for an African population, there is a need to first identify 
HCC risk factors in this population that could in future be incorporated in similar prediction models for African 
patients.  
 Risk factors of HBV-related HCC 
2.5.3.1 HBV-associated risk factors 
There are several known viral risk factors associated with HBV infection such as HBeAg status, HBV 
genotype, viral load, and specific mutations within the viral genome that influence disease progression and 
risk of HCC.  
Patients who remain HBeAg positive for long periods of time are 60.2 times more likely to develop HCC than 
those negative for both HBsAg and HBeAg (Yang, Lu, Liaw, You, Sun, et al., 2002) and an increase in survival 
rate has been associated with HBeAg clearance (Chu, Hung, Lin, Tai & Liaw, 2004; Lin, Yu, Lee, Chien, 
Sheen, et al., 2007; Niederau, Heintges, Lange, Goldmann, Niederau, et al., 1996). This could be linked to the 
repeated exacerbations observed in certain patients during the immune-active HBeAg positive phase of CHB 
leading to hepatic inflammation and subsequent injury. HBV DNA levels have also been shown to be 
associated with an increased incidence of HCC, independent of other risk factors, including HBeAg (Chen, 
Yang, Su, Jen, You, et al., 2006). In patients who are in the immune-active HBeAg negative phase of CHB, 
HBsAg levels ≥ 1000 IU/mL, even in patients with low HB viral loads, have been associated with increased 
risk of disease progression and HCC (Tseng, Liu, Yang, Su, Wang, et al., 2012, 2013). 
Studies on Asian subjects infected with HBV genotype B or C have found mutations in the BCP (Yin, Xie, 
Liu, Zhang, Han, et al., 2011) and precore regions and pre-S deletions (Liu, Zhang, Gu, Yin, He, et al., 2009) 
which are thought to play a role in the evolution of HCC. These mutations have also been described in African 
subjects in association with HCC (Baptista, Kramvis & Kew, 1999; Kramvis, 2008; Ochwoto, Chauhan, 
Gopalakrishnan, Chen, Ng, et al., 2013). 
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Kew et al., 2005 reported the impact of HBV genotype on HCC development in South Africa showing that 
genotype A presents 4.5-fold increased risk of HCC, as compared to non-A genotypes. Genotype A has also 
been associated with increased fibrosis in Gambian patients (Shimakawa et al., 2016) although the sample size 
of patients with HBV genotype A in that study was small.  
2.5.3.2 Environmental risk factors 
Established environmental risk factors for HCC include aflatoxin exposure and dietary iron overload (Kew, 
2013). Dietary iron overload is thought to occur due to the excessive consumption of traditional home-brewed 
beer prepared in non-galvanized iron drums and was associated with a 10.6-fold risk of HCC (95% CI: 1.5%–
76.8%) (Mandishona, MacPhail, Gordeuk, Kedda, Paterson, et al., 1998). 
Aflatoxin is a metabolite produced by the fungi Aspergillus flavus and Aspergillus parasiticus and together 
with HBV has a multiplicative impact on the risk of developing HCC (Kew, 2003). It contaminates foodstuffs 
such as corn, rice and peanuts. Aflatoxin B1 (AFB1) covalently binds to guanine and cytosine residues of DNA 
and forms AFB1-DNA, ribonucleic acid (RNA) and protein adducts which impair DNA, RNA and protein 
synthesis. Mutations of the p53 tumour suppressor gene (TP53) are the most frequently observed gene mutation 
in human cancers. The evidence suggests that aflatoxin exposure and HCC are associated with mutations in 
TP53 such as a point mutation at the third position of codon 249 resulting in an amino acid change from 
arginine to serine due (commonly referred to as the R249S mutation) (Bressac, Kew, Wands & Ozturk, 1991; 
Hsu, Metcalf, Sun, Welsh, Wang, et al., 1991). Mitotic recombinations and genetic instability are other 
mechanisms whereby aflatoxin may contribute to the development of HCC (Zhang, 2010). The highest 
prevalence of the mutation has been reported in Senegal (67% – Coursaget, Depril, Chabaud, Nandi, Mayelo, 
LeCann & Yvonnet, 1993), Mozambique (53% – Ozturk, 1991), and The Gambia (35% – Szymańska, Lesi, 
Kirk, Sam, Taniere, Scoazec, Mendy, Friesen, Whittle, Montesano & Hainaut, 2004). South Africa, on the 
other hand, may have a lower prevalence of the R249S mutation (18% – Kimbi, Kew, Yu, Arakawa & 
Hodkinson, 2005) because of the lower risk of exposure to dietary aflatoxins (Carr & Cooper, 1997). Another 
study from the Gambia reported on the co-occurrence of the R249S mutation and the full integration of the 
HBx sequence in the genome (Gouas, Villar, Ortiz-Cuaran, Legros, Ferro, et al., 2012). In SSA, high 
prevalence rates of HIV, HBV and aflatoxin exposure overlap and may lead to a dramatic increase in the 
incidence of HCC. 
2.5.3.3 Socio-economic/Lifestyle risk factors 
Alcohol misuse is a well-known independent risk factor of HCC and can account for as many as half of all 
HCC cases in developed countries (Hellerbrand, Hartmann, Richter, Knöll, Wiest, et al., 2001). A meta-
analysis showed that consuming 25 g of alcohol per day was significantly associated with liver cirrhosis 
(relative risk [RR] = 2.90; 95% CI:2.71–3.09%) and liver cancer (RR = 1.19; 95% CI:1.12%–1.27%) and that 
these risks increased with higher daily alcohol consumption (Corrao, Bagnardi, Zambon & La Vecchia, 2004). 
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Similarly, a South African study has previously shown alcohol misuse to be a risk factor for HCC, independent 
of HBV status (Mohamed, Kew & Groeneveld, 1992). The same study also found that there was an additive 
risk for HCC between alcohol abuse and HBV infection. Similarly, a Taiwanese study reported an increase in 
annual incidence of HCC in patients with both HBV and alcoholism (7.8%) compared to patients with HBV 
alone (3.7%) or alcoholism alone (1.9%) (Lin, Lin, Mo, Chang, Perng, et al., 2013). Alcohol-associated HCC 
has been shown to have different DNA methylation levels to HBV-related HCC in certain genes (Hernandez-
Vargas, Lambert, Le Calvez-Kelm, Gouysse, McKay-Chopin, et al., 2010; Lambert, Paliwal, Vaissière, 
Chemin, Zoulim, et al., 2011) which may be one of the pathways affected during hepatocarcinogenesis. Other 
potential pathways include oxidative stress from alcohol metabolism (Seitz & Stickel, 2006) and acetaldehyde 
(a carcinogenic compound) formation (McKillop & Schrum, 2009). 
The effect of smoking on HCC development is less clear especially because of the strong correlation between 
smoking and drinking. While studies have shown a significant association between the two (Chen et al., 2006; 
Chen, Wang, Lu, Wu, You, et al., 1996) that was dose-dependent (Koh, Robien, Wang, Govindarajan, Yuan, 
et al., 2011), other studies have not found significant association between the two (Shimakawa, Lemoine, 
Bottomley, Njai, Ndow, et al., 2015; Tanaka, Hirohata, Takeshita, Hirohata, Koga, et al., 1992), including a 
South African study (Mohamed et al., 1992). However, Mohamed et al. 1992 only tested Black South Africans 
and it is therefore possible that smoking is not a significant risk factor for HCC in this particular demographic, 
especially since they are the lowest consumers of cigarettes in South Africa (Reddy, Zuma, Shisana, Kim & 
Sewpaul, 2015). Meta-analyses have shown a significant odds ratio of 1.55 (95% CI: 1.46 to 1.65; P < 0.00001) 
for HCC development in smokers (Abdel-Rahman, Helbling, Schöb, Eltobgy, Mohamed, et al., 2017) as well 
as an additive interaction between HBV infection and cigarette smoking (Chuang, Lee, Hashibe, Dai, Zheng, 
et al., 2010).  
Obesity and diabetes have also been reported to be independent risk factors of HCC (Dyson, Jaques, 
Chattopadyhay, Lochan, Graham, et al., 2014; Regimbeau, Colombat, Mognol, Durand, Abdalla, et al., 2004; 
Wolk, Gridley, Svensson, Nyrén, McLaughlin, et al., 2001) and a synergistic relationship with HBV infection 
has also been shown with 100-fold risk of HCC in patients with concomitant HBV infection, obesity, and 
diabetes (Chen, Yang, Yang, Liu, Chen, et al., 2008). These are serious risk factors to consider in the South 
African context, where besides the high HBV prevalence, 61% of the population is overweight, obese, or 
severely obese and 2 million have diabetes (Baleta & Mitchell, 2014). 
 
2.5.3.4 Demographics 
HCC affects men more than women worldwide (Akinyemiju, Abera, Ahmed, Alam, Alemayohu, et al., 2017; 
Ervik et al., 2016; Kirk, Lesi, Mendy, Akano, Sam, et al., 2004). In 2012, of the 782 000 HCC incident cases, 
554 000 occurred in men (Ervik et al., 2016). In Africa, the annual age-standardised incidence in men was 
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9.8/100 000 and that for women was 5.2/100 000 (Ervik et al., 2016). The same was observed in South Africa 
where the age-standardised incidence was 6.7/100 000 for men and 3.3/100 000 in women (Ervik et al., 2016). 
The reason for this disparity is poorly understood and it has been suggested that estrogen could play a protective 
role in women (Naugler, Sakurai, Kim, Maeda, Kim, et al., 2007). 
In addition to sex, racial disparities have been reported in HCC development. In America, Black Americans 
were shown to be significantly more likely to develop HCC and have poorer survival rates than Caucasian 
Americans (Sloane, Chen & Howell, 2006). Similarly, in South Africa, previous reports suggest that Black 
and Coloured men are at higher risk of HCC compared to other races (Kew, 2013; Maponga, 2016). This has 
been attributed to their higher exposure to HCC risk factors such as HBV infection and dietary iron overload 
(Kew, 2008; Mandishona et al., 1998).  
In Asia and countries of low HBV endemicity, being older (> 50 years) is an additional risk factor for HCC 
development (Wong et al., 2010; Yang, Sherman, Su, Chen, Liaw, et al., 2010; Yang et al., 2011; Yuen et al., 
2009). In SSA however, 40% of HBV-associated HCC cases develop before the age of 40 (Yang et al., 2015) 
further emphasising the importance of better understanding this disease in an African setting. 
2.5.3.5 HIV co-infection 
There is little evidence to fully support HIV as an independent risk factor for HCC although a previous cohort 
study has shown that immunosuppression in HIV-infected individuals was significantly associated with HCC 
(Clifford, Rickenbach, Polesel, Dal Maso, Steffen, et al., 2008). However, with the discovery and increased 
availability of highly active antiretroviral therapy (HAART), patients with HIV are living longer and liver-
related mortality has become an important cause of death in this group. A large study of 23 441 HIV infected 
people from Europe, the United States and Australia has shown that liver-related death was the most frequent 
cause of non-AIDS-related death (Weber, Sabin, Friis-Møller, Reiss, El-Sadr, et al., 2006). The French 
National Mortalité study showed that liver-related deaths from HCC increased from 15% in 2000 to 25% in 
2005 (Salmon-Ceron, Rosenthal, Lewden, Bouteloup, May, et al., 2009). (Thio, Seaberg, Skolasky, Phair, 
Visscher, et al., 2002) describe an 18-fold increase in the death from liver-related mortality in men from the 
United States who were co-infected with HIV and HBV as compared to those monoinfected with HBV.  
The evidence for such an increase is less clear in SubSaharan Africans. Southern African studies have reported 
higher prevalence of HBV infections in HIV-infected patients (Andersson et al., 2013; Boyles & Cohen, 2011; 
Burnett, Francois, Kew, Leroux-Roels, Meheus, et al., 2005; Firnhaber, Reyneke, Schulze, Malope, Maskew, 
et al., 2008; Maponga, 2016) but previous findings from a meta-analysis suggested this apparent risk would 
probably be modest in comparison to that seen in Western countries (Barth, Huijgen, Taljaard & Hoepelman, 
2010).  
Theoretical mechanisms that might account for an increase in HCC risk include the loss of immune control 
associated with HIV, resulting in higher HBV viral loads and HBeAg positivity (Mayaphi et al., 2012) 
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increasing the risk of HCC. In patients who are on HAART, liver toxicity (Sulkowski 2003; Núñez 2006), 
increased risk of metabolic syndrome (Barbaro & Barbarini 2006; Núñez 2006), Non-alcoholic Fatty Liver 
Disease (NAFLD) (Guaraldi, Squillace, Stentarelli, Orlando, D’Amico, et al., 2008), Non-Alcoholic 
Steatohepatitis (NASH) (Núñez 2006) and immune restoration (Carr & Cooper 1997; Núñez 2006) may 
potentially result in an increase in liver damage, accelerating the development of HCC. It also has been 
postulated that HIV may directly facilitate malignant transformation (Kew, Smuts & Stewart, 2010). Among 
transgenic mice, the HIV trans-activator of transcription (tat) protein expressed in the liver appears to enhance 
the effect of hepatitis viruses. Tat-binding protein interacts with HBx gene to regulate HBV transcription, and 
HBx protein induces HIV-1 replication (Altavilla, Caputo, Lanfredi, Piola, Barbanti-Brodano, et al., 2000).  
2.5.3.6 Epigenetics 
The development of HCC is a multistep process with accumulations of genetic and epigenetic alterations in 
regulatory genes, leading to activation of oncogenes and inactivation or loss of function of tumour suppressor 
genes (Lee, Lee, Kim, Lee, Jang, et al., 2003; Nishida, Nagasaka, Nishimura, Ikai, Boland, et al., 2008). Unlike 
the genetic events, the epigenetic processes are reversible, occur early in the process of evolution of 
malignancy and therefore may be used as markers of early malignant disease and even as targets of future 
therapeutic approaches. Epigenetic changes can occur through three main mechanisms (i) DNA 
hypermethylation leading to inactivation (ii) DNA hypomethylation causing genomic instability and, (iii) 
histone modifications affecting chromatin conformation (Tischoff & Tannapfel, 2008). Characteristically, 
DNA methylation differs from genetic mechanisms in that the DNA is not changed; methylation alters the 
readability of the DNA and results in inactivation of genes through mRNA transcript repression (Tischoff & 
Tannapfel, 2008). 
The Ras association domain-containing protein 1 gene (RASSF1A) is one of the most frequently inactivated 
genes in HCC (Hernandez-Vargas et al., 2010; Hu, Chen, Yu & Qiu, 2010; Yang, Guo, Herman & Clark, 
2003), and hypermethylation of the promoter region of this gene is suspected to be a major inactivation 
pathway (Dammann, Schagdarsurengin, Strunnikova, Rastetter, Seidel, et al., 2003). RASSF1A promoter 
hypermethylation is well-established in HBV-related HCC (Lambert et al., 2011; Zhang, Gao, Yu, Liu, Lu, et 
al., 2014; Zhong, Yeo, Tang, Wong, Lai, et al., 2003) and has been proposed as a biomarker for early HCC 
diagnosis as the gene is rarely found in a methylated form in normal tissue and patients with chronic liver 
disease (Lambert et al., 2011; Lee et al., 2003). 
The inactivation of cyclin-dependent kinase inhibitor 2A (CDKN2A) frequently occurs through promoter 
hypermethylation (Azechi, Nishida, Fukuda, Nishimura, Minata, et al., 2001; Jin, Piao, Kim, Park, Shin, et al., 
2000) and has been shown to occur in the early stage of HCC (Lee et al., 2003) as well as HBV-related HCC. 
This gene codes for two proteins, p16 and p14 by alternate splicing. So far, only CDKN2A/INK4 (p16) has 
been shown to be a true tumour suppressor gene and its silencing has been associated with increased risk of 
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cancer (Rocco & Sidransky, 2001). The hypermethylation of p16 has been suggested to be linked to HBx 
protein expression in patients with HBV-related HCC (Zhu, Zhu, Fan, Pan, Li, et al., 2010). It has also been 
associated with multistep hepatocarcinogenesis in the published literature (Zhang, Ahsan, Chen, Lunn, Wang, 
et al., 2002) and therefore has potential for use as a screening marker in HBV-related HCC (Lee et al., 2003). 
In contrast, global DNA hypomethylation leads to genomic instability, affects repeated DNA sequences 
(Wilson, Power & Molloy, 2007) and increases with tumour progression (Ehrlich, 2002). Long Interspersed 
Nuclear Elements-1 (LINE-1) hypomethylation is known to occur in several cancers including HCC (Gao, Qu, 
Chang, Lu, Bai, et al., 2014; Lin, Hsieh, Sheen, Lee, Chen, et al., 2001) and has been used as a surrogate for 
global hypomethylation which may be an integral part of hepatocarcinogenesis irrespective of aetiology 
(Shitani, Sasaki, Akutsu, Takagi, Suzuki, et al., 2012). 
Several studies have observed preferential hypermethylation of certain target genes, including RASSF1A and 
p16, in HCCs of differing etiologies, such as HBV and HCV infections, but these reports have not been 
consistent (Feng, Stern, Hawes, Lu, Jiang, et al., 2010; Lambert et al., 2011; Lv, Ye, Zhang & Huang, 2017). 
It is possible that this variability is due to differences in the population groups being tested, such as ethnic 
background, geography, and environmental exposures, that are known to influence methylation levels 
(Galanter, Gignoux, Oh, Torgerson, Pino-Yanes, et al., 2017; Lambert et al., 2011). In SSA, two studies 
comparing DNA methylation between South African HCCs and Australian HCCs showed promoter 
methylation in p16 in both populations, although the methylation levels in the South African HCC cases were 
lower than those in the Australian HCC cases (Herath, Kew, Walsh, Young, Powell, et al., 2002a; Herath, 
Purdie, Kew, Smith, Young, et al., 2009). The authors speculated that age at presentation as well as host genetic 
factors could have contributed to the differences in methylation observed confirming that methylation studies 
in African populations are required in order to assess their usefulness as HCC diagnostic biomarkers in this 
setting. 
2.5.3.7 Genetic predisposition 
Besides changes to the epigenome, there is growing evidence supporting the hypothesis that point mutations 
in the genome can increase the risk of cancer (Stadler, Schrader, Vijai, Robson & Offit, 2014). This is 
represented in the high penetrance germline mutations in the breast cancer 1, early-onset (BCRA1) and breast 
cancer 2, early-onset (BCRA2) genes which increase the risk of familial breast cancer by 10 to 30 times 
(Foulkes, 2008).  
The evidence for genetic predisposition to developing HCC is less clear although family history of HCC is 
considered to be a risk factor for HCC development in areas of low HBV prevalence (Donato, Gelatti, Chiesa, 
Albertini, Bucella, et al., 1999; Turati, Edefonti, Talamini, Ferraroni, Malvezzi, et al., 2012), where individuals 
with HBV or HCV and a family history of HCC were 61.9 times more likely to develop HCC than the controls 
(Hassan, Spitz, Thomas, Curley, Patt, et al., 2009a). Although familial clustering of HBV-related HCC has 
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also been observed in Asia (Tong, Huynh & Siripongsakun, 2013; Yu, Chang, Liaw, Lin, Lee, et al., 2000), it 
has been attributed to the high prevalence of HBV in the affected families (Volk & Lok, 2009). However, as 
early-onset cancers are more likely to have a strong hereditary component compared to sporadic cancers 
(Brandt, Bermejo, Sundquist & Hemminki, 2008a; Goldgar, Easton, Cannon-Albright & Skolnick, 1994a) and 
HCC is seen to develop in African men earlier than in Asia (Yang et al., 2017, 2015; Yang & Roberts, 2017), 
it is highly likely HCC is associated with a genetic predisposition in SSA. Moreover, although CHB is a 
significant risk factor for HCC development, only a fraction of HBV-infected individuals will develop HCC, 
suggesting that there may be host genetic factors involved in disease progression. However, no study to date 
has investigated the presence of single nucleotide polymorphisms (SNPs) that could potentially genetically 
predispose Africans to developing HCC. 
Elsewhere, several genome-wide association studies (GWAS) have investigated the potential role of SNPs in 
HCC in non-African populations (Chen, Wang, Xu, Liu & Zhao, 2013; Jiang, Sun, Cao, Liu, Lin, et al., 2013; 
Sawai, Nishida, Mbarek, Matsuda, Mawatari, et al., 2012). More recently, the use of whole exome sequencing 
(WES) where only the coding regions of the genome (which make up less than 2% of the whole genome) are 
sequenced and analysed for the presence of rare disease-causing variants, has gained favour (Bick & Dimmock, 
2011). Whole exome sequencing has a greater coverage of the coding genes because of the smaller region 
being sequenced and can be done on fewer samples to identify rare cancer-predisposing variants. Moreover, 
WES will identify SNPs that are more likely to be clinically relevant (Popejoy & Fullerton, 2016). Exome 
sequencing has successfully identified inherited susceptibility genes in other cancers such as hereditary 
pheochromocytoma (Comino-Méndez, Gracia-Aznárez, Schiavi, Landa, Leandro-García, et al., 2011) and 
pancreatic cancer (Jones, Hruban, Kamiyama, Borges, Zhang, et al., 2009). 
One whole exome sequencing study identified HCC driver genes and mutational signatures that were specific 
for certain HCC risk factors (Schulze, Imbeaud, Letouzé, Alexandrov, Calderaro, et al., 2015). A small subset 
of their sample population (n = 5) was of African origin and was positive for both HBV and aflatoxin exposure 
and showed a mutational signature with a high rate of C>A that the authors speculate could be specific for 
AFB1. In contrast, another WES study conducted in Chinese HCC patients identified different sets of genes 
that were mutated and a T>A mutational signature (Zhan, Jiang, Sun, Ke, Hu, et al., 2017), suggesting that 
different populations and aetiologies will present with different susceptibility genes. To date, no WES studies 
have been conducted on South African HCC cases so that the susceptibility genes relevant to this setting remain 
unknown. 
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3. STUDY I: HEPATITIS B VIRUS POINT-OF-CARE TESTING STUDY 
3.1 MATERIALS AND METHODS 
 Study design 
3.1.1.1 Choice of study design 
This cross-sectional study was composed of two parts. In the first part, a point-of-care test (POCT) was used 
to determine the prevalence of active HBV infection in a community-based population from the Western Cape 
consisting mostly of manual workers and to a smaller degree (approximately 5%) of office workers. Individuals 
found to be positive were followed-up and linked to care at a tertiary healthcare facility.  
In the second part of the study, the HBV POCT’s performance and barriers to the implementation of HBV 
POC testing were investigated. Patient questionnaires were administered to one in five individuals approached 
for testing. A healthcare staff questionnaire was completed by the nursing staff administering the test to 
determine their perception of the test. 
3.1.1.2 Rationale for study design 
A cross-sectional design was selected for this study to determine the prevalence of active HBV infection at 
one time point. Study participants diagnosed with HBV infections through the study were linked to care and 
reviewed at least once by a gastroenterologist and radiologist to determine their baseline disease status. 
  Ethical approval and considerations 
Ethical approval for this study was granted by the Human Research Ethics Committee of Stellenbosch 
University in 2016 (S15/08/179). This approval was renewed on a yearly basis after submission of a progress 
report (Appendix A). 
Autonomy: Study participants were informed that participation in the present study was voluntary, that they 
could refuse testing at any point, and that refusal to participate in the study would not affect their medical care 
in any manner. 
Respect for persons: Data collected in this study were stored in a password-protected Excel sheet on a 
university computer. For backup purposes, data were also stored off-site in a password-protected format. 
Patients were de-identified in the study database that was only accessible to the study researcher. Identifiers of 
the study participants were kept in a separate password-protected Excel sheet.  
Beneficence: This study had direct benefits and effects on individual healthcare for those involved. Those 
found to be HBV-positive were reviewed by a gastroenterologist and radiologist for long-term follow-up and 
management at Tygerberg Hospital. The close contacts of HBV-positive study participants were offered free 
HBV testing and, if found to be positive, were managed in the same way as the HBV-positive study participants 
Stellenbosch University  https://scholar.sun.ac.za
 34 
 
enrolled in the present study. If found to be negative for both HBsAg and anti-HBc, they were advised to be 
vaccinated. 
Non-maleficence: This was a minimal risk study as study participants only received a finger prick for the 
HBV POCT. Subsequently, venous blood samples were collected from a proportion of HBsAg negative study 
participants and from all HBsAg positive study participants for confirmation of results. There was therefore 
no risk for those involved besides some discomfort from the finger prick and phlebotomy.  
Justice: All study participants were treated fairly and had equal access to the test being offered. Every study 
participant was also treated with the same level of respect and medical attention. 
 Sample size 
Sample size was calculated using an estimated HBsAg prevalence of 5% based on a previous epidemiological 
study conducted in the Western Cape (Andersson et al., 2013), a confidence interval width of 0.03 (3%) and a 
precision of ± 0.015 (3%). Based on these calculations, a sample size of 811 would provide sufficient statistical 
power to the study. 
 Study sites 
This study was conducted at Occupational Care South Africa (OCSA), a private company providing 
occupational health (OH) services to private South African companies. OCSA OH clinics screen employees 
from companies in the Western Cape to ensure they legally conform to the health requirements necessary for 
their occupations. These clinics were selected as the employees screened there were considered representative 
of the adult Western Cape community.  
The OH clinics targeted for this study were the stand-alone main office in Brackenfell, Cape Town, South 
Africa and additional clinics found on the premises of private companies in Parow and Paarl (Figure 3.1-1). 
Although OCSA has additional OH clinics located in Simon’s Town and St. Helena’s Bay, these clinics were 
excluded as they were located too far from the referral hospital (Tygerberg Hospital), which would have 
increased patient loss to follow-up. 
 
 
 Nursing staff training 
Before the study commenced, clinic nurses received a three-hour theoretical and practical training session in 
performing the HBV POCT conducted by the Determine™ HBV POCT product specialists. An intensive 
training session was also conducted by the researcher on the aim and objectives of the present study, HBV 
epidemiology and lifecycle, the consenting process, and the interviews to be conducted with study participants. 
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At the time of study initiation, as part of the training process, the first week of testing was considered a trial 
period during which the nurses actively carried out consenting, HBV POC testing, and counselling in a 
controlled environment. After the trial week, they were fully trained and capable of performing all the steps of 
the HBV POCT unsupervised. 
 Study population 
Study participants were recruited from the employees attending the OCSA OH clinics (Figure 3.1-1). Clinic 
attendees residing in the Western Cape, older than 18 years of age, and able to provide informed consent were 
enrolled. 
 Study flow 
Study participants were enrolled in the study following the algorithm presented in Figure 3.1-2. 
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Figure 3.1-1 Map showing clinics where study participant recruitment was conducted. These clinics (1–6) were all managed by OCSA, with the head clinic (Clinic 1) in 
Brackenfell and the other clinics found on-site in Parow/Bellville (Clinics 2–5) and Paarl (Clinic 6). These clinics were specifically chosen because they were close to Tygerberg 
Hospital (red pointer with black dot) where HBV-positive patients newly diagnosed through the study would be reviewed by a specialist. 
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 HBV Prevalence Study 
3.1.8.1 Pre-test phase 
3.1.8.1.1 Information session for eligible participants 
Clinic nurses conducted general verbal information sessions with the help of visual aids (Appendix B) 
on HBV and its long-term consequences, the POCT being offered, and the consequences of being tested. 
After the information session was conducted, eligible study participants were asked if they had any 
questions pertaining to the disease and the POCT and were offered the opportunity to be tested. 
3.1.8.1.2 Refusal to test 
Eligible participants who refused testing did not have any further involvement in the study but one in 
five were requested to complete an evaluation questionnaire to determine the reasons for refusal (see 
Figure 3.1-6 and section 3.1.10.5). 
3.1.8.1.3 Consent to test 
3.1.8.1.3.1 Pre-test counselling 
Eligible participants who agreed to be tested were further reviewed by the clinic nurses individually 
and were counselled on the implications of being tested for HBV, the chances of the result being a false 
positive or false negative, and the consequences of the result. Those who agreed to be tested were 
requested to sign a consent form (Appendix C). Translators were available if required by participants. 
3.1.8.1.3.2 Pre-test lifestyle interview 
A structured interview was conducted with each study participant to record their demographic 
information and assess their lifestyle habits and their exposure to risk factors for HCC, using a 
questionnaire (Figure 3.1-3) previously validated and used on residents of the Western Cape attending 
a healthcare facility (Maponga, 2016).  
One of the risk factors investigated was alcohol consumption and the information was recorded 
following WHO guidelines (Stockwell, Chikritzhs, Holder, Single, Elena, et al., 2000). According to 
those guidelines, the health risks associated with alcohol consumption can be categorised as low risk, 
Information 
session for 
eligible 
participants
Agreed to testing
1. Pre-test 
counselling
2. Pre-test lifestyle 
interview
HBV POC testing
Negative
1. Test result communication
2. Encouraged to get 
vaccinated
3. Proportion used as controls
4. Proportion given HBV 
evaluation questionnaire
Positive
1. Test result communication 
2. Post-test counselling
3. Proportion given HBV evaluation 
questionnaire
3. Blood sample collection for result 
serological confirmation
4. Genetic and clinical baseline 
testing
5. Follow-up at Tygerberg Hospital
6. Follow-up of close contacts
Indeterminate
1. POCT repeated
2. Blood sample 
collection for result 
serological confirmation
3. Confirmed result 
reported to patient
Refused testing
No further 
involvement
HBV evaluation 
questionnaire
Figure 3.1-2 Algorithm for study participant enrolment and management POCT: Point of care test; HBV: hepatitis B virus 
 
 
 
Pre-test 
 
Test 
 
 
 
Post-test 
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medium risk, high risk, and very high risk (Table 3.1-1) depending on the amount of alcohol consumed 
on a single drinking day. 
Table 3.1-1 WHO-Criteria for risk of consumption on a single drinking day in relation to acute 
problems, Stockwell et al., 2000 
 Male Female 
Low risk 1 to 40 g 1 to 20 g 
Medium risk 41 to 60 g 21-40 g 
High risk 61 to 100 g 41 to 60 g 
Very high risk 101 g and above 61 g and above 
g: gram 
Self-reported alcohol misuse, defined as excessive alcohol use that affected their relationships and/or 
employment, and cigarette smoking habits (current, past, or never) were also recorded. 
Herbal medicine was defined as any herbal medication that was not obtained over-the-counter or 
through prescriptions at the pharmacy. Responders were given the opportunity to elaborate on the herbal 
medication to ensure that it corresponded to the study’s definition of herbal medicine and to find out 
what was being consumed. 
This interview was conducted by the research team who asked the questions directly to the study 
participants and recorded the answers provided on the case record form. With this form of questioning 
study participants could be probed for more information where their answers were not specific enough 
for the study purposes so the information could be recorded in a consistent manner. On the other hand, 
however, some participants could withhold information if they felt uncomfortable sharing personal 
information with the clinic nurse. To minimise this risk, the interviewer ensured that the patient was 
aware that the information provided for study purposes would remain confidential and would not be 
recorded in their clinic files. 
 Statistical analyses 
The frequencies of the questionnaire responses were analysed using SPSS Statistics for Windows, 
Version 25.0 (IBM Corp., New York, USA). Cross-tabulations were used to compare the categorical 
demographics and risk factors between the HBsAg positive and negative study participants. Any 
statistically significant differences between the two groups were determined using Fisher’s exact test or 
Pearson’s Chi-Squared test. Fisher’s exact test was used where the sample size was less than 5 and 
Pearson’s Chi-Squared test was used for large sample sizes. Statistical significance was set at p < 0.05. 
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Figure 3.1-3 Demographic information and lifestyle interview case record form During their interview, study 
participants were asked the above questions by the research team and their answers were recorded on the case record 
form. The outcome of each participant’s test result was also recorded on the form. 
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3.1.8.2 HBV POC testing phase 
The Determine™ Point-of-care HBsAg test (Alere, Oxfordshire, UK) was used to test study participants 
for active HBV infection as per manufacturer’s instructions. This test has previously been validated for 
use in our setting (Kariem et al., 2015). After study participants received a finger prick, a capillary tube 
lined with ethylenediaminetetraacetic acid (EDTA) was used to collect approximately 50 µl of their 
blood which was placed on the test strip. A drop of chase buffer was added to help the blood flow up 
the immunochromatographic strip and a timer set for 20 minutes was started. The result was then read 
after 20 minutes. 
Figures 3.1-4 and 3.1-5 show possible valid results after a test was performed. If the control line alone 
was observed, the participant was deemed to be negative for active HBV infection. If both the control 
and test lines were present, the participant was deemed to be positive for active HBV infection. In the 
absence of a control line, the result was considered invalid, the POCT repeated, and a blood sample 
collected from the participant to confirm the result by enzyme-linked immunosorbent assay  (ELISA)  
Figure 3.1-5 HBV 
POCT positive result 
The control line is present 
confirming the test result 
is valid. A second line 
indicates the test is 
positive. 
Figure 3.1-4 HBV POCT 
negative result The control 
line is present confirming 
the test result is valid. The 
absence of a second line 
indicates the test is 
negative. 
Figure 3.1-6 HBV POCT 
invalid results 
Representation of invalid 
results. In the absence of a 
control line, whether the 
patient line is present or 
absent, the results are 
considered to be invalid. 
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using the ARCHITECT® HBsAg Qualitative assay on the automated ARCHITECT® i2000SR (Abbott 
Laboratories, Illinois, USA) system in the Division of Medical Virology, Stellenbosch University. 
Nurses were requested to take pictures of every POCT they carried out with the relevant study 
participant name included so that an external quality control could be performed for every POCT 
conducted. If the picture was blurry or missing part of the test strip and the result could therefore not be 
read accurately, it was discarded and that particular participant excluded from the study. 
3.1.8.3 Post-test phase 
3.1.8.3.1 HBV POCT result communication 
Each result was privately communicated to each study participant and the POCT strip shown to them 
with an explanation of the meaning of the results. 
3.1.8.3.1.1  Negative result 
If the result was negative, the study participant was advised to get vaccinated at their local hospital to 
prevent any future infection if they were exposed to the virus.  
Moreover, each fifth study participant found to be negative on the HBV POCT was consented to provide 
5 ml of blood to confirm the result by laboratory testing to determine the number of false negatives 
being potentially missed. These control blood samples were tested by ELISA using the ARCHITECT® 
HBsAg Qualitative assay on the automated ARCHITECT® i2000SR (Abbott Laboratories, Illinois, 
USA) system in the Division of Medical Virology, Stellenbosch University. 
In the eventuality of a false negative result, the study participant was recalled, counselled, and referred 
to Tygerberg Hospital. False negative results were also reported to the POCT supplier. Nurses who 
performed false-negative tests were retrained and all tests they conducted from the false negative test 
onward were excluded from the study. 
3.1.8.3.1.2  Positive result 
Participants whose test results were positive received a post-test counselling session and were referred 
to a gastroenterologist at the Liver Clinic of the Division of Gastroenterology and Hepatology at 
Tygerberg Hospital usually on the following Wednesday. Every positive result was confirmed by 
ELISA using the ARCHITECT® HBsAg Qualitative assay on the automated ARCHITECT® i2000SR 
(Abbott Laboratories, Illinois, USA) system in the Division of Medical Virology, Stellenbosch 
University.  
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In case of a false positive result, the study participant was recalled and counselled. The supplier was 
also informed of the false positive result. The nurse responsible for the testing was then retrained and 
the tests they conducted from the previous control sample onward were excluded from the study. 
3.1.8.3.1.3  Indeterminate results 
Indeterminate results were repeated and a venous blood sample collected from the participant for 
confirmation by ELISA using the ARCHITECT® HBsAg Qualitative assay on the automated 
ARCHITECT® i2000SR (Abbott Laboratories, Illinois, USA) system in the Division of Medical 
Virology, Stellenbosch University. Study participants were informed telephonically of their result if it 
was negative. If they were found to be HBV-positive, they were requested to come to Tygerberg 
Hospital where they received counselling and were reviewed by a gastroenterologist. 
3.1.8.3.2 HBV POCT result confirmation and baseline testing 
3.1.8.3.2.1 HBV serological testing 
Venous blood samples were collected from the HBsAg positive study participants for HBV serological 
confirmatory and additional tests (HBsAg, HBeAg, anti-HBe, anti-HBc [total and IgM], and anti-HBs) 
by ELISA on the automated ARCHITECT® i2000SR system. The corresponding ARCHITECT® 
immunoassays (ARCHITECT® HBsAg Qualitative, ARCHITECT® HBeAg, ARCHITECT® Anti-HBe, 
ARCHITECT® Anti-HBc II, ARCHITECT® Anti-HBc IgM, and ARCHITECT® Anti-HBs) were used 
following manufacturer’s protocols (Abbott Laboratories, Illinois, USA) at the SANAS-accredited 
Division of Medical Virology of the National Health Laboratory Services of Tygerberg Hospital. 
3.1.8.3.2.2 HB Viral load testing 
HB viral load was also determined using the COBAS® AmpliPrep/COBAS® TaqMan® HBV Test on 
the automated COBAS® AmpliPrep Instrument (Roche Molecular Diagnostics, California, USA) at the 
SANAS-accredited Division of Medical Virology of the National Health Laboratory Services of 
Tygerberg Hospital. 
3.1.8.3.2.3 HIV testing 
The HIV status of study participants who consented to testing was determined by HIV-1 
antigen/antibody testing using the Cobas® Elecsys® HIV combi PT 4th Gen (Roche Molecular 
Diagnostics, California, USA). Pre- and post-test counselling were provided by the HIV counsellors at 
Tygerberg Hospital. 
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3.1.8.3.2.4 HBV genotyping 
HBV genotyping was performed using an in-house assay developed by Public Health England (Public 
Health England, 2007) and established at the South African National Accreditation System (SANAS)-
accredited Division of Medical Virology of the National Health Laboratory Services of Tygerberg 
Hospital (Andersson et al., 2013; Chotun et al., 2017, in press; Maponga, 2016). This assay is described 
below. 
 DNA extraction 
Venous blood samples were centrifuged at 700 RCF for 10 minutes and the serum or plasma collected 
and stored at -20°C until testing. DNA was extracted from the serum or plasma of the HBsAg positive 
study participants using the QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) following 
manufacturer’s instructions. To 20 µl of proteinase-K, 200 µl of serum/plasma was added in a 1.5 ml 
microcentrifuge tube for tissue digestion followed by 200 µl of lysis buffer AL and the tubes mixed by 
pulse-vortexing for 15 s and incubated at 56°C for 10 min. The microcentrifuge tubes were briefly 
centrifuged and 200 µl of ethanol was added and the tubes mixed by pulse-vortexing for 15 s. The 
solution from each tube was then applied to a silica gel membrane spin column and centrifuged at 
maximum speed for one minute. The filtrate was discarded and the column placed back into the tube. 
The membrane-bound DNA was washed with 500 µl of two different buffers to remove leftover ethanol. 
The column was then placed in a new collection tube and centrifuged at full speed for one minute to 
eliminate possible wash buffer carry-over. Lastly, 50 µl of the elution buffer containing 10 mM Tris-Cl 
and 0.5 mM EDTA pH 9.0 was added and the column incubated at room temperature for five minutes 
and centrifuged at 5800 RCF for one minute. 
 PCR amplification 
Two rounds of PCR were performed on the DNA extracts of samples from the HBsAg-positive study 
participants. The primers shown in Table 3.1-2 and the PCR master mix in Table 3.1-3 were used in the 
pre-nested PCR. The master mix was distributed in volumes of 20 μl in 0.2 ml PCR tubes to which 5 μl 
of DNA extract was added and the PCR reaction performed as per the thermocycling parameters given 
in Table 3.1-4. 
Table 3.1-2 Primers used in pre-nested PCR of HBV genotyping Public Health England, 2007 
Primer name Primer sequence Amplicon size 
HBV Z_F 5′-AGC CCT CAG GCT CAG GGC ATA-3′ 
2008 bp 
HBV 3_R 5′-CGT TGC CKD GCA ACS GGG TAA AGG-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair 
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Table 3.1-3 Master mix used in pre-nested PCR of HBV genotyping, Public Health England, 2007 
Components Volume/µl Starting concentration Final concentration 
PCR buffer 2.50 10X 1X 
Magnesium chloride 0.75 50 mM 1.5 mM 
Deoxynucleoside triphosphate 0.50 10 mM 0.2 mM 
Taq Polymerase 0.10 5 U/µl 0.5 U/µl 
HBV Z_F 0.50 20 µM 0.4 µM 
HBV 3_R 0.50 20 µM 0.4 µM 
Nuclease-free water 15.15 n/a n/a 
Total volume 20.00 n/a n/a 
µl: microlitre; x: times; mM: millimolar;  U: unit; µM: micromolar; n/a: not applicable 
 
Table 3.1-4 Thermocycling conditions of pre-nested PCR for HBV genotyping, Public Health 
England, 2007 
Cycling parameter Cycles Temperature Time 
Initial denaturation  1 hold 95°C 5 min 
Denaturation 
34 
94°C 30 s 
Annealing 55°C 30 s 
Extension 72°C 1 min 
Final extension 1 hold 72°C 2 min 
°C: degrees Celcius; min: minute; s: second 
A second round of PCR amplification was performed on the pre-nested amplicons to increase reaction 
specificity and product yield. The primers shown in Table 3.1-5 and the master mix in Table 3.1-6 were 
used for the nested PCR. The master mix was aliquoted in volumes of 49 μl into 0.2 ml PCR tubes to 
which 1 μl of the pre-nested product was added and the PCR was performed following the 
thermocycling parameters given in Table 3.1-7. 
Table 3.1-5 Primers used in nested PCR of HBV genotyping, Public Health England, 2007 
Primer name Primer sequence Amplicon size 
HBV P_F 5′-TCA TCC TCA GGC CAT GCA GT-3′ 
 1014 bp 
HBV M_R 5′-GAC ACA CTT TCC AAT CAA TNG G-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair 
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Table 3.1-6 Master mix used in nested PCR of HBV genotyping, Public Health England, 2007 
Components Volume/µl Starting concentration Final concentration 
PCR buffer 5.0 10X 1X 
Magnesium chloride 1.5 50 mM 1.5 mM 
Deoxynucleoside triphosphate 1.0 10 mM 0.2 mM 
Taq Polymerase 0.2 5 U/µl 0.5 U/µl 
HBV Z_F 1.0 20 µM 0.4 µM 
HBV 3_R 1.0 20 µM 0.4 µM 
Nuclease-free water 39.3   
Total volume 49.0   
µl: microlitre; X: times; mM: millimolar;  U: unit; µM: micromolar 
 
 Table 3.1-7 Thermocycling conditions of nested PCR for HBV genotyping, Public Health 
England, 2007 
Cycling parameter Cycles Temperature Time 
Initial denaturation  1 hold 95°C 5 min 
Denaturation 
34 
94°C 30 s 
Annealing 50°C 30 s 
Extension 72°C 1 min 
Final extension 1 hold 72°C 7 min 
°C: degrees Celcius; min: minute; s: second 
 Gel electrophoresis 
A 1% agarose gel was prepared by melting 0.75 g of agarose powder (SeaKem® LE Agarose, Maine, 
USA) in 75 ml of 1X Sodium Borate (SB) Buffer. Five microlitres of each PCR product was mixed with 
one microlitre of 6X Novel Juice (GeneDireX Inc., Taoyuan, Taiwan) and pipetted into wells on the 
agarose gel to separate any PCR product according to size. The samples were electrophoresed alongside 
a 1 Kb DNA ladder (GeneRuler™ 100 bp DNA Ladder, ThermoFisher Scientific, Massachusetts, USA) 
for 30 minutes at 100 V. The agarose gel was then visualised under ultraviolet light at a wavelength of 
254 nm using the Platinum HD Gel Documentation System (UVItec Limited, Cambridge, UK) and the 
image acquired using the UVIband-1D gel analysis software. PCR products with visible bands of the 
correct size were selected for further testing downstream. 
 Purification of PCR products 
PCR products were purified using the QIAquick PCR Purification Kit (QIAGEN) by following 
manufacturer’s instructions. A buffer was first added to the PCR products and the mixture applied to 
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silica gel membrane spin columns to allow efficient binding of the amplified DNA to the column 
membrane. This was followed by a wash step using an ethanol-containing buffer to ensure the removal 
of primers and other impurities that could inhibit sequencing downstream. A centrifugation step in an 
empty tube then ensured the removal of residual ethanol-containing buffer. The DNA was finally eluted 
in 30 µl of elution buffer containing 10 mM Tris-Cl, pH 8.5. 
 Sequencing PCR 
Sequencing PCR reactions were carried out in a 96-well plate using four different primers (Table 3.1-
8) to sequence the region of interest. A master mix consisting of the components listed in Table 3.1-9 
was prepared and distributed in volumes of 8 µl into the appropriate number of wells. Next, 1 µl of each 
primer and 1 µl of purified template DNA (between 20–30 ng) from each sample was added to the 
appropriate wells. The cycling conditions shown in Table 3.1-10 were used. 
Table 3.1-8 Sequencing primers for HBV genotyping, Public Health England, 2007 
Primer name Primer sequence 
HBV P_F 5′-TCA TCC TCA GGC CAT GCA GT-3′ 
HBV M_R 5′-GAC ACA CTT TCC AAT CAA TNG G-3′ 
HBV H_F 5′-TAT CAA GGA ATT CTG CCC GTT TGT CCT-3′ 
HBV N_R 5′-ACT GAG CCA GGA GAA ACG GAC TGA GGC-3′ 
5′: 5 prime; 3′: 3 prime 
Table 3.1-9 Sequencing reaction master mix, adapted from manufacturer’s instructions 
(ThermoScientific) 
Table 3.1-10 Cycling parameters for HBV genotyping sequencing reaction, adapted from 
manufacturer’s instructions (ThermoScientific) 
Cycling parameter Cycles Temperature Time 
Denaturation 
30 
96°C 20 s 
Annealing 50°C 20 s 
Extension 60°C 4 min 
°C: degrees Celcius; min: minute; s: second 
 
Reagent Volume/µl 
ABI Sequencing Buffer 3 
Big Dye terminator 1 
Primer, 2 µM 1 
Water 3 
Total volume 8 
µl: microlitre; µM: micromolar 
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 Sequencing PCR purification 
The sequencing PCR reaction products were purified using the BigDye® Xterminator Purification Kit 
consisting of SAM™ and XTerminator® solutions as per manufacturer’s instructions 
(ThermoScientific); 45 μl of SAM solution and 10 μl of Xterminator® solution were added to each well 
before the wells were sealed with adhesive film. The 96-well plate was vortexed for 30 minutes at 
2000 RCF and centrifuged for 1 minute at 1000 RCF. 
 Capillary electrophoresis and sequencing data analysis 
Capillary electrophoresis was performed on the samples using the ABI Prism 3130XL Genetic Analyzer 
(ThermoFisher Scientific). The information obtained was converted to raw data files using DNA 
sequencing analysis software (ThermoFisher Scientific). The length of the capillaries allowed sequence 
reads of approximately 1 Kb. 
The raw trace files were further analysed using Geneious R11 (Biomatters Ltd., Auckland, New 
Zealand). The quality of each sequence was improved individually by looking at the chromatograms 
and trimming the ends where necessary. The forward and reverse sequences for each sample were 
aligned to create a consensus sequence. Mismatches or ambiguities were verified manually. A reference 
sequence was created using the corresponding primer sequences and was used to trim the sequences 
beyond the primer region. 
The consensus sequence was saved in FASTA format before being aligned against the Stanford 
University HBVSeq sequence database to obtain the HBV genotype (Rhee, Margeridon-Thermet, 
Nguyen, Liu, Kagan, et al., 2010). This allowed HBV genotype identification of study participant 
sequences. 
3.1.8.3.2.5 Clinical biochemical and haematological testing 
Venous blood specimens were also sent to the Division of Chemical Pathology, National Health 
Laboratory Services, Tygerberg Hospital, for liver function tests (bilirubin, albumin, ALT, AST, and 
AFP) and to the Division of Haematology, National Health Laboratory Services, Tygerberg Hospital, 
for platelet count testing to determine the baseline disease status. The biochemical tests were all 
performed on the automated Cobas® 6000 Chemistry Analyzer (Roche, Rotkreuz, Switzerland) using 
the Bilirubin Total Gen.3 kit (for total bilirubin levels), the Bilirubin direct Diazo Gen. 2 Jendrassik-
Grof kit (for conjugated bilirubin levels), the Albumin Gen. 2 kit (for albumin levels), the Alanine 
Aminotransferase according to IFCC with pyridoxal phosphate activation kit (for ALT levels), the 
Aspartate Aminotransferase according to International Federation of Clinical Chemistry and Laboratory 
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Medicine (IFCC) with pyridoxal phosphate activation kit (for AST levels), and the AFP α1-fetoprotein 
kit (for AFP levels), using the manufacturer’s recommended protocols. 
The AST platelet ratio index (APRI) and FIB-4 tests were used to determine the presence of hepatic 
fibrosis as recommended by the WHO (World Health Organization, 2015). The APRI score is as 
follows: APRI = (AST/upper limit of normal) x 100/platelet count where a score < 0.5 excluded fibrosis 
and a score > 1.5 suggested significant fibrosis (World Health Organization, 2015). The FIB-4 
calculation is as follows: (age (in years) x AST [IU/L])/(platelet count (109/L) x [ALT (IU/L)1/2]) where 
a score of 3.25 and above indicated significant fibrosis (World Health Organization, 2015). 
3.1.8.3.3 Study participant follow-up at Tygerberg Hospital 
Confirmed HBV-positive study participants were referred to the Liver Clinic of the Division of 
Gastroenterology and Hepatology at Tygerberg Hospital where they were reviewed by a 
gastroenterologist collaborating on the present study. Laboratory results available for the study 
participants were used to determine if they required treatment. As per the AASLD guidelines (Terrault, 
Bzowej, Chang, Hwang, Jonas, et al., 2016), treatment was discussed and offered to HBeAg-positive 
HBV monoinfected study participants with viral loads of greater than 20 000 IU/ml and abnormal liver 
function tests (ALT, AST, AFP) and to anti-HBe positive HBV monoinfected study participants with 
viral loads greater than 2000 IU/ml and abnormal liver function tests. Antiretroviral therapy including 
tenofovir was also initiated in HIV/HBV co-infected study participants who were not already on 
treatment. All HBV-positive participants received an abdominal ultrasound scan to determine the 
presence of cirrhosis or HCC. 
3.1.8.3.4 Follow-up of contacts of HBV-positive study participants 
The close contacts (children and sexual partners) of the HBV-positive study participants were offered 
free HBV testing at Tygerberg Hospital. They were tested for HBsAg, anti-HBc, and levels of anti-HBs 
as described in section 3.10.2.1. Any contact who was positive was treated the same way as previously 
described in section 3.10.1.2. Any contacts with negative anti-HBc results and levels of anti-HBs below 
10 mIU/ml were strongly encouraged to get vaccinated to protect them from any future exposure and 
infection.  
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 HBV POCT Implementation Study 
3.1.9.1 HBV POCT Performance 
Measures of sensitivity, specificity, negative predictive value (NPV), and positive predictive value 
(PPV) were used to assess the performance of the HBV POCT.  
The sensitivity of a POCT is its ability to detect a true positive. The formula used to calculate the 
sensitivity of a POCT is as follows: 
Sensitivity =   True positives   x  100 
True positives + False negatives 
A POCT’s specificity is its ability to exclude a true negative. The formula used to calculate the 
specificity of a POCT is as follows: 
Specificity =   True negatives   x  100 
True negatives + False positives 
The PPV is the probability that participants with a positive rapid test result truly have the disease. The 
formula used to calculate the PPV of a POCT is as follows: 
PPV =    True positives 
True positives + False positives 
The NPV is the probability that participants with a negative rapid test result truly do not have the 
disease. The formula used to calculate the NPV of a POCT is as follows: 
NPV =   True negatives 
True negatives + False negatives 
The results obtained from laboratory confirmation by ELISA of a proportion of HBsAg negatives 
(section 4.10.1.1) and all HBsAg positives (section 4.10.1.2) on the HBV POCT were used as reference 
(gold standard) to determine these values. 
3.1.9.2 Test perception by study population 
A questionnaire was administered to one in five study participant to determine their pre-test knowledge 
about HBV and perception of the test. The questionnaire was first piloted on 10 people and modified 
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based on the feedback given (Figure 3.1-7). Part of this questionnaire was also administered to one in 
five approached individuals who refused to get tested to determine the reasons for refusal.  
3.1.9.2.1 Statistical analyses 
The statistical analyses were performed using SPSS Statistics for Windows, Version 25.0 (IBM Corp., 
New York, USA). The median age of the questionnaire responders was calculated. The frequencies of 
the categorical gender data and questionnaire responses were also recorded. 
Figure 3.1-7 Questionnaire to determine study population's perception to testing. Study participants 
answered all questions except question 7. Eligible individuals who refused testing answered questions 1-
5, and 7. 
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3.1.9.3 Test perception by nursing staff 
Another standardised questionnaire was administered to the study nurses involved in study participant 
recruitment to determine the ease of use of the test and their perception of the test. The questionnaire 
was first piloted on two clinic nurses who were not involved with study testing and modified based on 
the feedback given (Appendix D).  
3.1.9.3.1 Statistical analyses 
The frequencies of the responses to questions with discrete answers in the questionnaires were analysed 
using SPSS Statistics for Windows, Version 25.0 (IBM Corp., New York, USA). Qualitative analyses 
were conducted on the open-ended questions and common themes were drawn from those responses. 
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3.2 RESULTS 
 HBV Prevalence Study 
3.2.1.1 Demographics of enrolled population 
Between April 2016 and February 2017, 960 individuals were recruited for this study. The 
demographics of the study participants are provided in Table 3.2-1. 
Table 3.2-1 Demographics of tested population 
 Study population 
n = 960 
Age, mean ± SD 37.19 ± 11.02 
Sex 
Male 663 (69.1%) 
Female 297 (30.9%) 
Race 
Black 319 (33.2%) 
Coloured 524 (54.6%) 
Indian 5 (0.5%) 
Caucasian 111 (11.6%) 
Other 1 (0.1%) 
Place of birth 
Urban 636 (66.3%) 
Rural 324 (33.7%) 
3.2.1.2 Prevalence of HBV 
Of the 960 tested individuals, 21 were found to be positive on the HBsAg POCT. All 21 were confirmed 
positive for active HBV infection by ELISA, giving an HBsAg prevalence of 2.2% (95% CI: 1.4%–
3.3%). The demographics and anthropometrics of the HBsAg-positive participants compared to the 
HBsAg-negative participants are given in Table 3.2-2. 
3.2.1.3 Demographics and Body Mass Index of HBsAg positive and negative groups 
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Table 3.2-2 Comparison of demographics and Body Mass Index between HBsAg positive and 
HBsAg negative groups 
 HBsAg positive 
group 
n = 21 
HBsAg negative 
group 
n = 939 
p-value 
Age, mean ± SD 42.48 ± 8.66 37.07 ± 11.04 0.026* 
Sex 
Male 17 (2.6%) 646 (97.4%) 
0.233 
Female 4 (1.3%) 293 (98.7%) 
Race 
Black 9 (2.8%) 310 (97.2%) 
0.518 
Coloured 12 (2.3%) 512 (97.7%) 
Indian 0 (0.0%) 5 (100.0%) 
Caucasian 0 (0.0%) 111 (100.0%) 
Other 0 (0.0%) 1 (100.0%) 
Place of birth 
Urban 15 (2.4%) 621 (97.6%) 
0.816 
Rural 6 (1.9%) 318 (98.1%) 
BMI 
Underweight < 18.5 0 (0.0%) 15 (100.0%) 
0.569 
Normal 18.5-24.9 4 (1.3%) 293 (98.7%) 
Overweight 25-29.9 9 (2.8%) 318 (97.2%) 
Obese ≥ 30 8 (2.6%) 300 (97.4%) 
Statistical analyses found that the mean age of HBsAg-positive individuals was significantly higher 
than the mean age of HBsAg-negative individuals (p < 0.05). Sex, race, place of birth, and BMI were 
not found to be significantly different between the HBsAg-positive and HBsAg-negative groups. 
3.2.1.4 Comparison of lifestyle risk factors between HBsAg positive and negative groups 
The pre-test lifestyle interview showed that more than half of study participants (57.1% 95% CI: 53.9%-
60.2%) were alcohol consumers. Among those, 49.1% (95% CI: 44.9%-53.3%) were exposed to very 
high-risk health behaviours as per WHO guidelines. 
Lifestyle risk factors for HCC were compared between the HBsAg positive and negative groups (Table 
3.2-3). Past alcohol misuse was the only risk factor that was statistically significant between the two 
groups (p = 0.049), indicating that HBsAg-positive individuals were more likely to consume an 
excessive amount of alcohol regularly than HBsAg-negative individuals. 
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Table 3.2-3 Comparison of lifestyle risk factors between HBsAg positive and negative groups 
 HBsAg positive 
group 
n = 21 
HBsAg negative 
group 
n = 939 
p-value 
Alcohol consumption 
Current 14 (2.6%) 534 (97.4%) 
0.669 Past 2 (1.7%) 114 (98.3%) 
Never 5 (1.7%) 291 (98.3%) 
Health risk related to alcohol consumption 
Low risk 2 (2.3%) 85 (97.7%) 
0.352 
Medium risk 1 (1.4%) 72 (98.6%) 
High risk 1 (0.9%) 112 (99.1%) 
Very high risk 10 (3.8%) 253 (96.2%) 
Past alcohol misuse 
Yes 3 (8.3%) 33 (91.7%) 
0.049* 
No 13 (2.0%) 623 (98.0%) 
Smoking habits 
Current 8 (2.5%) 317 (97.5%) 
0.887 Past 3 (1.8%) 164 (98.2%) 
Never 10 (2.1%) 458 (97.9%) 
Exposure to herbal medicine 
Current 1 (1.4%) 71 (98.6%) 
0.162 Past 4 (5.2%) 73 (94.8%) 
Never 16 (2.0%) 795 (98.0%) 
 
3.2.1.5 HBV-positive participant baseline testing and follow-up 
Additional testing for serological markers of HBV infection, HIV co-infection, and HB viral load was 
performed (Table 3.2-4) to determine the baseline status of the 21 HBV-positive participants, coded 
OCSA 1 to OCSA 21. 
Two study participants, OCSA 3 and OCSA 19 had viral loads too low to permit sequencing. In the 19 
patient samples sequenced, there was an equal prevalence of HBV genotypes A (10/19) and D (9/19) 
that could be further subcategorised as genotypes A1 (n = 10) and D1 (n = 1), D2 (n = 1), D3 (n = 6), 
and D4 (n = 1).  
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Three study participants, OCSA 2, OCSA 3, and OCSA 20, were co-infected with HIV. OCSA 3 was 
on antiretroviral therapy with tenofovir and was negative for both HBeAg/anti-HBe with a viral load of 
< 20 IU/ml. OCSA 2 and 20 were newly diagnosed with HIV through the present study. OCSA 20 was 
positive for HBeAg, negative for anti-HBe and had a viral load of 47 600 IU/ml. OCSA 2 was positive 
for anti-HBe, negative for HBeAg and had a viral load of 555 IU/ml. Both were immediately started on 
antiretroviral therapy, including tenofovir, which is available free-of-charge to all HIV-positive South 
African residents at their local primary healthcare clinics. 
In HBV mono-infected participants, the biochemical results (Table 3.2-5) were used in conjunction with 
the virological results and clinical presentation of the patients to make a decision as to whether treatment 
was required. OCSA 7 was positive for anti-HBe and negative for HBeAg but had a high viral load of 
469 000 IU/ml. She was infected with HBV sub-genotype D4 with a W28* BCP/PC mutation and her 
ALT levels were also elevated (70 U/L). She was therefore considered to have reached treatment 
threshold and started on treatment with tenofovir. Treatment for OCSA 7 was not available free-of-
charge and required a monthly visit to the tertiary hospital for collection of the tenofovir tablets. 
All study participants were reviewed at least once by a gastroenterologist during the study. The 
abdominal ultrasound scans of 20 of the patients were normal with no evidence of HCC or signs of 
cirrhosis. OCSA 12 consistently missed his ultrasound appointments and was therefore considered to 
have been lost to follow-up.
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 Table 3.2-4 Baseline serological and virological testing for HBV-positive patients. 
Patient HIV-1 status HBsAg anti-HBs HBeAg anti-HBe anti-HBc (total) anti-HBc (IgM) HB Viral load: IU/ml HBV genotype 
OCSA 1 Negative Positive Negative Negative Positive Positive Negative 3850 D3 
OCSA 2 Positive Positive Negative Negative Positive Positive Negative 555 A1 
OCSA 3 Positive Positive Negative Negative Negative Positive Negative < 20 NA* 
OCSA 4 Negative Positive Negative Negative Positive Positive Negative 137 A1 
OCSA 5 Negative Positive Negative Negative Positive Positive Negative 462 A1 
OCSA 6 Negative Positive Negative Negative Positive Positive Negative 769 D3 
OCSA 7 Negative Positive Negative Negative Positive Positive Negative 469 000 D4 
OCSA 8 Negative Positive Negative Negative Positive Positive Negative 4500 D3 
OCSA 9 Negative Positive Negative Negative Positive Positive Negative 1990 A1 
OCSA 10 Negative Positive Negative Negative Positive Positive Negative 254 D1 
OCSA 11 Negative Positive Negative Negative Positive Positive Negative 569 D3 
OCSA 12 Negative Positive Negative Negative Positive Positive Negative 6320 D2 
OCSA 13 Negative Positive Negative Negative Positive Positive Negative 132 A1 
OCSA 14 Negative Positive Negative Negative Positive Positive Negative 128 D3 
OCSA 15 Negative Positive Negative Negative Positive Positive Negative 79 A1 
OCSA 16 Negative Positive Negative Negative Positive Positive Negative 1240 A1 
OCSA 17 Negative Positive Negative Negative Positive Positive Negative 169 A1 
OCSA 18 Negative Positive Negative Negative Positive Positive Negative 57 A1 
OCSA 19 Negative Positive Negative Negative Positive Positive Negative < 20 NA* 
OCSA 20 Positive Positive Positive Positive Negative Positive Negative 47 600 A1 
OCSA 21 Negative Positive Negative Negative Positive Positive Negative 133 D3 
OCSA 3 and 4 had viral loads too low for sequencing. NA*: Not applicable; HIV-1: human immunodeficiency virus-1; HBV: hepatitis B virus; HBsAg: hepatitis B 
surface antigen; anti-HBs: antibody to hepatitis B surface antigen; HBeAg: hepatitis B envelope antigen; anti-HBe: antibody to hepatitis B envelope antigen; anti-HBc: 
antibody to hepatitis B core antigen; IgM: Immunoglobulin M; IU/ml: International Units per millilitre; <: less than.  
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Table 3.2-5 Haematological and clinical chemical laboratory results of HBV-positive study 
participants 
Tests 
 
 
Patient 
(Normal 
range) 
Albumin: 
g/L  
(35-52) 
Total bil: 
µmol/L 
(5-21) 
Conj bil: 
µmol/L 
(0-3) 
ALT: 
U/L  
(10-40) 
AST: 
U/L 
(15-40) 
AFP: 
µl 
(0-8)  
Platelet count: 
cells/L 
(171-388) 
APRI score 
(> 1.5) 
FIB-4 
score 
(> 3.25) 
OCSA 1 43 10 4 16 15 3.5 394 0.095 0.352 
OCSA 2 37 5 2 39 65 8.1 285 0.570 1.242 
OCSA 3 43 4 2 51 48 < 1.3 251 0.478 1.312 
OCSA 4 44 4 < 2 23 70 1.3 228 0.768 2.177 
OCSA 5 42 4 2 23 47 4.6 331 0.355 1.095 
OCSA 6 46 6 2 17 20 2.4 370 0.135 0.682 
OCSA 7 45 Unknown Unknown 70 37 2.7 226 0.409 0.626 
OCSA 8 44 8 3 34 26 2.1 225 0.289 1.050 
OCSA 9 42 6 3 26 23 18.9 173 0.332 1.069 
OCSA 10 45 5 < 2 45 35 2.4 202 0.433 1.395 
OCSA 11 45 10 4 15 15 4.3 240 0.156 0.613 
OCSA 12 46 6 < 2 19 18 2.6 319 0.141 0.544 
OCSA 13 46 Unknown 2 22 85 2.5 219 0.970 4.634 
OCSA 14 45 8 3 19 29 2.2 280 0.259 1.449 
OCSA 15 47 4 2 24 15 2 226 0.166 0.596 
OCSA 16 47 5 2 33 27 6.4 205 0.329 0.848 
OCSA 17 49 8 3 21 23 4.4 203 0.283 1.063 
OCSA 18 43 5 3 48 59 11.9 168 0.878 1.723 
OCSA 19 42 5 3 22 22 0.7 208 0.264 0.947 
OCSA 20 45 6 3 18 27 3.2 299 0.226 0.639 
OCSA 21 45 7 2 26 24 2.6 369 0.163 0.536 
bil: bilirubin; Conj bil: conjugated bilirubin; ALT: alanine aminotransferase; AST: aspartate transaminase; AFP: alpha-fetoprotein; 
APRI: Aminotransferase Platelet Ratio index; FIB-4: Fibrosis-4; g/L: grams per litre; µmol/L: micromoles per litre; U/L: units per 
litre; µl: microlitre; cells/L: cells per litre. An APRI score and FIB-4 score of greater than 1.5 and 3.25, respectively, suggested 
significant fibrosis.  
3.2.1.6 Follow-up of contacts of HBV-positive participants 
Two study participants (OCSA 2 and OCSA 16) did not have any sexual partners or children. The sexual 
contacts of 4 of the remaining 19 HBV-positive study participants (OCSA 1, OCSA 6, OCSA 17, and 
OCSA 20) were seen by a gastroenterologist and tested for anti-HBc, anti-HBs, and HBsAg. All were 
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negative for active HBV infection (HBsAg negative), were positive for anti-HBs, but showed evidence 
of past exposure to HBV (positive for total anti-HBc).  
Similarly, the children of 4 of the 19 HBV-positive study participants (OCSA 7, OCSA 10, OCSA 13, 
OCSA 15) were seen by a gastroenterologist and tested for anti-HBc, anti-HBs, and HBsAg. All were 
negative for active HBV infection (HBsAg negative), showed no past exposure to HBV (negative for 
anti-HBc), and showed immunity to HBV infection (positive for anti-HBs).   
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 HBV POCT Implementation Study 
3.2.2.1 POCT performance 
3.2.2.1.1 External validation of results 
A total of 963 result strips were photographed by the study nurses and the results validated by visual 
confirmation by the researcher. Three reported negative results were excluded from the study because 
the poor quality of the pictures taken prevented external validation.  
3.2.2.1.2 Indeterminate results 
There were no indeterminate results that needed laboratory confirmation. 
3.2.2.1.3 Test sensitivity and specificity 
Blood samples were collected from 81 study participants who had tested negative on the HBV POCT 
and were re-tested for HBsAg by ELISA to ensure the validity of negative HBV POCT results. All were 
confirmed to be negative serologically (8.6%; 95% CI: 7.0%-10.6%). Likewise, all HBV POCT positive 
results were confirmed to be positive serologically (2.2%; 95% CI: 1.4%–3.3%). 
Based on these results, the HBV POCT had 100% sensitivity and specificity (95% CI: 100%–100%) 
under clinic conditions in the present study (Table 3.2-6). 
3.2.2.1.4 Positive and negative predictive values 
In the present study, the PPV and NPV of the HBV POCT were both found to be 100% (95% CI: 100%–
100%) (Table 3.2-6). 
Table 3.2-6 2x2 contingency table showing calculations for sensitivity, specificity, positive and 
negative predictive values (PPV and NPV) 
 Positive on ELISA 
(Gold Standard) 
Negative on ELISA 
(Gold Standard) 
 
Positive on HBV POCT 21 0 
PPV = [21/(21+0)] x 100 
     = 100 
Negative on HBV POCT 0 81 
NPV = [81/(0+81)] x 100 
      = 100 
 Sensitivity = 
[21/(21+0)] x 100 
= 100 
Specificity = 
[81/(0+81)] x 100 
  = 100 
 
HBV POCT: hepatitis B virus Point of Care Test; ELISA: enzyme-linked immunosorbent assay; PPV: 
Positive Predictive Value; NPV: Negative Predictive Value 
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3.2.2.2 HBV POCT perception by study participants 
3.2.2.2.1 Demographics of questionnaire responders 
Evaluation questionnaires were completed by 195 study participants (38 females, 138 males, and 19 
unreported). The median age of the responders was 29 years (range: 19-64 years). 
3.2.2.2.2 Pre-study knowledge about HBV in tested population 
Of the 195 responders, 144 had never heard of HBV previously (73.8%; 95% CI: 67.1%–79.9%) and 
51 had prior knowledge of HBV (26.2%; 95% CI: 20.1%–32.9%). 
3.2.2.2.3 Study participant understanding and perception of HBV POC testing 
Of the 195 responders, 127 (65.1%; 95% CI: 58.2%-71.5%) had prior experience with receiving POC 
testing (such as HIV-1 POC testing). All found the explanation provided by the study nurses to be clear 
and that they had been given the opportunity to ask questions with regard to HBV and the POCT. Eleven 
responders (5.6%; 95% CI: 3.2%-9.8%) found the test to be painful. All were satisfied with the rapid 
test. One responder additionally suggested that the HBV vaccine be made available at the same clinic 
where the test was offered. In this way, individuals who tested negative on the POCT could immediately 
get vaccinated for protection from future exposure.  
3.2.2.2.4 Study participants’ reasons for taking the test 
Study participants were asked their reasons for taking the test and could choose multiple options. Most 
responders (165/195) reported that they wanted to know their status. A smaller number (76/195) also 
indicated that it was a good opportunity to be tested. Some responders (4/195) provided more detailed 
responses and said that getting tested for HBV was a good health initiative. 
3.2.2.3 Reasons for refusing HBV POC testing 
3.2.2.3.1 Demographics 
The HBV evaluation questionnaire was also administered to one in five individuals who were 
approached for testing and refused the test. Of the 86 people who refused testing, 14 (13 male and 1 
female) completed the evaluation questionnaire. The median age was 30 (age range: 20-46). 
3.2.2.3.2 Reasons for refusing testing 
Most responders (6/14) chose “other” as their reason for refusing testing; one refused because they lived 
in a different province, another because they had previously been tested as a kidney transplant patient, 
and a third one because they were reluctant to sign the consent form. The remaining three reported they 
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were not ready to be tested and needed time to think about it. Responders also indicated that they did 
not have time to be tested (4/14), did not think they were at risk (3/14), were scared of needles (2/14), 
and did not have any particular reason why they did not want to be tested (1/14). 
3.2.2.4 Test perception by nursing staff 
A different questionnaire was also administered to eight nurses involved in participant enrolment at the 
five study clinics. 
3.2.2.4.1 Issues with performing the HBV rapid test 
When asked on a scale of 1-5 about the complexity of performing the HBV POCT, all nurses (8/8) 
selected 4 and above, indicating that they were found the POCT easy to perform. While none of the 
nurses (0/8) had problems performing the test itself, two of eight nurses reported that they found the 
blood collection difficult. The HBV POCT required 50 µl of blood and although lancets with a 
penetration depth of 1.6 mm were used to obtain the desired amount of blood, most study participants 
were manual workers with rough, callused hands that made it difficult to pierce the skin for adequate 
blood collection. 
All nurses (8/8) were very confident in their ability to read the results correctly. All (8/8) reported they 
received sufficient training to perform the HBV POCT and all (8/8) trusted the results of the test. This 
correlates with the lack of false positives and false negatives as well as no reported indeterminate results. 
3.2.2.4.2 Perception of the HBV rapid test 
All nurses (8/8) were experienced with performing POC testing having previously conducted HIV-1 
rapid tests. All (8/8) had access to sufficient resources to carry out the POCT in their respective clinics. 
Two of eight nurses reported that the test interfered with their routine clinic duties. When questioned 
on a scale of 1-5 on the importance of providing a patient with their result after only 20 minutes, all 
nurses (8/8) selected 4 and above, indicating that they were all inclined to agree that it was important 
to be able to report the result of the POCT quickly. 
3.2.2.4.3 Adequacy of patient counselling before and after testing 
All nurses (8/8) reported that they were able to provide adequate pre- and post-test information to the 
study participants. When asked to elaborate, they stated that they received proper documentation and 
training from the researcher that equipped them for the task.  
Moreover, five of eight nurses found they were able to provide adequate counselling to the HBV-
positive study participants, two did not encounter HBV-positive study participants and one was unable 
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to provide adequate counselling as there were too many clients being seen at the OH clinic and the 
participants therefore had to wait for a long time before receiving counselling.  
When questioned on the level of knowledge of study participants on HBV, six of eight were inclined to 
describe the level of knowledge of study participants as low. Five of eight nurses were also uncertain 
about whether their patients understood the information they received on HBV. 
3.2.2.4.4 Barriers to HBV POC testing 
All nurses (8/8) reported that patients were not offended when offered HBV POC testing. All (8/8) were 
comfortable discussing HBV POC testing with their patients. None (0/8) thought that offering the test 
affected the patients’ opinion of the clinic. In fact, seven of eight reported that patients were inclined to 
be interested when offered the HBV rapid test.  
The main barrier encountered when offering HBV POC testing was lack of patient awareness (6/8) 
followed by time taken for counselling (1/8), language barriers (1/8), and the fact that the test interrupted 
the routine workflow (1/8). None of the nurses (0/8) reported potential problems with performing the 
test or lack of patient interest as barriers to testing.  
3.2.2.4.5 Concerns with confidentiality of HBV POC testing 
Five of eight nurses observed that patients were concerned with whether their results would remain 
confidential. All (8/8) were able to convey each patient’s result in a confidential manner. 
3.2.2.4.6 Recommendations of nurses on implementation of HBV POCT 
Six of eight nurses agreed that HBV testing was an important part of healthcare while the remaining 
two were unsure of its importance. When asked if they would recommend the test at the clinic, six of 
eight responded affirmatively while two did not know whether to recommend it or not. One nurse was 
unable to recommend the test’s implementation, although they mentioned that the test was an important 
one to provide, as it would be difficult to include it in the routine OH services because of lack of staff 
and time. The other one thought that as an OH clinic, their main focus should be on education and 
prevention and not on active diagnosis. 
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3.3 DISCUSSION 
The aim of the present study was to evaluate the need for and feasibility of HBV POC testing in a South 
African community setting. The main finding of this study was that, in a community-based sample of 
960 patients, the prevalence of HBV was 2.2%. Further considerations of the test revealed excellent 
performance regarding sensitivity, specificity, NPV, and PPV, which were all 100% (95% CI: 100%–
100%). Moreover, study participants who were confirmed to be HBsAg-positive were successfully 
linked to standard care and reviewed by a gastroenterologist. Lastly, the HBV POC test was well-
perceived by the study population and by the nursing staff administering the test. 
 HBV prevalence 
The HBV prevalence of 2.2% observed in the present study is lower than that reported previously in 
two studies conducted in the Western Cape, where prevalences of 3.1% and 4.5% were observed 
respectively (Andersson et al., 2013; Chotun et al., 2017). Although these two studies provided HBV 
prevalence data on an important cohort, namely pregnant women, their results could not be extrapolated 
to the prevalence in the general population. In contrast, the present study was conducted in a 
community-based setting of generally healthy working individuals attending OH clinics and provides a 
more accurate estimate of the real HBV prevalence in the Western Cape Province. 
 Performance of HBsAg POCT 
The HBV POCT performed very well with sensitivity, specificity, NPV, and PPV of 100% (95% CI: 
100%–100%) demonstrating that in the present study, the Determine™ HBsAg test fulfilled the 
ASSURED criterion on sensitivity and specificity for POCTs. It also met the WHO procurement 
eligibility for HBsAg POCTs requiring that such tests have a sensitivity of ≥ 99% and specificity of 
≥ 98%. This finding stands in contrast to what has been reported in field testing of the same rapid test 
in Malawi where the sensitivity and specificity were lower (56% and 69% respectively) due to operator-
dependent variables (Nyirenda, Beadsworth, Stephany, Hart, Hart, et al., 2008). A lower sensitivity 
(88.5%) was also reported in a more recent study in The Gambia (Njai et al., 2015). These discrepancies 
may be explained by rigorous training and dedication to rapid testing as well as better logistics (timers 
were provided to the nurses to ensure that the results were read timeously) that enabled the study nurses 
in the present study to perform the test to the desired standard. 
 Management of HBsAg positive study participants 
The 21 HBsAg positive participants were successfully followed up using routine management protocols 
in place at the Liver Clinic of the Division of Gastroenterology and Hepatology at Tygerberg Hospital, 
a tertiary health care institution in Cape Town, South Africa. This process included baseline assessment 
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of HIV status, biochemical, serological, and virological testing as well as an abdominal ultrasound scan. 
However, in the present study, additional follow-up components were added which included HBV 
genotyping, an assessment and comparison of lifestyle risk factors between HBsAg positive and 
negative study participants, and follow-up of the family and close contacts of HBsAg positive 
individuals. 
3.3.3.1 Routine management 
Routine follow-up of all HBsAg positive study participants showed that most had low viral loads and 
were anti-HBe positive. In addition, HBV-positive study participants also had normal liver enzyme 
levels and normal ultrasound scans. These results suggest that most HBV-positive study participants 
were in the inactive chronic hepatitis phase characterised by the presence of anti-HBe, low viral loads 
(< 2000 IU/ml), and normal ALT levels, although this diagnosis should only be formally made after at 
least three testing events within a one-year follow-up period, according to international guidelines 
(Sarin et al., 2016; Terrault et al., 2016). These findings are important because there is currently little 
known about the natural history of CHB in SSA (Lemoine & Thursz, 2017). However, it has been 
shown elsewhere that HBeAg seroconversion occurs in the second and third decade of life of CHB 
patients and that HBeAg clearance increases with age (Liaw, Chu, Lin, Sheen, Yang, et al., 1984) which 
corresponds with the fact that the HBV-positive cohort in this study was on average in their fourth 
decade of life. 
In this cohort, 3/21 participants (14.3%) were HIV-positive. Only one male HBV-positive study 
participant was positive for HBeAg and co-infected with HIV and was immediately started on ART 
containing tenofovir. The proportion of HBeAg positive individuals in this study was much lower than 
that observed in other studies conducted in pregnant women from the Western Cape (4.8% vs 16.7%-
18.1%) (Andersson et al., 2013; Chotun et al., 2017). Combined with the relatively low viral loads 
observed in the present study, the small proportion of HBeAg positives further suggests that the study 
participants were at low risk of transmitting the virus to their sexual partners and other close contacts. 
There were difficulties encountered by HBV monoinfected study participants in accessing treatment 
compared to HIV/HBV co-infected study participants. The same treatment had to be paid for by HBV 
monoinfected patients but was available free-of-charge to the HBV/HIV co-infected patients as part of 
the national ART programme (Meintjes et al., 2017). Moreover, monoinfected patients had to collect 
monthly prescriptions from the tertiary health care facility compared to co-infected participants who 
could collect their prescriptions from the PHC facility closest to their place of residence. These 
differences are likely to impede adherence to treatment in the monoinfected patients, especially because 
CHB is asymptomatic, and therefore patients are likely to feel less motivated to receive treatment. 
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3.3.3.2 Additional follow-up procedures 
3.3.3.2.1 HBV genotyping 
In this cohort of 21 HBV-positive study participants, the HBV strains in 19 of them were successfully 
sequenced and were equally distributed as either HBV genotype A (subgenotype 1) or D (subgenotypes 
1-4). Although genotype A and D are the two major circulating genotypes in South Africa, genotype A 
is considered to be the predominant one in circulation (Kramvis & Kew, 2007a). However, a recent 
study from the Western Cape showed that 4/5 (80%) of HBV monoinfected mothers were carrying 
genotype D strains (Chotun et al., 2017). 
This finding indicates that genotype D could be increasing in circulation in the Western Cape, which is 
of clinical relevance as genotype D can form precore mutants. In the present study, 1/19 patients (5.3%) 
was infected with a precore mutant that did not express HBeAg and exponentially increased viral 
replication (Jammeh et al., 2008; Tong et al., 1990) despite a positive anti-HBe status (Friedt, Gerner, 
Lausch, Trübel, Zabel, et al., 1999). In fact, her viral load was higher than that of the patient who was 
HBeAg positive. These results suggest that this patient could be in the immune-active HBeAg-negative 
phase of CHB, putting her at risk of HCC despite treatment (Papatheodoridis, Manolakopoulos, 
Touloumi, Nikolopoulou, Raptopoulou-Gigi, et al., 2015). Moreover, these precore mutants can cause 
fulminant hepatitis B if passed on from mother-to-child at birth (Chotun et al., in press). This finding 
highlights the importance of genotyping and viral load testing when managing such patients since 
serological testing alone gives an incomplete picture of the CHB patient’s health status.  
3.3.3.2.2 Follow-up of HBsAg positive participants’ contacts 
None of the followed-up close contacts of the HBV-positive study participants had an active HBV 
infection. However, their sexual partners showed evidence of past exposure to HBV (positive for total 
anti-HBc), although it was not possible to determine the origin of their past infection. Although it is 
possible that the close contacts were exposed to HBV elsewhere, it was anticipated that repeated sexual 
contact with their HBsAg positive partners caused infection with HBV and subsequent clearance, as 
only 5% of adults will develop chronic infections if exposed to HBV in adulthood (Tassopoulos et al., 
1987). Although the HB viral loads at time of diagnosis was low for most of the HBV-positive study 
participants, it is possible that they could have experienced flares in HBV replication when they were 
in the immune-active phase of the HBV life-cycle that would have increased their viral loads (Liaw et 
al., 1987) and, therefore, risks of transmission to their sexual partners.  
 
 Comparison of risk factors between HBsAg-positive and negative cohorts 
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HBsAg positive participants were compared to HBsAg negative participants who were not subjected to 
further follow-up with regard to demographics and lifestyle risk factors. In the present study, the only 
variables that showed a significant difference between the two groups were mean age (p = 0.026) and 
past alcohol misuse (p = 0.049) although current alcohol use was not a significant factor (p = 0.669). 
3.3.4.1 Comparison of sociodemographic risk factors 
When comparing the demographics of the HBsAg positive and negative groups, the mean age of the 
HBsAg positive group was significantly higher than the mean age of the HBsAg negative group. The 
age range of the HBsAg positives was 30–61 and that of the HBsAg negatives was 19–63. As the HBV 
vaccine was introduced to the South African EPI in 1995, anyone below the age of 22 at time of testing 
would have been vaccinated. In the HBsAg-negative cohort, 7% of study participants were in that age 
category and would have been expected to be vaccinated which could explain why the HBV-infected 
cohort was older.  
Although 81% of the HBV-positive study participants were male, sex was not a significant risk factor 
for being infected with CHB (p = 0.233) although this could be caused by the underrepresentation of 
females in the study population. Race was also not a significant risk factor (p = 0.518) although this 
could also potentially be an artefact caused by the underrepresentation of Caucasian, Indian, and 
“Other” ethnicities in the present study. Place of birth (either rural or urban) was not considered to be a 
risk factor for HBV infection in this cohort (p = 0.816), suggesting that with urban expansion and 
development, the differences between urban and rural areas are less significant, making it less likely 
that the place of birth would contribute to CHB development as has been previously reported (Kew, 
1996). 
3.3.4.2 Comparison of clinical and lifestyle risk factors 
Comparisons of clinical and lifestyle risk factors that could contribute to liver disease independently of 
HBV infection were performed between the HBsAg positive and negative groups. This analysis showed 
that only past alcohol misuse was significantly higher in the HBV-positive group (p = 0.049), indicating 
that HBV-positive individuals were more likely to have experienced past excessive alcohol 
consumption. This finding is concerning because of the high reported rates of “binge-drinking” in South 
Africa, South Africans are already significantly exposed to liver damage including cirrhosis and HCC 
(Mohamed et al., 1992) and in the context of an HBV infection, the risk of cancer development is 
significantly increased (Lin et al., 2013; Mohamed et al., 1992). Alcohol misuse was self-reported in 
the present study so there is a possibility of recall and reporting bias in the HBV-positive group. 
However, this risk was minimised by having the participants complete the questionnaires prior to 
knowing their test result. 
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BMI was also not significantly different between the two groups suggesting that HBV-positive 
individuals were not more likely to be overweight or obese than the rest of the South African general 
population. It was concerning to note that 67.1% of the tested population were either overweight or 
obese, both independent risk factors of HCC (Regimbeau et al., 2004). 
Exposure to herbal medicine was not significantly different between the two groups but there was a 
trend in that HBV-positive individuals were more likely to have been exposed to herbal medicine. 
Herbal medicine in South Africa is widely used, from the Aloe vera that is grown in the garden to 
traditional medicine or muti such as the African potato that is given for certain ailments. While some of 
these plants may appear innocuous, they can potentially interact with other medication and reduce their 
efficacy or potency (Fasinu, Gurley & Walker, 2015; Mills, Foster, van Heeswijk, Phillips, Wilson, et 
al., 2005). Moreover, several studies have reported an association between herbal medicine and 
hepatocellular carcinoma because some components of the ingested herbs are metabolised in the liver 
(Ma, Peng & Hu, 2014; Ng, Poon, Huang, Lim, Boot, et al., 2017). 
 Perception of the tested population and nursing staff to the HBV POCT  
In addition to the HBV POCT performance, qualitative aspects of testing were also assessed that could 
impede or advance the application of the test in clinical practice. Towards this objective, perception to 
clinical application of the HBV POCT was assessed in the study population and the study nurses.  
There were no complaints from study participants on the HBV POCT although 5.6% found the test to 
be painful. Once the patients were informed about HBV and its consequences, they were keen on getting 
tested and, in fact, those getting tested reported wanting to know their health status. In addition, study 
nurses had a positive attitude toward the test and the majority agreed that the test should be implemented 
in a health care setting. Moreover, they reported that the test itself was easy to perform, although the 
volume of blood required was prohibitive to the test in instances where the patients had rough callused 
hands. An insufficient amount of blood can lead to a false negative result which is potentially a way in 
which other studies have experienced a decrease in sensitivity with this test (Njai et al., 2015; Nyirenda 
et al., 2008). None of the nurses experienced any trouble with reading the test results once the test had 
been performed, suggesting that with sufficient training and the appropriate resources the nurses 
involved with HIV-1 testing could perform HBV rapid testing. 
The nurses also reported that individuals approached for testing responded positively to being offered 
the HBV POCT. They were not offended when offered the test and were inclined to be interested in 
getting tested. The nurses also reported that study participants were concerned with the confidentiality 
of their test result, which was also mirrored in one of the responses offered by an approached study 
participant who refused testing because he had to sign the consent form before getting tested. This issue 
may be limited to the setting where the study was conducted; the study was carried out in an OH clinical 
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setting where the outcome of the health check performed on the study participants would determine 
whether they could keep their jobs or not. Therefore, this may not be an issue that would be relevant to 
a PHC setting that individuals would attend voluntarily. 
3.3.5.1 Barriers to implementing HBV POC testing 
Knowledge of HBV in this setting was low (only 26.2% of questionnaire responders had any prior 
knowledge of HBV), mirroring what has been reported elsewhere in Africa (Malungu Ngaira et al., 
2016). This lack of knowledge on HBV, in turn, increased the time taken for counselling prior to 
administering the HBV POCT and both factors were considered to be a barrier by 75% of the nurses 
involved in the present study. Similarly, a previous study investigating barriers to carrying out POCTs 
for STIs in general (excluding the test used in the present study) reported that the major issues were 
“time-frame required” (40%), interruption of workflow (30%), and perceived waiting time for patients 
(30%).  
These issues could potentially be resolved if HBV POC testing was offered in a clinical setting, in 
concomitance with HIV-1 testing, where dedicated counsellors would be available for HBV counselling 
and testing. Another potential solution could be the use of multiplex tests that allow simultaneous testing 
for HIV-1, HIV-2, anti-HCV, and HBsAg, once they are validated in this setting (Robin et al., 2018). 
Moreover, two main reasons given for refusing HBV testing were individuals not thinking they were at 
risk and not being ready to get tested, indicating that the reluctance to getting tested could potentially 
decrease as knowledge of HBV and its consequences become more widespread. Language was also 
reported to be a barrier by one nurse and was compounded by the fact that if a translator was not present 
at the time of testing, they could not consent and test the potential participant for HBV. 
The majority of the nurses agreed that the test should be implemented in a health care setting. One 
expressed reservations about its introduction given the lack of staff and the time taken from pre-test 
counselling to post-test counselling. These concerns reflect the need for dedicated staff to perform this 
test as is currently done for HIV-1 testing. 
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 Study strengths and limitations 
The strengths of this study lie in that this is the first cross-sectional South African study seeking to 
determine the prevalence of active HBV infection in a community setting. This study also demonstrated 
successful linkage to care of HBV-positive individuals and importantly followed up their close contacts 
to determine if horizontal transmission had occurred. It is also the first study looking at perception of 
the HBV POCT from both the patient’s and provider’s perspectives. Moreover, it is the first to utilise 
the HBV POCT in addition to HBV genotyping and lifestyle assessment to complement clinical 
assessment of HBsAg positive individuals. It made use of a comprehensive framework to better 
understand the risk factors that may be predisposing HBsAg positive individuals to developing HCC. 
However, there were some limitations that should also be considered. Firstly, cross-sectional studies 
conducted in HIV-infected and uninfected pregnant women in other provinces of South Africa have 
shown significant differences between the HBV prevalence observed in those provinces (Diale, 
Pattinson, Chokoe, Masenyetse & Mayaphi, 2015; Thumbiran, Moodley, Parboosing & Moodley, 2014) 
and that encountered in the Western Cape (Andersson et al., 2013; Chotun et al., 2017). This would 
indicate that the results from the present study cannot be extrapolated to the general South African 
population. Secondly, the present study was conducted at an OH clinic and not a PHC facility, which 
means that the feasibility of implementation of HBV POC testing into routine clinical duties could not 
be studied. However, primary OHCs were targeted so that a healthy population representative of the 
Western Cape could be tested. Thirdly, study participants were not tested for so-called occult HBV 
infections (negative for HBsAg but positive for anti-HBc and levels of HBV DNA ≤ 200 IU/ml) because 
it was beyond the scope of the study objectives. It is therefore possible that the observed HBV 
prevalence has been underestimated. Lastly, although alcohol misuse was the only significant risk factor 
between the HBsAg positive and negative groups, no objective test was used such as the Alcohol Use 
Disorders Identification Test (AUDIT). Future studies should include the use of this test or similar 
objective tests to determine the proportion of patients who misused alcohol.
3.4 CONCLUSION 
The present study has added to the current body of evidence that supports the call for the implementation 
of HBV POC testing in South Africa by demonstrating the feasibility of HBV POC testing 
implementation in a community setting. The HBV point-of-care testing study found the general 
prevalence of HBsAg in a South African community setting to be 2.2%. Moreover, in this study, the 
Determine™ HBsAg test fulfilled the ASSURED criteria, as it was reported to be user-friendly, it was 
inexpensive, rapid and could be stored at room temperature (robust), did not require technical equipment 
to be utilised in a clinical setting, and showed excellent performance in the field with sensitivity, 
specificity, NPV, and PPV of 100%. The test was well-received by study participants and by the nursing 
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staff responsible for administering the test and HBV-positive individuals were successfully linked to 
long-term care and reviewed by a gastroenterologist at a local tertiary health care facility. 
A recent WHO report on HBV surveillance and elimination strongly recommends that HBV screening 
be implemented, at the very least in pregnant women, in regions where the prevalence of HBV in the 
general population is higher than 2% (World Health Organization, 2017c). Importantly, the prevalence 
observed in the general population in the present study shows that South Africa meets this requirement. 
The implementation of HBV POC testing in pregnant women would, at the very least, break the cycle 
of mother-to-child transmission in this setting and move South Africa closer to the possibility of 
eliminating HBV as a major public health issue. Moreover, a recent South African study has shown that 
the implementation of a screen-and-treat HBV intervention for pregnant women alone within the 
framework of a Hepatitis Action Plan had an ICER of $5021 per additional DALY averted was less 
than one times of South Africa’s gross domestic product per capita ($7620) and, therefore, highly cost-
effective (Hecht et al., 2018). 
Most barriers to testing (such as time taken for counselling) that were encountered in the present study, 
were linked to a lack of knowledge of HBV (73.8% of study participants had no prior knowledge of 
HBV). It is therefore recommended that HBV POC testing implementation in South Africa be preceded 
by health campaigns providing information on HBV and its long-term consequences and management. 
It is expected that with increased knowledge of the disease, uptake of the test would be high. Moreover, 
so as to maximise the use of resources, it would be helpful to introduce the HBV POCT to specific 
clinics already involved with STD testing, such as HIV clinics. Although this could potentially 
introduce an additional layer of stigmatisation by association with HIV, this strategy would allow 
counsellors with specialised knowledge in HBV counselling to carry out the test and effectively address 
patient concerns. This is especially important in cases where positive results are obtained and where 
post-test counselling needs to be performed on patients newly diagnosed with HBV. 
As this study was conducted in the Western Cape, it is also recommended that similar studies be carried 
out in community settings in other South African provinces to confirm the results seen in the present 
study.
4. STUDY II: BIOMARKER STUDY 
4.1 MATERIALS AND METHODS 
 Study design 
4.1.1.1 Choice of study design 
In this retrospective case-control study, molecular and histological tests were performed on formalin 
fixed paraffin embedded (FFPE) liver tissue samples previously collected from individuals with and 
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without HCC to identify potential biomarkers that could be used for the early detection of malignancy. 
Toward this aim, FFPE liver tissue samples from patients with a confirmed histological diagnosis of 
HCC irrespective of aetiology were compared to FFPE liver tissue samples from controls without HCC 
for risk factors of HCC development. Molecular testing was performed on the liver tissue samples to 
test for HBV status, HIV status, methylation levels in tumour promoter genes RASSF1A, LINE-1, and 
p16, and presence of the R249S mutation in the human genome within the TP53 gene which is indicative 
of aflatoxin exposure, all well-known risk factors for HCC (see sections 2.5.3.2 and 2.5.3.6). In 
particular, RASSF1A and p16 were selected because of their described involvement in multistep 
hepatocarcinogenesis in the published literature (Um, Kim, Oh, Kim, Kim, et al., 2011; Zhang et al., 
2002) and potential for use as screening markers in HBV-related HCC (Lambert et al., 2011; Lee et al., 
2003). LINE-1 was included as there are 0.5 million long interspersed nucleotide elements (LINE-1 
elements) that are normally heavily methylated, and it is estimated that more than one-third of DNA 
methylation occurs in repetitive elements. Thus, the analysis of the LINE-1 methylation would act as a 
surrogate marker of global hypomethylation (Yang, Estécio, Doshi, Kondo, Tajara, et al., 2004) that 
has been reported to contribute to carcinogenesis through its ability to promote genomic instability 
(Ehrlich, 2002), including hepatocarcinogenesis (Lin et al., 2001). Histological testing was also 
performed to test for cirrhosis.  
4.1.1.2 Rationale for study design 
HCC is rarely diagnosed histologically in SSA (Maponga, 2016) because HCC patients present too late 
to necessitate a biopsy for diagnosis (Kew, 2012). Imaging studies (such as ultrasound and CT scans) 
and biochemical testing (such as serum ALT and AFP levels) are often deemed sufficient to confirm 
the presumptive clinical diagnosis and disease management is often palliative (Bruix & Sherman, 2005; 
Kew, 2012). Therefore, the retrospective nature of this study design enabled the identification of 
multiple cases in a short period of time. Costs associated with recruitment were also avoided as sampling 
(in the form of liver biopsies) was already done and existing hospital records could be used to retrieve 
demographic and medical information on selected samples. However, these data could not be verified 
and in certain instances, were missing which made case-control matching difficult (Lewallen & 
Courtright, 1998; Singh & Mahmud, 2009). 
Samples were divided into two groups, one with HCC (HCC group) and one without HCC (non-HCC 
group), to allow comparison of neoplastic liver tissue to non-neoplastic liver tissue for the identification 
of potential biomarkers that could be used to screen for HCC. 
 Ethical approval and considerations 
This study was first granted ethical approval by the Health Research Ethics Committee (HREC) of 
Stellenbosch University in 2013 (S13/04/084) and by the HREC of the University of Cape Town in 
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2014 (057/2014) (Appendix E). This approval was renewed on a yearly basis after submission of a 
progress report. 
Respect for persons: The hospital records of the patients were reviewed and only their demographical 
information (age, sex, and race) and medical history were retrieved. Since the additional testing 
performed on the retrieved samples was expected to generate information that would be of no clinical 
relevance, either to the patient or any family members of the patient, a waiver of consent was obtained 
from the HREC of Stellenbosch University and all samples were de-identified.  
Autonomy: There was no direct contact between patients and the researcher as this was a retrospective 
study. 
Beneficence: Although there was no benefit for patients from whom these samples were previously 
collected, the results of the study are relevant to a better understanding of HCC in South Africa. 
Non-maleficence: This was a minimal-risk study as retrospective samples in storage were accessed for 
testing.  
Justice: Understanding HCC in the South African context is a prerequisite for developing reliable 
diagnostic tools for its early detection in a setting where HCC affects primarily men in their early forties 
(Yang et al., 2017) and is often diagnosed too late for treatment to be possible (Kew, 2012). 
 Sample size 
This was an exploratory study and therefore all accessible HCC cases matching the study inclusion 
criteria (Figure 4.1-1) were reviewed for potential inclusion in the study. Non-HCC controls matching 
the study inclusion criteria were also reviewed and at least one control per case was included in the 
present study. 
 Study flow 
Stringent search and selection criteria were applied to the study and selected samples were then tested 
as outlined in Figure 4.1-1. 
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Database search 
for cases and 
controls
Histological 
assessment
Selected:
Sufficient tissue
Macroscopic assessment
Selected:
Microtome sectioning
Histological testing
Cirrhosis status by 
Sirius Red staining
Molecular testing
RNase P assay to determine 
amplifiability of gDNA
Cases and controls 
excluded:
Unamplifiable gDNA
HBV testing by real-
time PCR
HBV genotyping by 
Sanger sequencing
Mutation in TP53 testing 
by Sanger sequencing
Methylation level testing in LINE-1, p16, 
and RASSF1A by pyrosequencing
Cases and controls 
excluded:
1. Missing block
2. Insufficient tissue in block
Cases excluded:
1. Insufficient tumour tissue
2. Normal, necrotic, or cirrhotic 
liver tissue
Controls excluded:
1. Insufficient healthy tissue
2. Healthy and tumour tissue 
overlap
Figure 4.1-1 Algorithm for sample selection and study flow  
RNase P: Ribonuclease P; gDNA: genomic DNA; HBV: hepatitis B virus; PCR: polymerase chain reaction; 
TP53: Tumour protein 53; LINE-1: Long interspersed nuclear elements-1; p16: Cyclin-dependent kinase 
inhibitor 2A (CDKN2A)/inhibitor of CDK4; RASSF1A: Ras association domain family 1 isoform A. 
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 Pre-testing phase 
4.1.5.1 Database search for cases and controls 
The Disa*Lab and TrakCare Patient Databases of the National Health Laboratory Services at Tygerberg 
Hospital and Groote Schuur Hospital, two tertiary hospitals in Cape Town, South Africa, as well as the 
National Health Laboratory Services Western Cape Database were searched to identify the case 
numbers of histologically diagnosed HCC and metastatic liver cancer from January 1995 to August 
2017.  
Non-neoplastic (healthy) liver tissue excised from liver biopsies obtained from patients with 
histologically confirmed metastatic liver cancers were used as controls in the present study. In those 
individuals, the tumour did not originate in the liver (in most cases, the tumour originated in the colon 
and metastasised to the liver) and would therefore not have the characteristics of the organ where it 
originated and therefore not have the characteristics of a primary liver cancer such as HCC (Lambert et 
al., 2011). In the biopsies that were selected for the present study, there was sufficient non-neoplastic 
(healthy) liver tissue, adjacent to the metastatic tumour tissue, that could be isolated for DNA extraction 
and testing to be possible.  
Although ideally, liver tissue from healthy individuals should have been used as controls in the present 
study, it is difficult to obtain because liver biopsies are not typically performed on individuals with 
healthy livers. Other options for obtaining control liver tissue included the use of non-neoplastic liver 
tissue from each HCC case (so each HCC case would act as its own control) or cadaverous liver tissues 
from otherwise healthy individuals who had died from trauma or other non-liver related liver diseases. 
The former option was excluded as most liver biopsies in this setting target the neoplastic tissue with 
very little non-neoplastic background liver tissue that could have been used as control. Moreover, 
although a proportion of HCC samples had background tissue that appeared to be non-neoplastic, 
genetic studies would be performed on the samples downstream and it was not possible to ascertain that 
the genome of the non-neoplastic cells of a patient with HCC had not undergone pre-malignant change 
(Sherman, 2008). The second option was excluded after discussion with collaborators on the study 
because most individuals’ livers would have started autolysing at the time of autopsy, making it difficult 
to obtain sufficiently undamaged samples for the present study. 
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4.1.5.2 Selection of cases and controls 
4.1.5.2.1 Histological assessment 
Once potential cases and controls were identified, the corresponding H&E slides were re-assessed 
histologically to confirm the initial diagnosis by a consultant anatomical pathologist with 10 years of 
experience in the field and with a special interest in gastrointestinal and hepatobiliary pathologies 
(Figure 4.1-2 A). Tissue staining and morphology were assessed to determine whether the cases had 
sufficient neoplastic tissue and the controls sufficient non-neoplastic tissue (Figure 4.1-2 B) to be 
included in the present study.  
 
 
 
 
 
 
 
 
 
 
 
 
The consultant anatomical pathologist manually marked neoplastic areas on the HCC H&E slides to aid 
subsequent manual macrodissection (Figure 4.1-2 C) and ensure that DNA could be extracted from 
neoplastic tissue and minimise contamination with non-neoplastic liver tissue DNA. Potential cases 
were discarded if the corresponding H&E-stained sections showed only normal, necrotic, or cirrhotic 
liver tissue or if the neoplastic area was too small to permit DNA extraction. Similarly, when the non-
HCC slides were examined, the consultant anatomical pathologist outlined non-neoplastic liver tissue 
areas to minimise contamination with neoplastic liver tissue DNA in the subsequent DNA extraction 
step. Potential controls were discarded if the corresponding H&E-stained sections showed insufficient 
A    B      C 
Figure 4.1-2 Histological assessment of HCC cases and non-HCC controls Haemotoxylin & 
Eosin stained slides. A The consultant anatomical pathologist assessed the slides to determine 
whether the corresponding cases/controls were suitable for inclusion in the study. B The black arrow 
shows a microscopic view of non-neoplastic (healthy) liver parenchyma. The hepatocytes are 
arranged in plates that are one to two cells thick separated by sinusoids and have a maintained portal 
tract-central vein relationship. The red arrow shows a microscopic view of neoplastic tissue. Here, 
atypical hepatocytes are arranged in plates that are three or more cells thick and have lost portal tract-
central vein relationship. The hepatocyte nuclei are larger, more hyperchromatic, and have less 
abundant cytoplasm. C The neoplastic areas were manually outlined on the hepatocellular carcinoma 
case slides with a fine point permanent marker to aid with manual macrodissection during the 
subsequent DNA extraction step. Similarly, the non-neoplastic liver areas were manually outlined on 
the metastatic liver cancer control slides. 
. 
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non-neoplastic liver tissue or if there were patches of neoplastic tissue within the non-neoplastic 
regions. 
4.1.5.2.2 Macroscopic assessment of FFPE tissue blocks 
Formalin-fixed paraffin-embedded tissue blocks corresponding to cases and controls were thus selected 
and retrieved from storage. Blocks that were missing or were found to have insufficient liver tissue after 
macroscopic examination were excluded from the study. 
4.1.5.3 FFPE tissue sectioning 
FFPE tissue blocks that were included in the study were sectioned using a microtome by a laboratory 
technologist who was experienced in sectioning slides for molecular testing. Since the samples were 
used downstream for molecular applications, several steps were taken to minimise potential nucleic 
acid contamination. Before sectioning any samples, the microtome blade and microtome surfaces were 
wiped down first with 0.35% bleach followed by 70% ethanol. The first few sections of each block 
were discarded as they would have been exposed to the atmosphere and contaminants during storage. 
A new microtome blade was used to section each tissue block to prevent cross-contamination. Each 
section was cut to a thickness of 8 µM and floated on a water bath at 45°C. A non-polarised slide was 
used to capture a maximum of three sections per slide, depending on the surface area of the section and 
air-dried. 
 Testing phase 
4.1.6.1 Molecular testing of cases and controls 
4.1.6.1.1 Nucleic acid extraction from FFPE liver tissue 
A slide extraction protocol previously described by Baker et al. (2013) was modified for the extraction 
process. The slides were incubated overnight at 60°C to melt the wax after which they were 
deparaffinised using three xylene washes. This was followed by two wash steps with 100% ethanol and 
95% ethanol to remove the xylene and two final wash steps with distilled water to remove the ethanol. 
The wash steps were all performed in separate Coplin staining dishes on a shaking tray for five minutes 
at room temperature under a fume hood. The deparaffinised slides were wiped to remove excess water 
(without touching the tissue) and left to air dry. Three sections of appendix tissue were included with 
each batch of extractions to act as controls for the extraction process. 
Subsequently, DNA extraction was carried out on the deparaffinised tissue using either the DNA FFPE 
Tissue Kit or DNeasy Mini Tissue Kit (QIAGEN). The DNA FFPE Tissue Kit (QIAGEN) was initially 
used following manufacturer’s instructions but gave low yields of DNA of poor quality. The slide 
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extraction method was subsequently found to produce the best DNA yield and quality. Therefore, DNA 
was extracted from a first batch of 10 samples using the DNA FFPE Tissue Kit and the remaining 
samples were extracted with the DNeasy Mini Tissue Kit (QIAGEN) which was less expensive than 
the DNA FFPE Tissue Kit and used the same reagents, with the exception of the elution buffer. 
Firstly, 180 µl of lysis buffer from the kits were aliquoted into 1.5 ml microcentrifuge tubes 
corresponding to each sample or control. Manual macrodissection was performed using scalpels on all 
FFPE tissue sections using the marked H&E slides to guide the dissection. Next, tissue digestion was 
achieved by adding 20 µl proteinase-K to each tube and incubating at 56°C. Where the overnight 
incubation was insufficient for digestion, 2 µl proteinase-K solution was added to the tubes and 
incubated for a further hour until the solution was clear. FFPE samples often present with degraded 
DNA because of crosslink formation between formaldehyde and DNA. In order to remove the 
crosslinks, the samples were further incubated at 90°C for one hour. After incubation, the tubes were 
vortexed for 15 s and centrifuged briefly to remove drops from the lids. Then, 200 µl of lysis buffer and 
100% ethanol were added to the tubes and the solutions transferred to silica gel membrane spin columns 
and centrifuged at 5800 RCF for two minutes. The membrane-bound DNA was washed with 500 µl of 
two different buffers to remove all ethanol. The columns were then placed in new collection tubes and 
centrifuged at full speed for three minutes to eliminate wash buffer carry-over. Finally, the DNA was 
eluted twice in 30µl of elution buffer in two separate tubes. The FFPE kit used elution buffer ATE (10 
mM Tris-Cl pH 8.3, 0.1 mM EDTA, and 0.04% sodium-azide) that was meant to help preserve sensitive 
DNA. The DNeasy kit, on the other hand, used buffer AE (10 mM Tris-Cl, 0.5 mM EDTA, pH 9.0). 
The use of either buffer did not compromise the extracted DNA or the molecular applications conducted 
downstream. 
4.1.6.1.2 RNase-P assay to assess amplifiability of genomic DNA from tissue samples 
A commercially available human Ribonuclease (RNase) P assay was used to determine whether the 
genomic DNA extracted was amplifiable as described previously (Life Technologies, 2013). This 
housekeeping gene was chosen as it is present in all cells. In addition, the assay produced an amplicon 
of 87 bp that was small enough to be detectable by real-time PCR on degraded FFPE DNA. This real-
time assay used a ready-made primer-probe master mix and followed a demonstrated protocol on the 
ABI 9700 (ThermoFisher Scientific) platform (Life Technologies, 2013).  
A 1:10 and 1:20 dilution of each DNA extract was prepared using the same elution buffer provided with 
the kit. A PCR master mix was then prepared for 20 µl reactions using the components given in table 
4.1-1. 
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Table 4.1-1 RNase-P assay master mix components according to manufacturer’s instructions 
(ThermoFisher Scientific) 
Component Volume/µl 
Taqman® Universal PCR Master Mix (2X) 10.0 
20X RNase P primer-Probe mix 1.0 
Nuclease-free water 6.5 
µl: microlitre; X: times; RNase: ribonuclease 
A 96-well plate was used for real-time PCR and 17.5 µl of master mix was added to each well to be 
used. This was followed by 2.5 µl of each sample DNA in their 1:10 and 1:20 dilutions in triplicate. 
Lastly, 2.5 µl of nuclease-free water was added to the plate in triplicate. The plate was then sealed 
securely with adhesive film, vortexed briefly to mix the reagents and template DNA in each well, and 
centrifuged at 100 RCF for five minutes to collect the contents at the bottom of the plate. The plate was 
then loaded onto the Applied Biosystems® 7500 Real-Time PCR instrument (ThermoFisher Scientific) 
and the real-time PCR performed at the cycling parameters in Table 4.1-2. 
Table 4.1-2 Real-time PCR cycling parameters, according to manufacturer’s instructions 
(ThermoFisher Scientific) 
Cycling parameter Cycles Temperature Time 
UNG Incubation Hold 50°C 2 min 
Enzyme activation Hold 95°C 10 min 
PCR denaturation 
40 cycles 
95°C 15 s 
PCR annealing/extension 60°C 1 min 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.3 Determination of HBV status by real-time PCR 
Two methods were used to determine the HBV status of samples tested in the present study. Firstly, the 
hospital records of the patients were reviewed to determine whether the HBV status of the patient was 
known. Secondly, irrespective of whether the HBV status was known or unknown, the samples were 
all subjected to a monoplex, hydrolysis probe-based, real-time PCR assay modified from Garson et al. 
2005 to determine their HBV status. 
The HBV primers and probe used in this assay target a highly conserved 97 base-pair area in the pre-
S2 region of the surface gene (Table 4.1-3). The probe used a tetramethyl-6-Carboxyrhodamine 
(TAMRA) quencher and FAM as the reporter dye. 6-carboxyfluorescein (FAM) has an emission 
wavelength of 517 nm which can be detected by the green channel of the real-time PCR instrument. 
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A master mix was prepared for the desired number of samples and controls using the appropriate 
volumes and concentrations for each reagent (Table 4.1-4). The QuantiTect Probe PCR Kit (QIAGEN) 
was used for this reaction because of its high sensitivity in detecting low-copy numbers.  
Table 4.1-3 Primer sequences for HBV real-time PCR and amplicon size, Garson et al. 2005 
Name of primer Sequence Amplicon size 
HBV_Forward 5′-GTG TCT GCG GCG TTT TAT CA-3′ 
97 bp 
HBV_Reverse 5′- GAC AAA CGG GCA ACA TAC CTT-3′ 
HBV_Probe 5′ FAM-CCT CT(T/G) CAT CCT GCT GCT ATG CCT CAT C-
3′-TAMRA 
 
5′: 5 prime; 3′: 3 prime; bp: base pair; FAM: 6-carboxyfluorescein; TAMRA: tetramethyl-6-
Carboxyrhodamine 
 
 Table 4.1-4 Master mix composition for HBV real-time PCR, Garson et al. 2005 
Fifteen microlitres of the master mix were distributed in individual 0.2 ml PCR tubes and 10 μl of DNA 
extract from each sample or nuclease-free water as control was added to their respective tubes for a 
final reaction volume of 25 μl. The real-time PCR was then performed using the cycling parameters in 
Table 4.1-5. 
Table 4.1-5 Cycling parameters of HBV real-time PCR, Garson et al. 2005 
Cycling parameter  Cycles  Temperature Time 
Initial denaturation  1 hold  95°C 15 min 
Denaturation  
45 cycles 
95°C 15 s 
Annealing/Extension  60°C 60 s 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.4 HBV genotyping 
All cases and controls found to be positive by real-time PCR were also subjected to an HBV genotyping 
assay previously described (Ruiz-Tachiquín, Valdez-Salazar, Juárez-Barreto, Dehesa-Violante, Torres, 
et al., 2007) with some modifications to the PCR master-mix (4.1-7).  
 
 Volume/μl Starting Concentration Final Concentration 
QuantiTect Probe PCR Buffer  12.50 2X 1X 
HBV_Forward Primer 0.10 100 μM 400 nM 
HBV_Reverse Primer 0.10 100 μM 400 nM 
HBV_Probe 0.05 100 μM 200 nM 
Water 2.25 n/a n/a 
Total volume 15.00 n/a n/a 
X: times; mM: millimolar;  U: unit; µM: micromolar; n/a: not applicable 
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This assay targeted the “a-determinant” region of the HB viral genome and amplified a fragment of 279 
bp that was short enough to be amplified from DNA extracted from FFPE tissue samples and large 
enough for accurate genotyping. 
4.1.6.1.4.1 Amplification using PCR 
Two rounds of PCR were carried out using primer sets described in Table 4.1-6. The pre-nested PCR 
master mix (Table 4.1-7) was aliquoted in volumes of 20 µl to which 5 µl of sample DNA was added. 
The nested PCR master mix (Table 4.1-8) was aliquoted in volumes of 49 µl to which 1 µl of the pre-
nested product was added. The thermocycling parameters for the pre-nested and nested PCRs are given 
in Tables 4.1-9 and 4.1-10. 
Table 4.1-6 Pre-nested and nested primers used for HBV genotyping, Ruiz-Tachiquín et al. 2007 
Name of primer Sequence Amplicon size 
HBV-1 sense 5'-CGCTGGATGTGTCTGCGGCGT-3' 
334 bp 
HBV-2 antisense 5'-CGAACCACTGAACAAATGGCA CT-3' 
HBV-3 sense 5'-CATCCTGCTGCTATGCCTCATCT-3' 
279 bp 
HBV-4 antisense 5'-GGCACTAGTAAACTGAGCCA-3' 
5′: 5 prime; 3′: 3 prime; bp: base pair 
 
 Table 4.1-7 Pre-nested PCR master mix for HBV genotyping, Ruiz-Tachiquín et al. 2007 
(adapted) 
 
 
 
Components Volume/µl Starting concentration Final concentration 
QIAGEN Taq Buffer 2.5 10X 1X 
HBV 1-sense 0.4 25 µM 0.4 µM 
HBV 2-antisense 0.4 25 µM 0.4 µM 
Deoxynucleoside triphosphate mix 1 10 mM each 0.32 mM each 
Hot Star DNA polymerase 0.1 5 U/µl 0.5 U/µl 
Nuclease-free water 15.6 n/a n/a 
Total (excluding DNA) 20 n/a n/a 
X: times; mM: millimolar;  U/µl: unit per microlitre; µM: micromolar; n/a: not applicable 
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Table 4.1-8 PCR cycling parameters for pre-nested PCR, Ruiz-Tachiquín et al. 2007 
Cycling parameter Cycles Temperature Time 
Initial denaturation  1 hold 95°C 15 min 
Denaturation 
45 
94°C 30 s 
Annealing 55°C 90 s 
Extension 72°C 60 s 
Final extension 1 hold 72°C 15 min 
°C: degrees Celsius; min: minute; s: second 
Table 4.1-9 Nested PCR master mix for HBV genotyping, Ruiz-Tachiquín et al. 2007 
 
Table 4.1-10 PCR cycling parameters for nested PCR, Ruiz-Tachiquín et al. 2007 
Cycling parameter Cycles Temperature Time 
Initial denaturation  1 hold 95°C 15 min 
Denaturation 
40 
94°C 30 s 
Annealing 55°C 90 s 
Extension 72°C 60 s 
Final extension 1 hold 72°C 15 min 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.4.2 Gel electrophoresis 
A 2% agarose gel was prepared by melting 1.5 g of agarose powder (SeaKem® LE Agarose, Maine, 
USA) in 75 ml of 1X SB Buffer. Five microlitres of each PCR product was mixed with one microlitre 
of Novel Juice (GeneDireX Inc., Taoyuan, Taiwan) and pipetted into wells on the agarose gel to separate 
any PCR product according to size. The samples were electrophoresed alongside a 100 bp DNA ladder 
(GeneRuler™ 100 bp DNA Ladder, ThermoFisher Scientific) for 30 minutes at 100 V. The agarose gel 
was then visualised under ultraviolet light at a wavelength of 254 nm using the Platinum HD Gel 
Components Volume/µl Starting concentration Final concentration 
QIAGEN Taq Buffer 5 10X 1X 
HBV 1-sense 0.8 25 µM 0.4 µM 
HBV 2-antisense 0.8 25 µM 0.4 µM 
Deoxynucleoside triphosphate mix 2 10 mM each 0.32 mM each 
Hot Star DNA polymerase 0.2 5 U/µl 0.5 U/µl 
Nuclease-free water 40.2 n/a n/a 
Total (excluding DNA) 49 n/a n/a 
X: times; mM: millimolar;  U/µl: unit per microlitre; µM: micromolar; n/a: not applicable 
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Documentation System (UVItec Limited, Cambridge, UK) and the image acquired using the UVIband-
1D gel analysis software. PCR products with visible bands of the correct size were selected for further 
testing downstream. 
4.1.6.1.4.3 Purification of PCR products 
PCR products were purified using the QIAamp PCR Purification Kit (QIAGEN) by following 
manufacturer’s instructions. Five volumes of binding buffer were first added to one volume of PCR 
product and the mixture applied to silica gel membrane spin columns to allow efficient binding of the 
amplified DNA to the column membrane. This was followed by a wash step using 750 µl of an ethanol-
containing buffer to ensure the removal of primers and other impurities that could inhibit sequencing 
downstream. A centrifugation step in an empty tube then ensured the removal of residual ethanol-
containing buffer. The DNA was finally eluted in 30 µl of elution buffer containing 10 mM Tris-Cl, pH 
8.5. 
4.1.6.1.4.4 Sequencing PCR 
Sequencing PCR reactions were carried out in a 96-well plate using the two nested PCR primers (Table 
4.1-6) to sequence the region of interest, as per manufacturer’s instructions. A master mix consisting of 
the components listed in Table 4.1-11 was prepared and distributed in volumes of 8 µl into the 
appropriate number of wells. Next, 1 µl of each primer and 1 µl of purified template DNA (20–30 ng) 
from each sample was added to the appropriate wells. The cycling conditions shown in Table 4.1-12 
were used. 
Table 4.1-11 Sequencing reaction master mix, adapted from manufacturer’s instructions 
(ThermoFisher Scientific) 
 
 
 
 
Reagent Volume/µl 
ABI Sequencing Buffer 3 
Big Dye Terminator 1 
Primer, 2 µM 1 
Water 3 
Total volume 8 
µl: microliter;  µM: micromolar 
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Table 4.1-12 Cycling parameters for HBV genotyping sequencing reaction, adapted from 
manufacturer’s instructions (ThermoFisher Scientific) 
Cycling parameter Cycles Temperature Time 
Denaturation 
30 
96°C 20 s 
Annealing 50°C 20 s 
Extension 60°C 4 min 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.4.5 Sequencing PCR purification 
The sequencing PCR reaction products were purified using the BigDye® Xterminator Purification Kit 
consisting of SAM™ and XTerminator® solutions as per manufacturer’s instructions (ThermoFisher 
Scientific); 45 μl of SAM solution and 10 μl of Xterminator® solution were added to each well before 
the wells were sealed with adhesive film. The 96-well plate was vortexed for 30 minutes at 2000 RCF 
and centrifuged for 1 minute at 1000 RCF. 
4.1.6.1.4.6 Capillary electrophoresis and sequencing analysis 
Capillary electrophoresis was performed on the samples using the ABI Prism 3130XL Genetic Analyzer 
(ThermoFisher Scientific). The information obtained was converted to raw data files using DNA 
sequencing analysis software (ThermoFisher Scientific). The length of the capillaries allowed sequence 
reads of approximately 1 Kb. 
The raw trace files were further analysed using Geneious R11 (Biomatters Ltd., Auckland, New 
Zealand). The quality of each sequence was improved individually by looking at the chromatograms 
and trimming the ends where necessary. The forward and reverse sequences for each sample were 
aligned to create a consensus sequence. Mismatches or ambiguities were verified manually. A reference 
sequence was created using the corresponding primer sequences and used to trim the sequences beyond 
the primer region. 
The consensus sequence was saved in FASTA format before being aligned against the Stanford 
University HBVSeq sequence database to obtain the HBV genotype (Rhee et al., 2010). 
The HBV genotype was further confirmed by phylogenetic analysis and comparing the sample 
sequences with reference sequences obtained from GenBank. 
4.1.6.1.5 Testing for past exposure to aflatoxin 
All cases and control liver samples were also tested for past exposure to aflatoxin by testing for the 
presence of the R249S mutation in exon 7 of the human gene TP53, which codes for the tumour 
Stellenbosch University  https://scholar.sun.ac.za
 84 
 
suppressor protein p53, using an established Sanger sequencing protocol developed by the International 
Agency for Research on Cancer (IARC) (International Agency for Research on Cancer, 2010). 
4.1.6.1.5.1  Amplification using PCR 
Two separate PCR reactions were carried out using two different sets of primers covering exon 7 (Table 
4.1-13). 
 Table 4.1-13 Primer sequences and amplicon size, International Agency for Research on Cancer, 
2010 
Name of primer Sequence Amplicon size 
P-237 F 5′-aggcgcactggcctcatctt-3′ 
177 bp 
P-238 R 5′-tgtgcagggtggcaagtggc-3′ 
P-333 F 5′-cttgccacaggtctccccaa-3′ 
237 bp 
P-313 R 5′-aggggtcagaggcaagcaga-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair 
PCR master mixes were prepared for the corresponding number of samples and controls according to 
the primer set being used (Tables 4.1-14 and 4.1-15) using a minimum of 3 ng of DNA. The PCR was 
carried out using the parameters given in Table 4.1-16 and 4.1-17. 
 Table 4.1-14 PCR Master mix used with primers P-237 F and P-238 R, International Agency for 
Research on Cancer, 2010 
 
 
Components Volume/µl Starting concentration Final concentration 
PCR buffer without magnesium chloride 4 5X 1X 
Magnesium chloride 1.2 25 mM 1.5 mM 
P-237 F 0.8 10 µM 0.4 µM 
P-238 R 0.8 10 µM 0.4 µM 
Deoxynucleoside triphosphate mix 0.8 5 mM each 0.2 mM each 
GoTaq Hot Start DNA polymerase 0.1 5 U/µl 0.5 U/µl 
Nuclease-free water 
12.3 
n/a n/a 
DNA ~ 3 ng n/a 
Total 20 n/a n/a 
µl: microlitre; X: times; mM: millimolar; U/µl: unit per microliter; µM: micromolar; ng: nanogram; n/a: not 
applicable 
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 Table 4.1-15 PCR Master mix used with primers P-333 F and P-313 R, International Agency for 
Research on Cancer, 2010 
 
 Table 4.1-16 PCR cycling parameters with primers P-237 F and P-238 R, International Agency 
for Research on Cancer, 2010 
Table 4.1-17 PCR cycling parameters with primers P-333 F and P-313 R, International Agency 
for Research on Cancer, 2010 
Cycling parameter Cycles Temperature Time 
Initial denaturation  1 hold 95°C 15 min 
Denaturation 
50 
94°C 30 s 
Annealing 60°C 30 s 
Extension 72°C 30 s 
Final extension 1 hold 72°C 10 min 
°C: degrees Celsius; min: minute; s: second 
Components Volume/µl Starting concentration Final concentration 
PCR buffer with 15 mM magnesium 
chloride  
2 10X 1X 
Q-Solution 4 5X 1X 
Deoxynucleoside triphosphate mix 0.8 5 mM each 0.2 mM each 
P-333 F 0.8 10 µM 0.4 µM 
P-313 R 0.8 10 µM 0.4 µM 
Hot StartTaq DNA polymerase 0.1 5 U/µl 0.5 U/µl 
Nuclease-free water 
11.5 
n/a n/a 
DNA 3 ng n/a 
Total 20 n/a n/a 
µl: microlitre; X: times; mM: millimolar; U/µl: unit per microlitre; µM: micromolar; ng: nanogram; n/a: not 
applicable 
Cycling parameter Cycles Temperature Time Special parameters 
Initial denaturation  1 hold 94°C 2 min  
Denaturation 
20 
94°C 30 s  
- 0.5°C every 3 cycles 
Annealing 63°C 45 s 
 Extension 72°C 1 min 
Denaturation 
30 
94°C 30 s 
None Annealing 60°C 45 s 
Extension 72°C 1 min 
Final extension 1 hold 72°C 10 min  
°C: degrees Celsius; min: minute; s: second 
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4.1.6.1.5.2 Agarose gel electrophoresis 
A 2% agarose gel was prepared by melting 1.5 g of agarose powder (SeaKem® LE Agarose, Maine, 
USA) in 75 ml of 1X SB Buffer. Five microlitres of each PCR product was mixed with one microlitre 
of 6X Novel Juice (GeneDireX Inc., Taoyuan, Taiwan) and pipetted into wells on the agarose gel to 
separate any PCR product according to size. The samples were electrophoresed alongside a 100 bp 
DNA ladder (GeneRuler™ 100 bp DNA Ladder, ThermoFisher Scientific) for 30 minutes at 100 V. 
The agarose gel was then visualised under ultraviolet light at a wavelength of 254 nm using the Platinum 
HD Gel Documentation System (UVItec Limited, Cambridge, UK) and the image acquired using the 
UVIband-1D gel analysis software. PCR products with visible bands of the correct size were selected 
for further testing downstream. 
4.1.6.1.5.3 Purification of PCR products 
The PCR products were purified using the MinElute PCR Purification Kit (QIAGEN) by following 
manufacturer’s instructions. A buffer was first added to the PCR products and the mixture applied to 
silica gel membrane spin columns to allow efficient binding of the amplified DNA to the column 
membrane. This was followed by a wash step using an ethanol-containing buffer to ensure the removal 
of primers and other impurities that could inhibit sequencing downstream. A centrifugation step in an 
empty tube then ensured the removal of residual ethanol-containing buffer. The DNA was finally eluted 
in 10 µl of elution buffer containing 10 mM Tris-Cl, pH 8.5. 
4.1.6.1.5.4 Sequencing PCR 
Sequencing PCRs were carried out in a 96-well plate using the same primers used for PCR amplification 
reactions (Table 4.1-14). A master mix consisting of the components listed in Table 4.1-19 was prepared 
and distributed in volumes of 8 µl into the appropriate number of wells. Next, 1 µl of each primer and 
1 µl of purified template DNA from each sample was added to the appropriate wells. The cycling 
conditions shown in Table 4.1-20 were used. 
Table 4.1-18 Sequencing PCR master mix, adapted from manufacturer’s instructions 
(ThermoScientific) 
Reagent Volume/µl 
ABI Sequencing Buffer 3 
Big Dye Terminator 1 
Primer, 2 µM 1 
Water 3 
Total volume 8 
µl: microlitre; µM: micromolar 
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 Table 4.1-19 Cycling parameters for TP53 sequencing reaction, adapted from manufacturer’s 
instructions (ThermoScientific) 
Cycling parameter Cycles Temperature Time 
Denaturation 
30 
96°C 10 s 
Annealing 58°C 5 s 
Extension 60°C 2.5 min 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.5.5 Sequencing PCR purification 
The sequencing PCRs were purified using the BigDye® Xterminator Purification Kit consisting of 
SAM™ and XTerminator® solutions as per manufacturer’s instructions (ThermoScientific); 45 μl of 
SAM solution and 10 μl of Xterminator® solution were added to each well before the wells were sealed 
with adhesive film. The 96-well plate was vortexed for 30 minutes at 2000 RCF and centrifuged for 
1 minute at 1000 RCF. 
4.1.6.1.5.6 Capillary electrophoresis and sequencing data analysis 
Capillary electrophoresis was performed on the samples using the ABI Prism 3130XL Genetic Analyzer 
(ThermoFisher Scientific). The information obtained was converted to raw data files using DNA 
sequencing analysis software (ThermoFisher Scientific). The length of the capillaries allowed sequence 
reads of approximately 1 Kb. 
The raw trace files were further analysed using Geneious R11 (Biomatters Ltd., Auckland, New 
Zealand). The quality of each sequence was improved individually by looking at the chromatograms 
and trimming the ends where necessary. The forward and reverse sequences for each sample were 
aligned to create a consensus sequence. Mismatches or ambiguities were verified manually. A reference 
sequence was created using the corresponding primer sequences and was used to trim the sequences 
beyond the primer region. 
The consensus sequence was renamed and saved in FASTA format before being aligned against the 
National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) 
Human Genome GRCh37.p13. Aflatoxin exposure would cause a non-synonymous G>C transversion 
that would cause an amino acid change at codon 747 (R249S) on chromosome 17. 
4.1.6.1.6 Determination of methylation levels in tumour promoter genes 
Pyrosequencing on the Pyromark Q96 ID (QIAGEN) was used to quantitatively analyse the level of 
DNA methylation in CpG islands in the promoter regions of the following human genes of interest: 
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RASSF1A, LINE-1, and p16. This assay was applied to all HCC cases and non-HCC controls included 
in the present study. 
The seven p16 deoxycytidylyl-deoxyguanosine dinucleotides (CpG) sites targeted in this study were 
located in the CpG island of the promoter region of exon 1 of the cyclin-dependent kinase Inhibitor 2A 
(CDKN2A) gene located in chromosome 9 of the human genome (Huang, Krocker, Kirk, Merwat, Ju, 
et al., 2014). The six RASSF1A CpG sites targeted in the present study were located in the CpG island 
of the promoter region of exon 6 of the RASSF1A gene located in chromosome 3 of the human genome 
(Vaissière, Cuenin, Paliwal, Vineis, Hainaut, et al., 2009). Altered CpG island methylation in those 
genes has been associated with their silencing in cancers (Matsuda, Ichida, Matsuzawa, Sugimura & 
Asakura, 1999; Merlo, Herman, Mao, Lee, Gabrielson, et al., 1995). The LINE-1 primers amplified 
repetitive elements of 146-148 bp present on all chromosomes and contained three CpG sites (Yang et 
al., 2004). LINE-1 was included as there are 0.5 million long interspersed nucleotide elements (LINE-
1 elements) that are normally heavily methylated, and it is estimated that more than one-third of DNA 
methylation occurs in repetitive elements. Thus, the analysis of the LINE-1 methylation would act as a 
surrogate marker of global hypomethylation (Yang et al., 2004) that has been reported to contribute to 
carcinogenesis through its ability to promote genomic instability (Ehrlich, 2002), including 
hepatocarcinogenesis (Lin et al., 2001). 
The gold standard for DNA methylation analysis is bisulfite sequencing where bisulfite treatment of 
DNA converts unmethylated cytosines to uracil, which is subsequently read as thymine, whereas 
methylated cytosines resist this conversion and the CG sequence is preserved (Frommer, McDonald, 
Millar, Collis, Watt, et al., 1992). Several technologies can be used to distinguish between methylated 
and unmethylated DNA, such as methylation-specific PCR, microarray, or COLD-PCR. However, these 
methods are expensive, time-consuming, and are limited because they are not quantitative or can only 
quantify a few CpG sites at a time. Pyrosequencing overcomes these constraints by allowing the 
simultaneous analysis of multiple CpG sites within a target sequence of up to 200 bp (Kurdyukov & 
Bullock, 2016). Pyrosequencing also requires a low amount of input DNA (10 ng) for accurate and 
reproducible analysis. These features make pyrosequencing ideal for FFPE DNA methylation analysis. 
The following steps were followed for DNA methylation analysis in RASSF1A, LINE-1, and p16: 
1. Bisulfite conversion of sample DNA 
2. PCR amplification using primers targeting the region of interest 
3. Pyrosequencing 
4.1.6.1.6.1 Bisulfite conversion of DNA 
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Bisulfite conversion was performed on DNA extracted from all cases and controls using the EpiTect® 
Fast Bisulfite Conversion Kit (QIAGEN) according to the manufacturer’s instructions. A master mix 
was prepared using the components and volumes provided in Table 4.1-20. 
Table 4.1-20 Bisulfite reaction master mix according to manufacturer’s instructions (QIAGEN) 
The amount of input DNA was between 1 ng and 2 µg and the final combined volume of DNA and 
RNase-free water added to each PCR tube was 20 µl. After DNA addition, the master mix was aliquoted 
in volumes of 120 µl to each PCR tube. One additional tube was used as a negative control and contained 
20 µl of RNase-free water and the master mix. Each PCR tube was closed and vortexed thoroughly to 
ensure proper mixing and centrifuged briefly to bring the solution to the bottom of the tube. The bisulfite 
conversion was carried out in a thermocycler using the cycling conditions in Table 4.1-21 with 
incubation times of 20 minutes to ensure complete bisulfite conversion. 
Table 4.1-21 Bisulfite conversion thermal cycling conditions, according to manufacturer’s 
instructions (QIAGEN) 
Cycling parameter Time Temperature 
Denaturation 5 min 95°C 
Incubation 20 min 60°C 
Denaturation 5 min 95°C 
Incubation 20 min 60°C 
Hold Indefinite 20°C 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.6.2 Purification of bisulfite-converted DNA 
The purification of bisulfite-converted DNA was carried out according to manufacturer’s instructions 
(QIAGEN). The PCR tubes were removed from the thermocycler and centrifuged before their contents 
were transferred to sterile 1.5 ml microcentrifuge tubes. Carrier-RNA at a final concentration of 
10 µg/ml was first added, followed by a buffer promoting binding of the converted single-stranded DNA 
to the silica gel membrane spin columns. The tubes were mixed by vortexing and centrifuged briefly; 
100% ethanol was added and the tubes mixed and vortexed for 15 s and centrifuged briefly to collect 
the contents at the bottom of the tubes. The contents of each PCR tube were transferred to silica gel 
membrane spin columns with collection tubes provided with the kit. These columns were then 
Reagent Volume per reaction, µl 
Bisulfite Solution 85 
DNA Protect Buffer 35 
Total volume 120 
µl: microliter 
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centrifuged at 15 500 RCF for one minute and the flow-through discarded. The membrane-bound DNA 
was washed with a buffer to remove residual bisulfite solution and the columns were centrifuged at 
15 500 RCF for one minute. A desulfonation buffer was then added and the columns were incubated at 
room temperature (15–25°C) for 15 minutes. After incubation, the columns were centrifuged at 
15 500 RCF for one minute and the flow-through discarded. Two consecutive wash steps were 
performed each followed by a centrifugation step at 15 500 RCF for one minute. After a final wash step 
with 100% ethanol and centrifugation at 15 500 RCF for one minute, the columns were placed in new 
2 ml collection tubes and centrifuged for a further minute at maximum speed to remove any residual 
ethanol. Columns were then placed into sterile 1.5 ml microcentrifuge tubes and incubated, with the lids 
open, at 60°C for five minutes to ensure evaporation of any remaining ethanol. Lastly, the columns 
were placed in 1.5 ml microcentrifuge tubes and 15 µl of an elution buffer was added to the centre of 
each column and incubated for one minute before being centrifuged at 15 500 RCF for one minute to 
elute the DNA. Bisulfite-converted DNA was stored at 2–8°C if it was used within 24 hours or at -20°C 
if it needed to be stored for longer. 
4.1.6.1.6.3 PCR amplification 
A master-mix containing HotStarTaq DNA polymerase (QIAGEN), PCR buffer (QIAGEN) with 
1.5 mM MgCl2, dNTPs, and two primers was prepared for this PCR. One of the two primers used was 
biotinylated at its 5′ end in order to prepare a single-stranded PCR product for use in the subsequent 
pyrosequencing procedure. The amplicon produced was short in length and was less than 200 bp long 
which is an optimal length for pyrosequencing. 
The Pyromark PCR Master Mix (QIAGEN) containing the above-listed components, except for the 
primers, was recommended for PCR amplification of bisulfite-converted DNA which is a difficult PCR 
template to use as all unmethylated cytosines would have been converted to uracils, resulting in a less 
complex DNA template consisting of adenines, guanines, and thymidines/uracils only. The components 
of this kit ensured that the PCR retained its specificity and sensitivity while preventing the accumulation 
of biotinylated PCR primer and artefacts that could interfere with the subsequent pyrosequencing step 
(QIAGEN).  
For each primer pair used in this study (Table 4.1-22), trial PCR reactions were first conducted to ensure 
that the primers were working optimally. Reactions were performed in parallel with and without Q-
solution (Table 4.1-23) provided with the kit to determine the effect the Q-solution would have on PCR 
yield (amplification of a reaction that previously failed, increased efficiency, no effect, or reduced 
efficiency). 
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Table 4.1-22 Primers used in PCR reaction prior to pyrosequencing. *p16 primers were obtained 
from Huang et al. 2014, #RASSF1A primers from Vaissière et al. 2009, and †LINE-1 primers from Yang 
et al., 2004 
Name of primer Sequence Amplicon size 
p16-F* 5′- aggggttggttggttattag-3′ 
75 bp 
p16-R* 5′- Biotin-ctacctactctccccctctc-3′ 
RASSF1A-F# 5′-agtttggattttgggggagg-3′ 
136 bp 
RASSF1A-R# 5′- Biotin-caactcaataaactcaaactcccc-3′ 
LINE-1 F† 5′-ttttgagttaggtgtgggatata-3′ 
148 bp 
LINE-1 R† 5′-aaaatcaaaaaattccctttc-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair 
 
Table 4.1-23 PCR reaction prior to pyrosequencing, according to manufacturer’s instructions 
(QIAGEN) 
Reagent 
Volume/reaction 
with Q-solution, µl 
Volume/reaction 
without Q-solution, µl 
Final 
concentration 
Pyromark PCR Master Mix 2X 12.5 12.5 1X 
Coral load concentrate 10X 2.5 2.5 1X 
Q-solution 5X 5.0 0.0 1X 
Primer A, 50 µM 0.1 0.1 0.2 µM 
Primer B, 50 µM 0.1 0.1 0.2 µM 
Total volume 20.2 15.2 n/a 
µl: microlitre; X: times; µM: micromolar; n/a: not applicable 
The additional components of the reaction were RNase-free water and the DNA template. These were 
added separately according to the amount of input bisulfite-converted DNA. RNase-free water was first 
added to each corresponding well in a PCR plate, followed by 20 ng of bisulfite-converted DNA for a 
total volume of 4.8 µl for the reactions with Q-solution and 9.8 µl for the reactions without Q-solution. 
The master mixes were then gently mixed by pipetting up and down before being aliquoted into the 
PCR wells. An adhesive film cover was then used to cover the wells of the plate. The plate was 
centrifuged at 1000 RCF for one minute and placed in the thermocycler. The PCR reactions were then 
performed according to the thermal cycling conditions in Table 4.1-24 to Table 4.1-26. Two-fold serial 
dilutions were also performed on a sample of known high DNA concentration to determine the 
minimum amount of DNA required for successful PCR reactions for each primer pair. 
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Table 4.1-24 Thermal conditions for p16 PCR reaction prior to pyrosequencing, Huang et al. 2014 
(adapted) 
Step  Time Temperature 
Enzyme activation step 15 min 95°C 
Denaturation 
45 cycles 
30 s 94°C 
Annealing* 30 s 56°C 
Extension 30 s 72°C 
Final extension  10 min 72°C 
°C: degrees Celsius; min: minute; s: second; p16: cyclin-dependent kinase inhibitor 2A/inhibitor of 
CDK4 
 
Table 4.1-25 Thermal conditions for RASSF1A PCR reaction prior to pyrosequencing, Vaissière 
et al. 2009 (adapted) 
Step  Time Temperature 
Enzyme activation step 15 min 95°C 
Denaturation 
45 cycles 
30 s 94°C 
Annealing* 30 s 60°C 
Extension 30 s 72°C 
Final extension  10 min 72°C 
°C: degrees Celsius; min: minute; s: second 
 
Table 4.1-26 Thermal conditions for LINE-1 PCR reaction prior to pyrosequencing adapted from 
Yang et al., 2004 
Step  Time Temperature 
Enzyme activation step 15 min 95°C 
Denaturation 
45 cycles 
30 s 94°C 
Annealing* 30 s 50°C 
Extension 30 s 72°C 
Final extension  10 min 72°C 
°C: degrees Celsius; min: minute; s: second 
4.1.6.1.6.4 Pyrosequencing of PCR products 
Pyrosequencing uses sequencing-by-synthesis and detection of visible light by a charged coupled device 
camera attached to the pyrosequencer. After PCR amplification of the region of interest, the amplicon 
was denatured into single-stranded form to which a sequencing primer was annealed. Nucleotides were 
added in a predetermined order in each pyrosequencing cycle. Complementary nucleotides were 
incorporated into the DNA strand releasing pyrophosphate which was converted to ATP by ATP 
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sulfurylase in the presence of adenosine 5' phosphosulfate. The ATP produced was then used to convert 
luciferin to oxyluciferin by luciferase, generating visible light. The amount of light generated was 
proportional to the number of nucleotides incorporated. The results were then displayed in the form of 
peaks in a pyrogram with an average methylation level for each CpG site being analysed (Choudhuri, 
2014). The methylation detection limit at individual CpG sites was approximately 5% (Mikeska, 
Felsberg, Hewitt & Dobrovic, 2011; Wu, Yang, Wang, Chen & Santella, 2017). 
The first time each assay was performed, the following controls were included to ensure that none of 
the reagents and primers being used would create background amplification and signals that would 
compromise the results obtained during pyrosequencing of the samples included in the present study: 
1. A non-template PCR control to verify that the PCR primers were not interacting and to verify there 
was no DNA contamination from an external source. 
2. A PCR control with template DNA but no sequencing primer to verify that the template was not 
looping back on itself. 
3. Sequencing primer without any PCR product to verify that the sequencing primer was not forming 
duplexes or hairpins. 
4. Biotinylated primer without any PCR product to verify that the biotinylated primer was not forming 
duplexes or hairpins. 
5. Sequencing primer and biotinylated primer together without PCR product to verify that the 
sequencing primer and the biotinylated primer were not forming. 
 Pyrosequencing assay setup 
The pyrosequencing assay was first set up on the computer linked to the Pyromark Q96 ID using the 
Pyromark Q96 ID Version 2.5.10 software (QIAGEN). Each assay had a “Sequence to Analyse” which 
corresponded to the CpG sites being analysed after bisulfite treatment within the gene of interest (Table 
4.1-27) and which was kindly provided by collaborators at the Mailman School of Public Health, 
Department of Environmental Health Sciences, Columbia University in the City of New York (Prof 
Regina Santella, personal communication). Based on this sequence, a nucleotide dispensation order was 
automatically generated by the software. A bisulfite conversion control was also inserted within the 
Sequence to Analyse to ensure completeness of the bisulfite conversion process performed prior to the 
PCR reaction. Three different assays were prepared for p16, RASSF1A, and LINE-1, respectively. A 
virtual plate corresponding to the wells to be analysed was created for each reaction. 
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Table 4.1-27 “Sequence to Analyse” for genes of interest, Prof Regina Santella (personal 
communication) 
Gene Sequence to Analyse 
RASSF1A YGTTYGGTTYGYGTTTGTTAGYGTTTAAAGTTAGYG 
P16 GGGGYGGATYGYGTGYGTTYGGYGGTTGYGGAGA 
LINE-1 TTYGTGGTGYGTYGTTT 
P16: cyclin-dependent kinase inhibitor 2A/inhibitor of CDK4; LINE-1: Long Interspersed 
Nuclear Elements-1; RASSF1A: Ras association domain family 1 isoform A; YG: CpG site after 
bisulfite conversion, Y could be a T or a C 
 
 Immobilisation of PCR product to sepharose beads 
Biotinylated PCR products were immobilized on streptavidin-coated Sepharose beads (GE Healthcare, 
Chicago, Illinois) as per manufacturer’s instructions (QIAGEN). A master mix of streptavidin-coated 
Sepharose beads, binding buffer, and high-purity water was prepared (Table 4.1-28) for use with 20 µl 
of biotinylated PCR product and aliquoted in volumes of 60 µl into the wells of a PCR plate (QIAGEN). 
Table 4.1-28 Master mix for immobilisation of PCR product to sepharose beads, as per 
manufacturer’s instructions (QIAGEN) 
Reagent Volume per reaction, µl 
Streptavidin-coated Sepharose beads 1.5 µl 
PyroMark Binding Buffer 40 µl 
High-purity water Variable 
µl: microlitre 
The PCR plate was then sealed with an adhesive film and agitated for at least 10 minutes at 1400 rpm 
using a mixer. 
 PCR product strand separation 
During the shaking step, a master mix with sequencing primer (Table 4.1-29) in annealing buffer was 
prepared (Table 4.1-30) and aliquoted in volumes of 40 µl into wells of a PyroMark Q96 Plate Low 
(QIAGEN) corresponding to the PCR plate, all as per manufacturer’s instructions (QIAGEN). 
Table 4.1-29 Pyrosequencing primer sequence, p16 sequencing primer from Huang et al. 2014, 
RASSF1A sequencing primer from Vaissière et al. 2009, and LINE-1 sequencing primer from 
Yang et al., 2004 
Name of primer Sequence 
p16-S 5′-ggttggttattagagggt-3′ 
RASSF1A-S 5′-gggttagttttgtggttt-3′ 
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LINE-1 S 5′-agttaggtgtgggatatagt-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair; p16: cyclin-dependent kinase inhibitor 2A/inhibitor of CDK4; 
RASSF1A: Ras association domain family 1 isoform A; LINE-1: Long Interspersed Nuclear 
Elements-1 
 
Table 4.1-30 Master mix for annealing primer, as per manufacturer’s instructions (QIAGEN) 
Reagent Initial concentration Final Concentration Volume per reaction, µl 
Annealing Buffer   38.4 µl 
Sequencing primer 10 µM 0.4 µM 1.6 µl 
Total volume   40 µl 
µl: microlitre; µM: micromolar 
Following manufacturer’s instructions, the vacuum workstation was prepared for the next step, strand 
separation. The five different troughs of the vacuum workstation (Figure 4.1-3) were filled with the 
following different solutions:  
1. Approximately 110 ml of 70% ethanol (Position 1) 
2. Approximately 90 ml Denaturation Solution (Position 2) 
3. Approximately 110 ml Wash Buffer (Position 3) 
4. Approximately 110 ml high-purity water (Position 4) 
5. Approximately 180 ml high-purity water (Parking Position, “P”) 
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Figure 4.1-3 Vacuum workstation with different working solutions for strand separation  
ml: millilitre; %: per cent 
The vacuum pump was switched on and the filter probes flushed with 180 ml Milli-Q water. After 
shaking, the PCR plate was placed onto the workstation (Figure 4.1-3). The tool with the filter probes 
was lowered into the PCR plate to capture the beads with the immobilized template. The tool was then 
transferred to trough 1 with 70% ethanol to wash residual salts and unlabelled DNA, then to trough 2 
with denaturing solution to denature the DNA to single-stranded form and finally to trough 3 with wash 
buffer to neutralise the denaturing solution and allow pyrosequencing to proceed at the right conditions. 
The tool was then raised beyond 90° vertical for 5 s to drain all the liquid from the filter probes. The 
probes were aligned to the Pyromark Q96 Plate Low (QIAGEN), the vacuum switched off and the 
probes lowered into the wells and shaken vigorously to transfer the samples.  
 Annealing of sequencing primer 
The Pyromark Q96 Plate Low (QIAGEN) was then placed onto a heating block at 80°C for two minutes 
to eliminate any secondary structure in the single-stranded template that could interfere with primer 
annealing or enzymatic addition of nucleotides. It was then allowed to cool to room temperature (15–
25°C) for at least 5 min. 
 Preparing the pyrosequencer 
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The appropriate volumes of enzyme, substrate, and nucleotides were obtained from the Pyromark Q96 
ID Version 2.5.10 software (QIAGEN). These reagents were pipetted into a cartridge using filter-free 
tips. The cartridge was loaded onto the Pyromark Q96 ID instrument. 
 Performing pyrosequencing reaction 
After the cool-down period, the Pyromark Q96 Plate Low (QIAGEN) was placed onto the Pyromark 
Q96 ID instrument (QIAGEN) and the pyrosequencing reaction was started. 
 Pyrosequencing results analysis 
The results of the pyrosequencing reaction were analysed in CpG mode using the PyroMark Q96 
Version 2.5.10 software (QIAGEN). A pyrogram with peaks corresponding to the sequence of interest 
was generated. The methylation levels for each targeted CpG site were evaluated by converting the peak 
heights of the pyrograms to numerical values and expressed either as the percentage of methylation for 
individual CpG sites or as the mean of all CpG sites analysed in the region of interest. Quality control 
verifications were performed by the Pyromark software to determine the reliability of the results. Non-
CpG sites were used as reference peaks and compared to the expected peak heights generated from the 
original Sequence to Analyse input into the assay file. Typically, CpG sites that passed the quality 
control stage were marked in blue, those that deviated from expected peak heights were indicated in 
yellow, and CpG sites that failed were assigned red. Pyrograms that failed the quality control checks 
were verified individually to determine if the sample needed to be retested. 
4.1.6.2 Histological testing 
4.1.6.2.1 Determination of cirrhosis status 
Two methods were used to determine if cirrhosis was observed on the tissue sections. Firstly, 
histopathological reports associated with each liver sample were reviewed to determine if a diagnosis 
of cirrhosis was recorded. Secondly, sample sections were stained with Sirius Red and were reviewed 
histologically by an experienced consultant anatomical pathologist to determine the level of fibrosis 
(Sweat, Puchtler & Rosenthal, 1964). 
 Post-testing phase – statistical analyses 
Statistical analyses were performed using SPSS Statistics for Windows, Version 25.0 (IBM Corp., New 
York, USA). A p value of less than 0.05 was considered statistically significant. Ages were reported as 
mean ± SD. The methylation data were analysed as reported previously (Lambert et al., 2011). The 
hypermethylation frequency in the HCC group was calculated based on the number of HCC samples 
with methylation levels above the 95th percentile observed in the non-HCC group.  
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Cross-tabulations with frequency tables were first used to determine significance of all variables tested 
in the present study. Subsequently, the Mann-Whitney U test was used to determine the significance of 
the differences between cases and controls for non-parametric data. Logistic regression analysis was 
performed to verify whether any of the risk factors (HBsAg positivity, HBV genotype, aflatoxin 
exposure, promoter hypermethylation levels in p16, RASSF1A, and LINE-1) or clinical characteristics 
(sex, age, race, and cirrhosis status) could be predictors of HCC. Univariate logistic regressions were 
first performed to identify potential confounding variables that were then included in a multivariate 
model. A backward stepwise approach was used to build a parsimonious multivariate model; 
independent variables identified from the univariate model were removed in a stepwise manner from 
the full model and the fit of the new model tested at each step. The best predictive variables and their 
corresponding predicted probabilities were used to calculate sensitivity, specificity, NPV, and PPV. No 
corrections for multiple testing were performed in the present study because it was considered to be too 
conservative for two reasons. First, all the comparisons that were performed in the present study were 
pre-specified in the protocol. Second, this was an exploratory study and did not have sufficient power 
to apply correction for multiple testing. 
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4.2 RESULTS 
 Selection of cases and controls 
From a pool of 87 potential cases and 119 potential controls histologically diagnosed from January 1995 
to August 2017, 34 cases and 33 controls fitted the inclusion criteria and were included in the present 
study. After DNA extraction from all FFPE liver tissues, one case and one control were further excluded 
from the study as the RNase P assay showed that they had unamplifiable DNA. 
 Demographics of cases and controls 
A comparison of the demographics of unmatched cases and controls is given in Table 4.2-1. Mean age 
was found to be different between the case and control groups and this was statistically significant. 
Table 4.2-1 Comparison of demographics of cases and controls included in study 
 Cases 
n = 33 
Controls 
n = 32 
p-value 
Age, Mean ± SD 42.09 ± 15.37 54.53 ± 13.01 0.001* 
Sex 
Female 10 (30.3%) 16 (50%) 
0.105 
Male 23 (69.7%) 16 (50%) 
Race 
Black 8 (24.2%) 7 (21.9) 
0.896 
Coloured 5 (15.2%) 5 (15.6) 
Caucasian 6 (18.2%) 6 (18.7) 
Indian 1 (3.0%) 0 (0.0) 
Unknown 13 (39.4%) 14 (43.8) 
*: level of significance set at p < 0.05; SD: Standard deviation; %: per cent; n: number 
 
 HBV status retrieved from medical records 
Of the 33 HCC cases selected for the present study, only two had records of prior HBV testing. One 
was positive for HBV infection and the other was negative for HBV infection. Of the 32 controls, none 
had a medical record of previous HBV testing.  
All cases and controls were subjected to HBsAg testing by real-time PCR. Of the 33 HCC cases, 25 
(75.8%) were positive for HBsAg (including the case that was known to be HBV-positive) and of the 
32 non-HCC controls, 10 (31.3%) were positive for HBsAg. 
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 Results from molecular testing of cases and controls 
Table 4.2.2 shows the hypermethylation cut-offs calculated for each CpG site in RASSF1A and p16. 
Table 4.2-2 95th percentile hypermethylation cut-off 
p16 CpG site 95th percentile (hypermethylation cut-off) 
CpG site 1 6.8% 
CpG site 2 6.0% 
CpG site 3 2.4% 
CpG site 4 0.0% 
CpG site 5 6.0% 
CpG site 6 6.0% 
CpG site 7 9.8% 
Overall % methylation 2.8% 
RASSF1A CpG site 95th percentile (hypermethylation cut-off) 
CpG site 1 64.4% 
CpG site 2 68.4% 
CpG site 3 60.2% 
CpG site 4 47.4% 
CpG site 5 51.8% 
CpG site 6 62.6% 
Overall % methylation 51.8% 
p16: cyclin-dependent kinase inhibitor 2A/inhibitor of CDK4; RASSF1A: Ras 
association domain family 1 isoform A; CpG: deoxycytidylyl-deoxyguanosine 
dinucleotides 
Molecular testing showed that HBsAg status, p16 hypermethylation levels at CpG sites 2, 4-6, and 
RASSF1A overall hypermethylation levels as well as hypermethylation levels at CpG sites 1, 3-6, were 
significantly different between the case and control groups (Table 4.2-3). The distribution of the 
methylation percentages observed in all cases and controls is shown using the box-whisker plots 
(Figures 4.2-1 and 4.2-2). 
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Table 4.2-3 Comparison of results from molecular testing between the HCC and non-HCC groups 
 HCC group 
n = 33 
Non-HCC group 
n = 32 
p-value 
HBsAg status    
Positive 25 (75.8%) 10 (31.3%) 
0.0005* 
Negative 8 (24.2%) 22 (68.8%) 
Aflatoxin exposure n = 33 n = 32  
Yes 1 (3.0%) 0 (0.0%) 
0.297 
No 30 (90.9%) 27 (84.4%) 
Unknown 2 (6.1%) 5 (15.6%)  
p16 hypermethylation n = 33 n = 31  
CpG site 1 6 (18.2%) 1 (3.2%) 0.105 
CpG site 2 6 (18.2%) 0 (0.0%)   0.025* 
CpG site 3 7 (21.2%) 1 (3.2%) 0.054 
CpG site 4 8 (24.2%) 0 (0.0%) 0.005* 
CpG site 5 6 (18.2%) 0 (0.0%) 0.025* 
CpG site 6 6 (18.2%) 0 (0.0%) 0.025* 
CpG site 7 6 (18.2%) 1 (3.2%) 0.105 
Overall % methylation 6 (18.2%) 1 (3.2%) 0.105 
RASSF1A hypermethylation  n = 31 n = 31  
CpG site 1 8 (25.8%) 1 (3.2%) 0.026* 
CpG site 2 6 (19.4%) 1 (3.2%) 0.104 
CpG site 3 11 (35.5%) 1 (3.2%) 0.003* 
CpG site 4 14 (45.2%) 1 (3.2%) < 0.01* 
CpG site 5 11 (35.5%) 1 (3.2%) 0.003* 
CpG site 6 10 (32.3%) 1 (3.2%) 0.006* 
Overall % methylation 14 (45.2%) 1 (3.2%) < 0.01* 
*: level of significance set at p < 0.05; CpG: deoxycytidylyl-deoxyguanosine dinucleotides; %: per 
cent; p16: cyclin-dependent kinase inhibitor 2A/inhibitor of CDK4; RASSF1A: Ras association 
domain family 1 isoform A 
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Figure 4.2-2 Box-whisker plot demonstrating distribution of percentage (%) methylation at the 
different RASSF1A CpG sites in cases and controls RASSF1A: Ras association domain family 1 
isoform A 
 Results from comparisons of HBsAg positive cases and controls 
Sub-group analyses were conducted between HBsAg positive cases and controls. As none of the HBsAg 
positive controls belonged to genotype A, the odds ratio could not be calculated. Hence, one control of 
unknown HBV genotype was reclassified as belonging to genotype A to remove the zero frequency. 
Figure 4.2-1 Box-whisker plot demonstrating distribution of percentage (%) methylation at the 
different p16 CpG sites in cases and controls The median, 25th percentile, and 75th percentile were 
all zero. p16: Cyclin-dependent kinase inhibitor 2A (CDKN2A)/inhibitor of CDK4 
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Significant differences in age, HBV genotype, and overall promoter methylation in RASSF1A as well 
as at CpG sites 3–5 were observed between the two groups (Tables 4.2-4 and 4.2-5). 
Table 4.2-4 Comparison of demographics of HBsAg positive cases and controls included in study 
 HBsAg +ve cases 
n = 25 
HBsAg +ve controls 
n = 10 
p-value 
Age, Mean ± SD 41.40 ± 15.17 55.60 ± 16.02 0.019* 
Sex    
Female 7 (28.0%) 4 (40.0%) 
0.689 
Male 18 (72.0%) 6 (60.0%) 
Race    
Black 5 (20.0%) 4 (40.0%) 
0.636 
Coloured 4 (16.0%) 1 (10.0%) 
Caucasian 3 (12.0%) 2 (20.0%) 
Indian 1 (4.0%) 0 (0.0%) 
Unknown 12 (48.0%) 3 (30.0%) 
*: level of significance set at p < 0.05; SD: Standard deviation; %: per cent; +ve: positive; -ve: negative 
 
Table 4.2-5 Comparison of molecular testing results of HBsAg positive cases and controls 
included in study 
 HBsAg +ve cases 
n = 25 
HBsAg +ve controls 
n = 10 
p-value 
HBV genotype    
A 9 (36%) 1 (10%) 
0.012* 
D/E 3 (12%) 6 (60%) 
Unknown 13 (52%) 3 (30%)  
Aflatoxin exposure n = 25 n = 10  
Yes 1 (4%) 0 (0%) 
0.804 No 22 (88%) 9 (90%) 
Unknown 2 (8%) 1 (10%) 
p16 hypermethylation n = 25 n = 10  
CpG site 1 4 (16%) 1 (10%) 1.000 
CpG site 2 4 (16%) 1 (10%) 1.000 
CpG site 3 5 (20%) 0 (0%) 0.292 
CpG site 4 5 (20%) 1 (10%) 0.649 
CpG site 5 4 (16%) 1 (10%) 1.000 
CpG site 6 4 (16%) 1 (10%) 1.000 
CpG site 7 4 (16%) 0 (0%) 0.303 
Overall % methylation 4 (16%) 1 (10%) 1.000 
RASSF1A hypermethylation  n = 23 n = 10  
CpG site 1 6 (26.1%) 0 (0.0%) 0.145 
CpG site 2 5 (21.7%) 0 (0.0%) 0.291 
CpG site 3 9 (39.1%) 0 (0.0%) 0.032* 
CpG site 4 11 (47.8%)  0 (0.0%) 0.013* 
CpG site 5 9 (39.1%) 0 (0.0%) 0.032* 
CpG site 6 8 (34.8%) 0 (0.0%) 0.071 
Overall % methylation 11 (47.8%)  0 (0.0%) 0.013* 
*: level of significance set at p < 0.05; %: per cent; +ve: positive; HBV: hepatitis B virus; p16: cyclin-
dependent kinase inhibitor 2A/inhibitor of CDK4; RASSF1A: Ras association domain family 1 
isoform A; CpG: CpG: deoxycytidylyl-deoxyguanosine dinucleotides 
Stellenbosch University  https://scholar.sun.ac.za
 104 
 
 Results from logistic regression analyses 
Univariate analyses showed that none of the p16 CpG sites were significant predictors of HCC (Table 
4.2-6). However, when adjusted for HBV status and age, p16 CpG 4 was a significant predictor of HCC 
(OR: 10.905, 95% CI: 1.113–106.821) and had an improved sensitivity of 84.8%, specificity of 67.7%, 
PPV of 73.7%, and NPV of 80.8% (Table 4.2-8).  
Univariate analyses showed that RASSF1A CpG sites 1, 3-6 and overall percentage methylation of the 
promoter region of RASSF1A were significant predictors of HCC (p < 0.05 for all) (Table 4.2-7), 
although they had poor sensitivities as HCC predictors (19.4%–45.2%) (Table 4.2-8). After controlling 
for HBV status, these variables were still significant predictors of HCC and had improved sensitivities 
(77.4%–83.9%) (Table 4.2-8). 
The sub-group univariate analyses in HBsAg positive cases and controls showed that age and HBV 
genotype, in particular, HBV genotype A, were significant predictors for HCC (Table 4.2-9). Logistic 
regression analyses could not be performed on the RASSF1A methylation data as there was a zero 
frequency in the control group (none of the HBsAg positive controls were hypermethylated) and the 
sample size was too small (n = 10) to move one of the non-hypermethylated controls to the 
hypermethylated group to remove this zero frequency (Appendix F).  
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Table 4.2-6 Univariate and multivariate logistic regression analyses for demographics and p16 hypermethylation 
 
 Cases  
n = 33 
Controls  
n = 31 
    
Variable   Crude OR (95% CI) Significance OR (95% CI)* Significance 
Age - - 0.941 (0.905–0.979) 0.002* 0.942 (0.903–0.983) 0.006* 
HBsAg status - - 6.875 (2.307–20.490) 0.001* - - 
Hypermethylation status       
p16 CpG site 1       
Negative 27 (81.8%) 30 (96.8%) 1.0 
0.088 
1.0 
0.119 
Positive 6 (18.2%) 1 (3.2%) 6.667 (0.754–58.970) 6.332 (0.621–64.525) 
p16 CpG site 2       
Negative 27 (81.8%) 30 (96.8%) 1.0 
0.088 
1.0 
0.119 
Positive 6 (18.2%) 1 (3.2%) 6.667 (0.754–58.970) 6.332 (0.621–64.525) 
p16 CpG site 3       
Negative 26 (78.8%) 30 (96.8%) 1.0 
0.058 
1.0 
0.050 
Positive 7 (21.2%) 1 (3.2%) 8.077 (0.931–70.043) 10.113 (1.002–102.023) 
p16 CpG site 4       
Negative 25 (75.8%) 30 (96.8%) 1.0 
0.039 
1.0 
0.040* 
Positive 8 (24.2%) 1 (3.2%) 9.600 (1.123–82.048) 10.905 (1.113–106.821) 
p16 CpG site 5       
Negative 27 (81.8%) 30 (96.8%) 1.0 
0.088 
1.0 
0.119 
Positive 6 (18.2%) 1 (3.2%) 6.667 (0.754–58.970) 6.332 (0.621–64.525) 
p16 CpG site 6       
Negative 27 (81.8%) 30 (96.8%) 1.0 
0.088 
1.0 
0.119 
Positive 6 (18.2%) 1 (3.2%) 6.667 (0.754–58.970) 6.332 (0.621–64.525) 
p16 CpG site 7       
Negative 27 (81.8%) 30 (96.8%) 1.0 
0.088 
1.0 
0.062 
Positive 6 (18.2%) 1 (3.2%) 6.667 (0.754–58.970) 9.367 (0.897–97.787) 
p16 overall methylation       
Negative 27 (81.8%) 30 (96.8%) 1.0  1.0 
0.062 
Positive 6 (18.2%) 1 (3.2%) 3.222 (0.598–17.358) 0.173 9.367 (0.897–97.787) 
p16: cyclin-dependent kinase inhibitor 2A/inhibitor of CDK4; OR: odds ratio; CI: confidence interval *adjusted for HBsAg status 
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Table 4.2-7 Univariate and multivariate logistic regression analyses for RASSF1A hypermethylation status 
 
 
 Cases n = 31 Controls n = 31     
Hypermethylation status   Crude OR (95% CI) Significance OR (95% CI)* Significance 
RASSF1A CpG site 1 
Negative 23 (74.2%) 30 (96.8%) 1.0 
0.032* 
1.0 
0.036* 
Positive 8 (25.8%) 1 (3.2%) 10.435 (1.217–89.461) 11.318 (1.168–109.636) 
RASSF1A CpG site 2 
Negative 25 (80.6%) 30 (96.8%) 1.0 
0.076 
1.0 
0.108 
Positive 6 (19.4%) 1 (3.2%) 7.200 (0.812–63.854) 6.627 (0.659–66.663) 
RASSF1A CpG site 3 
Negative 20 (64.5%) 30 (96.8%) 1.0 
0.010* 
1.0 
0.018* 
Positive 11 (35.5%) 1 (3.2%) 16.500 (1.973–137.996) 14.463 (1.595–131.173) 
RASSF1A CpG site 4 
Negative 17 (54.8%) 30 (96.8%) 1.0 
0.003* 
1.0 
0.005* 
Positive 14 (45.2%) 1 (3.2%) 24.706 (2.983–204.639) 23.043 (2.568–206.766) 
RASSF1A CpG site 5 
Negative 20 (64.5%) 30 (96.8%) 1.0 
0.010* 
1.0 
0.018* 
Positive 11 (35.5%) 1 (3.2%) 16.500 (1.973–137.996) 14.463 (1.595–131.173) 
RASSF1A CpG site 6 
Negative 21 (67.7%) 30 (96.8%) 1.0 
0.014* 
1.0 
0.022* 
Positive 10 (32.3%) 1 (3.2%) 14.286 (1.698–120.203) 13.315 (1.441–123.037) 
RASSF1A overall methylation 
Negative 17 (54.8%) 30 (96.8%) 1.0 
0.003* 
1.0 
0.005* 
Positive 14 (45.2%) 1 (3.2%) 24.706 (2.983–204.639) 23.043 (2.568–206.766) 
RASSF1A: Ras association domain family 1 isoform A; OR: odds ratio; CI: confidence interval *adjusted for HBsAg status 
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Table 4.2-8 Sensitivity and specificity of variables in discriminating between HCC and non-HCC cases 
Variable Sensitivity Specificity PPV NPV Sensitivity* Specificity* PPV* NPV* 
HBsAg status 75.8% 68.8% 71.4% 73.3% - - - - 
p16         
CpG site 1 18.2% 96.8% 85.7% 52.6% 81.8% 67.7% 73.0% 77.8% 
CpG site 2 18.2% 100.0% 100.0% 53.4% 81.8% 67.7% 73.0% 77.8% 
CpG site 3 21.2% 96.8% 87.5% 53.6% 81.8% 64.5% 71.1% 77.0% 
CpG site 4 24.2% 100.0% 100.0% 55.4% 84.8% 67.7% 73.7% 80.8% 
CpG site 5 18.2% 100.0% 100.0% 53.4% 81.8% 67.7% 73.0% 77.8% 
CpG site 6 18.2% 100.0% 100.0% 53.4% 81.8% 67.7% 73.0% 77.8% 
CpG site 7 18.2% 96.8% 85.7% 52.6% 81.8% 64.5% 71.1% 77.0% 
Overall methylation 18.2% 96.8% 85.7% 52.6% 81.8% 64.5% 71.1% 77.0% 
RASSF1A         
CpG site 1 25.8% 96.8% 88.9% 56.6% 80.6% 64.5% 69.4% 77.0% 
CpG site 2 19.4% 96.8% 85.7% 54.5% 77.4% 64.5% 68.6% 74.1% 
CpG site 3 35.5% 96.8% 91.7% 60.0% 80.6% 64.5% 69.4% 77.0% 
CpG site 4 45.2% 96.8% 93.3% 63.8% 83.9% 64.5% 74.3% 80.0% 
CpG site 5 35.5% 96.8% 91.7% 60.0% 80.6% 64.5% 69.4% 77.0% 
CpG site 6 32.3% 96.8% 90.9% 58.8% 80.6% 64.5% 69.4% 77.0% 
Overall methylation 45.2% 96.8% 93.3% 63.8% 83.9% 64.5% 74.3% 80.0% 
PPV: positive predictive value; NPV: negative predictive value; HBsAg: hepatitis B surface antigen; p16: cyclin-dependent kinase inhibitor 2A/inhibitor of 
CDK4; RASSF1A: Ras association domain family 1 isoform A; CpG: CpG: deoxycytidylyl-deoxyguanosine dinucleotides. *adjusted for HBsAg status 
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 Table 4.2-9 Univariate and multivariate logistic regression analyses for age, genotype, and p16 hypermethylation status in HBsAg positive cases and 
controls 
 Cases 
n = 25 
Controls 
n = 10 
    
 Crude OR (95% CI) Significance OR (95% CI)* Significance 
HBV genotype       
A 9 1 18.000 (1.496–216.620) 0.023* - - 
Age 25 10 0.943 (0.895–0.994) 0.030* 0.963 (0.904–1.025) 0.236 
Hypermethylation status 
p16 CpG site 1       
Negative 21 (84%) 9 (90%) 1.0 
0.650 
1.0 
0.374 
Positive 4 (16%) 1 (10%) 1.714 (0.167–17.554) 3.601 (0.214–60.588) 
p16 CpG site 2 
Negative 21 (84%) 9 (90%) 1.0 
0.650 
1.0 
0.374 
Positive 4 (16%) 1 (10%) 1.714 (0.167–17.554) 3.601 (0.214–60.588) 
p16 CpG site 3 
Negative 20 (80%) 10 (100%) 1.0 
- 
1.0 
- 
Positive 5 (20%) 0 (0%) - - 
p16 CpG site 4 
Negative 20 (80%) 9 (90%) 1.0 
0.487 
1.0 
0.309 
Positive 5 (20%) 1 (10%) 2.250 (0.229–22.144) 4.110 (0.270–62.477) 
p16 CpG site 5 
Negative 21 (84%) 9 (90%) 1.0 
0.650 
1.0 
0.374 
Positive 4 (16%) 1 (10%) 1.714 (0.167–17.554) 3.601 (0.214–60.588) 
p16 CpG site 6 
Negative 21 (84%) 9 (90%) 1.0 
0.650 
1.0 
0.374 
Positive 4 (16%) 1 (10%) 1.714 (0.167–17.554) 3.601 (0.214–60.588) 
p16 CpG site 7 
Negative 21 (84%) 10 (100%) 1.0 
- 
1.0 
- 
Positive 4 (16%) 0 (0%) - - 
p16 overall methylation 
Negative 21 (84%) 9 (90%) 1.0 
0.650 
1.0 
0.374 
Positive 4 (16%) 1 (10%) 1.714 (0.167–17.554) 3.601 (0.214–60.588) 
p16: Cyclin-dependent kinase inhibitor 2A (CDKN2A)/inhibitor of CDK4; RASSF1A: Ras association domain family 1 isoform A; HBV: hepatitis B 
virus; OR: odds ratio *adjusted for HBV genotype 
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4.3 DISCUSSION 
The present case-control study sought to identify biological predictors of HCC, including viral (HBsAg 
and HBV genotype), genetic (methylation levels of promoter regions of p16 and RASSF1A), and 
environmental (aflatoxin exposure) biomarkers. The most important study findings were that HBsAg, 
methylation levels in RASSF1A, and HBV genotype A were significant predictors of HCC that could 
potentially be used to develop prediction models for predicting HCC risk, as has been done previously 
in Asia (Hsu et al., 2018; Wong et al., 2010; Yang et al., 2011; Yuen et al., 2009). 
 Variables with diagnostic potential 
Univariate logistic regression analysis identified HBsAg status, age, hypermethylation of RASSF1A 
CpG sites 1, 2–4 and overall hypermethylation of RASSF1A as significant predictors of HCC (p < 0.05). 
RASSF1A hypermethylation at all CpG sites as well as overall RASSF1A hypermethylation were still 
significant after adjusting for HBsAg status. 
These variables (except age) were then used in multivariate logistic regression models to identify a 
model with the best sensitivity, specificity, NPV, and PPV for HCC diagnosis. Age was excluded from 
the model because control tissues were obtained from older patients with primary colon cancer which 
would have already skewed the age of the control population included in the present study. The best 
predictive model was obtained using the variables overall promoter hypermethylation of RASSF1A and 
HBsAg status (sensitivity: 83.9%; specificity: 64.5%; PPV: 74.3%; NPV: 80.0%). These values 
demonstrate the improved overall diagnostic potential of combining both variables, although further 
work is needed to verify this finding. 
While early detection of HCC is desirable to improve survival outcomes, this is currently hampered by 
the lack of available screening biomarkers (Bruix & Sherman, 2005). In the present study, the use of 
methylation as an additional biomarker to HBsAg status improved the ability to discriminate between 
HCC and non-HCC cases. Although the methylation data were collected in HCC tissue samples, it has 
been shown that hypermethylation of tumour promoter genes occurs early in HCC development 
(Araújo, Rosa, Fernandes, Niel, Villela-Nogueira, et al., 2016; Shen, Wang, Zhang, Kappil, Wu, et al., 
2012), further suggesting that it should be possible to use this biomarker for the early diagnosis of HCC 
in this setting. 
Predictive models used in non-SubSaharan African populations have shown the value of using multiple 
variables including methylation data to increase model sensitivity and specificity (Dong, He, Zhang, 
Yu, Wang, et al., 2015; Wu et al., 2017). Dong et al. 2015 showed that in a Chinese population, 
combining AFP levels and the hypermethylation levels of RASSF1A improved the sensitivity of their 
diagnostic model from 64.2% to 80.9%. Wu et al. 2017 reported that incorporating promoter 
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methylation levels of TBX2 increased the Area Under the Curve of the Wen-HCC risk score from 68% 
to 71%. 
In addition, in the HBsAg positive sub-group analysis, HBV genotype, and specifically, HBV genotype 
A was found to be a significant predictor of HCC, independent of methylation level. Previous HCC risk 
prediction scores have only incorporated genotypes B and C within their models as the latter are the 
predominant genotypes in Asia, where the scores were developed (Lee, Yang, Liu, Batrla-Utermann, 
Jen, et al., 2013; Yang et al., 2011). As these scores were not externally validated in different 
populations, the present results suggest they would not be applicable in a SubSaharan African setting. 
 Viral biomarkers 
In this study, as expected from previous published studies (Beasley et al., 1981), the proportion of 
HBsAg-positive individuals was higher in the HCC group compared to the control group and this was 
statistically significant (p = 0.0005). Moreover, HBV genotype A was the most dominant genotype in 
the HCC group (75% [9/12]) compared to HBV genotype D/E in the non-HCC group (25% [3/12]). The 
differences in proportions of the A compared to non-A genotypes was statistically significant 
(p = 0.009), which is consistent with a previous report that HBV genotype A was 4.5 times more likely 
to cause HCC in Southern Africans compared to other genotypes in circulation in South Africa (Kew 
et al., 2005). Moreover, a study from The Gambia found an association between genotype A and risk 
of fibrosis (crude OR: 21.0 (95% CI:1.7–266.1) suggesting that individuals infected with HBV genotype 
A were at higher risk of disease progression when compared to those infected with HBV genotype E 
(Shimakawa et al., 2016). 
 Epigenetic biomarkers 
The HCC group had significantly higher levels of RASSF1A promoter hypermethylation than the non-
HCC group and this was statistically different (p < 0.05). This finding is similar to what has been 
reported elsewhere in non-African populations as RASSF1A is one of the most frequently inactivated 
genes in cancer development (Pfeifer & Dammann, 2005), including HCC (Hu et al., 2010), and 
hypermethylation of the promoter region of this gene is suspected to be a major inactivation pathway 
(Dammann et al., 2003). 
The frequency of hypermethylation observed in the present study in RASSF1A (45.2%) and p16 (18.2%) 
were lower than those reported in previous studies conducted in HCC samples from Taiwan (RASSF1A: 
85% and p16: 47%) (Zhang et al., 2002) and China (RASSF1A: 88.6% and p16: 54.3%) (QU, JIANG, 
LI, YU & DING, 2015). As ethnicity, geographic location, and environmental exposures are known to 
affect the epigenome (Galanter et al., 2017), it is possible that the differences observed between those 
studies and the present one were due to the populations being tested. These studies used a semi-
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quantitative methylation-specific PCR to assess methylation levels in the study population. In contrast, 
the present study used a robust, quantitative assay to determine methylation levels for each CpG site 
and used specific cut-offs that were CpG site-specific. It is therefore also possible that the previous 
studies overestimated the levels of hypermethylation observed. However, a study on Thai and French 
HCC cases where the authors used the same pyrosequencing techniques and methylation analysis as in 
the present study found that RASSF1A was hypermethylated in 76% of all tumours (Lambert et al., 
2011). They also found that the Thai HCCs showed higher DNA methylation levels than the French 
HCCs in multiple genes, including RASSF1A, making it more likely that the differences observed in the 
present study are due to ethnic differences. Previous studies have also shown a statistically significant 
lower prevalence of p16 hypermethylation in the South African HCCs when compared to Australian 
HCCs further supporting this theory (Herath, Kew, Walsh, Young, Powell, et al., 2002b; Herath et al., 
2009). These findings would suggest that in a South African population, either non-epigenetic pathways 
contribute significantly to deactivation of RASSF1A during HCC development or that other pathways 
are preferentially targeted in hepatocarcinogenesis such as loss of heterozygosity (Herath et al., 2002b, 
2009). 
 Environmental biomarkers 
Aflatoxin was not found to be a significant risk factor (p > 0.05) and was of minimal prevalence (1.5%; 
95% CI: 0.0%-4.5%) in this cohort of cases and controls, demonstrating that aflatoxin exposure is not 
a major issue in the Western Cape. The observed aflatoxin prevalence is much lower than what has been 
reported in a previous study from South Africa (Kimbi et al., 2005). In that study, however, they 
targeted South African Black individuals from rural areas who regularly consumed grains as part of 
their daily meals only, whereas the present study comprised of samples taken from individuals from 
multiple races. Moreover, as previous studies have also shown, rural inhabitants tend to be affected by 
aflatoxin exposure when compared to urban dwellers due to subsistence farming and improper storage 
of grains (Ncube, Flett, Waalwijk & Viljoen, 2010).  
 Study strengths and limitations 
The strengths of the present study include the fact that this is the first study in SSA to assess the use of 
methylation levels in tumour suppressor genes as potential predictors of HCC. Although the sample 
size was small, it was sufficiently powered to show statistically significant significance. Stringent 
selection criteria were also applied so as to select the best possible tissue samples for testing. 
However, the study must be interpreted within the context of its limitations. First, DNA was extracted 
from FFPE liver tissue samples in the present study. Formalin-fixation causes DNA damage in several 
ways such as the formation of crosslinks between DNA and formaldehyde and DNA fragmentation and 
affected the quality of DNA extracted which limited the testing that could be performed downstream. 
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Second, healthy liver tissue was isolated from secondary liver cancer tissue samples and used as controls 
in the present study and it is possible that the methylation levels observed in the controls do not reflect 
the methylation levels that would be normally observed in completely healthy liver tissue samples. 
However, microscopic examination and macrodissection were used to minimise contamination with 
neoplastic liver tissue and the methylation levels observed in the present study reflect what has been 
previously observed in other studies. Third, the sample size resulted in large confidence intervals for 
the odds ratios observed, thus limiting the generalizability of the results obtained in the present study. 
However, the sample size was influenced by the small number of cases and controls histologically 
diagnosed in the Western Cape (Maponga, 2016). Moreover, there were geographic restrictions on 
where sampling for cases and controls could be performed for the present study so that methylation 
levels, that are influenced by environmental exposures and geography, could be accurately quantified. 
Fourth, LINE-1 methylation levels could not be analysed in the present study because of the low yields 
of DNA extracted from FFPE liver samples. It is expected that LINE-1 would have been significantly 
hypomethylated in HCC cases compared to the controls as has been previously described elsewhere 
(Gao et al., 2014; Lin et al., 2001). Fifth, HIV status could not be included in the analysis because HIV 
testing could not be reliably performed on FFPE liver tissue. The tissue samples were collected over a 
23-year period when it was not common practice to test for HIV status. Moreover, serum samples were 
unavailable that could have enabled the determination of HIV status by ELISA. Although attempts to 
determine HIV status were conducted using PCR protocols, none could reliably amplify the HIV 
proviral DNA that could have been present in FFPE liver tissue. Further studies in patients with known 
HIV status or in whom HIV status can be confirmed serologically should be performed to investigate 
the influence of HIV status on HCC risk. Sixth, the effect of race on the methylation levels observed 
could not be assessed because of the unavailability of this information for most samples tested in the 
present study. As race is known to influence DNA methylation levels in individuals of different 
ethnicities (Adkins, Krushkal, Tylavsky & Thomas, 2011), including in HCC cases (Ally, 
Balasundaram, Carlsen, Chuah, Clarke, et al., 2017; Cheng, Wei, Ji, Chen, Yang, et al., 2018), future 
studies should assess whether race is a potential risk factor associated with HCC. Last, the influence of 
cirrhosis on methylation levels could not be ascertained as most HCC cases did not have sufficient non-
neoplastic liver tissue for a diagnosis of cirrhosis to be made. 
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4.4 CONCLUSION 
The present biomarker study found that 73.5% of HCC cases were positive for HBsAg. Moreover, there 
were statistically significant differences observed in methylation levels in RASSF1A and p16 between 
the HCC and non-HCC groups. Logistic regression analyses found HBsAg status and overall 
methylation levels of the promoter region of RASSF1A to be predictors of HCC. In addition, in this 
study, patients with HBV genotype A were shown to be at higher risk of developing HCC compared to 
those infected with non-A genotypes. Lastly, the use of a combination of these biomarkers had a higher 
sensitivity and specificity than the individual biomarkers, indicating that they could potentially be used 
to develop HCC risk prediction scores for use in HCC screening. 
Typically, in SSA, HCC is diagnosed at a late stage, past the point of cure. In Asia, where HBV is 
endemic, HCC risk scores have been developed using biomarkers specific for their populations that can 
be used to screen for HCC. However, those scores were based on patient populations with different risk 
profiles to SubSaharan Africans and were also not externally validated, making them unreliable for use 
in SSA. The results of the present study have further demonstrated that the HCC predictors, including 
methylation levels, in South Africa are different from those found in Asia. 
While the present study has added to the body of knowledge on the utility of biomarkers, such as 
RASSF1A, in an African setting, as this was an exploratory study, these biomarkers need to be further 
validated before they can be used in a clinical setting. In addition, similar studies should also be 
conducted in other areas of South Africa to determine whether the results observed in the present study 
are generalizable to the South African population. Future studies should also focus on addressing the 
limitations of the present study and investigate the effect of the missing risk factors such as HIV status, 
presence of cirrhosis, and LINE-1 hypomethylation. They should also consider further utilising the HCC 
biomarkers identified in the present study to develop HCC risk prediction scores that could be used 
clinically to identify those at highest risk of HCC. Investigating methylation levels in non-invasive 
specimens such as serum or plasma is therefore also recommended to make such tests more accessible. 
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5. STUDY III: EXOME SEQUENCING STUDY 
5.1 MATERIALS AND METHODS 
 Study design 
5.1.1.1 Choice of study design 
A genetic case-sibling study using next-generation sequencing was conducted in a group of patients 
with HBV-related HCC, comparing them to their HBV-positive siblings not suffering from HCC. In 
this context, whole exome sequencing was selected as the preferred method for the identification of 
novel driver mutations that could potentially contribute to early-onset HCC in HBV-positive 
individuals, in accordance with the study aim. 
5.1.1.2 Rationale for study design 
As comparisons would be made between HBV-positive affected cases and HBV-positive unaffected 
controls, the case-sibling study design was selected because familial clustering of HBV infection has 
previously been reported (Chen, Huang, Lee, Yang, Chen, et al., 1998). Moreover, siblings would have 
had the same environmental exposures as the cases. 
Parental controls were not used in the present study as it was expected that the potential cases would 
have at least one missing parent because, in 2016, the life expectancy of South Africans living in the 
Western Cape was only 64.2 years for males and 69.0 years for females (Statistics South Africa, 2016). 
 Ethics approval and considerations 
The cases for this study were selected from a parent project ongoing at the Division of Medical 
Virology, with prior ethics approval from the Stellenbosch University HREC (N11-09-284). The cases 
were consented for genetic studies on their PBMC samples already in storage at the Division of Medical 
Virology, Stellenbosch University (N11-09-284). The inclusion of controls for the present study was 
added as a genomic sub-study to the main study and received ethics approval from the Stellenbosch 
University HREC (N11-09-284a-Appendix G). 
Respect for persons: Hospital and laboratory records of cases were reviewed and their demographical 
information (age, sex, and race) retrieved. This information was stored in an Excel sheet and de-
identified by record suppression (removal of identifying information such as name, surname, date of 
birth, and hospital numbers) and introducing codes for sample identification before genetic testing to 
protect the identities of the patients. DNA samples sent for sequencing to Otogenetics Corp. (Atlanta, 
USA) were destroyed by the company after completion of testing. 
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Autonomy: The cases in the present study had already provided consent for future genetic studies on 
their stored PBMC samples. The sibling controls approached for enrolment in the present study were 
informed that their participation was entirely voluntary. 
Beneficence: There was a direct benefit for the cases’ family members as they were tested for HBV 
and those found to be actively infected were referred to the Liver Clinic of the Division of 
Gastroenterology and Hepatology at Tygerberg Hospital for further follow-up and long-term 
management. The de-identified genetic sequencing results were not expected to benefit the patients or 
their families as the functional effects, if any, of the novel variants identified were not determined. 
Moreover, as the study was only investigating novel mutations of unknown penetrance and significance, 
the risk of incidental findings was considered minimal. 
Non-maleficence: This was a minimal-risk study with no risk for the cases and only some discomfort 
and minor bruising from the phlebotomy for the sibling controls enrolled in the study. 
Justice: Although there was no benefit for the cases involved in the study, the results of the present 
study have provided insight on a disease that affects young South Africans. Few genetic studies and no 
whole exome sequencing studies have been carried out on HCC in an African setting. 
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 Algorithm for selection of cases and controls 
Figure 5.1-1 shows the algorithm that was used to select the cases and the controls. 
Figure 5.1-1 Algorithm showing the selection process of study cases and controls. PBMCs: Peripheral Blood Mononuclear Cells; HBV: hepatitis B virus.
Case assessment
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Fits selection 
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Contact siblings
Refuse 
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2. PBMCs isolation
3. HBV testing
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Case and matching 
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 Pre-testing phase 
5.1.4.1 Assessment of available cases 
The cases for the present study were selected from an ongoing parent project at the Division of Medical 
Virology that enrolled HCC patients at the time of diagnosis and collected PBMC, sera, and plasma 
samples from them for HBV, HCV, and HIV-1 marker testing. Structured interviews were also 
conducted on the study participants where their demographics, lifestyle habits, and medical history that 
could have contributed to hepatocarcinogenesis were recorded (Appendix H).  
This information was then used to select cases that fit the selection criteria listed below: 
1. Male sex. Male cases were chosen as early-onset HBV-related HCC affects men predominantly 
(Ervik et al., 2016). 
2. Early-onset HCC (younger than 30 years of age at time of HCC diagnosis). This was an 
important criterion because early-onset HCC was more likely to be triggered by underlying host 
genetic factors (Brandt, Bermejo, Sundquist & Hemminki, 2008b; Goldgar, Easton, Cannon-
Albright & Skolnick, 1994b). 
3. Diagnosed with HBV-related HCC. The focus of the present study was on HBV-related HCC 
more than 75% of HCC cases in SSA are associated with HBV infection. 
4. No other risk factors for HCC such as HCV, HIV co-infection, or alcohol misuse.  
5. Optionally, a family history of HCC (self-reported if known). Although family history is 
usually considered an important risk factor for familial HCC (Hassan, Spitz, Thomas, Curley, 
Patt, et al., 2009b), patients are typically unaware of the medical histories of their relatives, 
which is why this criterion was optional. 
5.1.4.2 Assessment of study controls 
The selection criteria for the controls were as follows: 
1. Siblings older than case at time of testing, who were unlikely to develop HCC. Older siblings 
were chosen, where possible, as they would have very similar genetic backgrounds, ethnicities, 
and environmental exposures that are known to influence genetic expression. 
2. Male sex. The risk of HCC development is 6-8 times higher in HBV-positive males compared 
to HBV-positive females (Ervik et al., 2016). The reason for this disparity is poorly understood 
and it has been suggested that estrogen could play a protective role in women (Naugler et al., 
2007). Therefore, in the present study, male controls were selected to control for any 
confounders that could arise from utilising female controls. It was expected that some genomic 
variants from the unaffected siblings would overlap with genomic variants from the cases. 
Stellenbosch University  https://scholar.sun.ac.za
 118 
 
Therefore, variants which were common to both case and control could be eliminated as they 
would be unlikely to have a cancer-causing potential. 
3. Past or current HBV infection. This increased the chances of identifying variants which could 
potentially predispose an individual to developing HBV-related HCC. 
4. No past or current history of liver disease besides HBV infection. 
5. No other risk factors for HCC such as HCV, HIV co-infection, and alcohol misuse that could 
act as potential confounders in the present study. 
5.1.4.3 Sample size 
Previous published reports have shown that whole exome sequencing studies require as few as three or 
four individuals to be sufficiently powered to detect novel potentially pathogenic driver mutations 
(Bilgüvar, Öztürk, Louvi, Kwan, Choi, et al., 2010; Esser, Holze, Haag, Schreiber, Krüger, et al., 2017; 
Miller, Garcia, Pressey, Beierle, Kelly, et al., 2017; Wang, Wang, Yang, Xia, Hu, et al., 2010). 
Moreover, the present study did not aim to identify variants that were statistically significantly 
associated with HBV-related HCC development but rather those that had the highest biological 
plausibility of contributing to the hepatocarcinogenic process. Therefore, a sample size of two cases 
and two controls per case were selected for the present study. 
5.1.4.4 Contacting potential controls 
The siblings of the potential cases were contacted and invited to join the study. If they accepted, they 
were consented during a face-to-face interview and given further information on the study. 
5.1.4.5 Pre-selection interview 
A structured interview was conducted with each potential control to record their demographic 
information (age, sex, and race), exposures to HCC risk factors (Appendix H), and HIV status. 
5.1.4.6 Liver fibrosis screening 
Transient elastographic scans (Fibroscan, Echosens) were performed as described previously (Castera, 
Forns & Alberti, 2008) to ensure that there was no evidence of hepatic fibrosis in the potential controls. 
This scan measures shear wave velocity and converting those values into liver stiffness expressed in 
kilopascal (kPa). The harder the tissue the faster the shear wave propagation. A cut-off of 7.2 kPa was 
used for significant fibrosis (Marcellin, Ziol, Bedossa, Douvin, Poupon, et al., 2009). 
5.1.4.7 Clinical biochemical screening 
Venous blood samples were collected from the potential controls for further testing and processing. 
Blood specimens were sent to the Division of Chemical Pathology, National Health Laboratory 
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Services, Tygerberg Hospital, for liver function tests (bilirubin, albumin, ALT, AST, and AFP). These 
tests were all performed on the automated Cobas® 6000 Chemistry Analyzer (Roche, Rotkreuz, 
Switzerland) using the Bilirubin Total Gen.3 kit (for total bilirubin levels), the Bilirubin direct Diazo 
Gen. 2 Jendrassik-Grof kit (for conjugated bilirubin levels), the Albumin Gen. 2 kit (for albumin levels), 
the Alanine Aminotransferase according to IFCC with pyridoxal phosphate activation kit (for ALT 
levels), the Aspartate Aminotransferase according to International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) with pyridoxal phosphate activation kit (for AST levels), and the AFP α1-
fetoprotein kit (for AFP levels), using the manufacturer’s recommended protocols. The results from 
these tests were communicated telephonically to the patients. 
5.1.4.8 Serological and molecular screening 
A blood sample from each potential control was also processed for markers of HBV (HBsAg, anti-HBc 
[total and IgM], anti-HBs, and if positive for HBsAg, HBeAg and anti-HBe testing were also 
performed) by ELISA on the automated ARCHITECT® i2000SR system. The corresponding 
ARCHITECT® immunoassays (ARCHITECT® HBsAg Qualitative, ARCHITECT® HBeAg, 
ARCHITECT® Anti-HBe, ARCHITECT® Anti-HBc II, and ARCHITECT® Anti-HBc IgM) were used 
following manufacturer’s protocols (Abbott Laboratories, Illinois, USA). HB viral load was also 
determined using the COBAS® AmpliPrep/COBAS® TaqMan® HBV Test on the automated COBAS® 
AmpliPrep Instrument (Roche Molecular Diagnostics, California, USA). They were also tested for 
HCV (anti-HCV) using an in-house ELISA assay, and HIV (HIV-1 Ag/Ab) using the Cobas® Elecsys® 
HIV combi PT 4th Gen (Roche Molecular Diagnostics, California, USA). All serological assays were 
conducted at the SANAS-accredited Division of Medical Virology, National Health Laboratory 
Services, Tygerberg Hospital. These results were conveyed to the potential controls telephonically if 
they were negative. If any result was positive they were requested to attend a follow-up appointment 
and were counselled after being given their results (also see section 5.1.4.9.1).  
5.1.4.9 PBMC isolation 
One EDTA blood sample was processed within two hours of collection for PBMC isolation. The whole 
blood was poured into a 50 ml sterile conical centrifuge tube and an equal volume of Roswell Park 
Memorial Institute (RPMI) 1640 medium added. Twenty-five millilitres of Histopaque was added to a 
new sterile 50 ml centrifuge tube and the diluted blood carefully layered on top of the Histopaque using 
a seropipette. The centrifuge tube was then centrifuged at 400 RCF for 30 minutes with an acceleration 
and brake of zero. In the interim, freezing medium made of 2.4 ml RPMI 1640 medium, 0.6 ml 
dimethyl-sulfoxide (DMSO), and 3 ml fetal calf serum (FCS) per sample was prepared and placed on 
ice for a minimum of 20 minutes. After the centrifugation step, the plasma layer above the PBMC layer 
was carefully discarded without aspirating any cells. The PBMC layer was carefully aspirated using a 
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Pasteur pipette and placed in a fresh 50 ml centrifuge tube containing 10 ml of RPMI 1640. The 
centrifuge tube was centrifuged for 12 minutes at 320 RCF at an acceleration of 9 and brake of 5. After 
the centrifugation step, the supernatant was discarded and the centrifuge tube tapped firmly to dislodge 
the pellet formed. This pellet was washed with 10 ml of RPMI 1640 containing 10% FCS and 
centrifuged at 260 RCF for 10 minutes at an acceleration and brake of 9. After centrifugation, the 
supernatant was discarded and the pellet was dislodged by flicking the tube firmly. Then, 4 ml of 
freezing medium was added to the pellet in a dropwise manner while the centrifuge tube was shaken 
simultaneously.  
Once the PBMCs were isolated and distributed into cryovials, they were transferred to a Mr. Frosty™ 
freezing container containing 100% isopropyl alcohol and placed at -80°C. The Mr. Frosty™ system 
ensured that the cells would cool at a rate of approximately -1°C/minute, which is optimal for cell 
preservation. After staying overnight in the Mr. Frosty™ freezer container, the cryovials with the 
PBMCs were transferred to a liquid nitrogen storage tank for long-term storage at -196°C until further 
processing. 
5.1.4.9.1 Management of newly diagnosed HBV-positive individuals and close contacts 
If any potential control was newly diagnosed with an active HBV infection through the study, they were 
reviewed by a gastroenterologist at the Liver Clinic of the Division of Gastroenterology and Hepatology 
at Tygerberg Hospital and underwent an abdominal ultrasound scan to ensure that there was no evidence 
of active liver disease (cirrhosis or space-occupying lesions). Their immediate contacts (children and 
sexual partners) were invited to come to Tygerberg Hospital for HBV testing and if found to be positive 
were offered the same treatment options. If the close contacts were negative for HBsAg, anti-HBc, and 
had levels of anti-HBs below 10 IU/ml, vaccination was recommended. 
 Testing phase 
5.1.5.1 DNA processing 
5.1.5.1.1 Cell counting 
PBMC cryovials were defrosted by transferring them from liquid nitrogen to a 4°C fridge. A cell count 
was performed on the PBMC-freezing medium mixture to determine the volume that would be required 
for DNA extraction. 
Twelve microlitres of the PBMC-freezing medium mixture were added to twelve microlitres of Trypan 
Blue and mixed. 10 µl were then placed in duplicate in a cell counting slide and placed in an automated 
cell counter (Biorad, California, USA). The cell sizes to be counted were set at 6–17 µM as immature 
PBMCs are usually 6–10 µM in diameter and mature PBMCs are usually 8–17 µM in diameter. The 
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two slots on each slide were read twice and the average number of cells present per millilitre was 
calculated from the four readings taken. 
5.1.5.1.2 DNA extraction 
Genomic DNA was extracted from the PBMCs of the selected cases and controls using the QIAamp 
DNA Blood Mini Kit (QIAGEN) following manufacturer’s instructions. To up to 5 x 106 lymphocytes 
in a total volume of 200 µl, 20 µl of proteinase-K was added in a 1.5 ml microcentrifuge tube for cell 
digestion followed by followed by 0.4 mg of RNase A for residual RNA elimination and incubation at 
room temperature for one minute. Then, 200 µl of lysis buffer AL was added and the tubes mixed by 
pulse-vortexing for 15 s and incubated at 56°C for 10 min. The microcentrifuge tubes were briefly 
centrifuged and 200 µl of ethanol was added and the tubes mixed by pulse-vortexing for 15 s. The 
solution from each tube was then applied to a silica gel membrane spin column and centrifuged at 
maximum speed for one minute. The filtrate was discarded and the column placed back into the tube. 
The membrane-bound DNA was washed with 500 µl of two different buffers to remove leftover ethanol. 
The column was then placed in a new collection tube and centrifuged at full speed for one minute to 
eliminate possible wash buffer carry-over. Lastly, 50 µl of the elution buffer containing 10 mM Tris-Cl 
and 0.5 mM EDTA pH 9.0 was added and the column incubated at room temperature for five minutes 
and centrifuged at 5800 RCF for one minute. The eluted DNA was stored at 4°C prior to shipping and 
not frozen to avoid the shearing forces during freezing/thawing. 
5.1.5.1.3 DNA quality validation 
The quality of extracted DNA was determined by agarose gel electrophoresis and spectrophotometry. 
Five microlitres of each DNA sample was electrophoresed on a 1% agarose gel at 70 V for one hour 
Figure 5.1-2 Example of agarose gel electrophoresis showing 
acceptable and degraded genomic DNA (gDNA) samples 
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and the gel observed under ultraviolet light at a wavelength of 254 nm using the Platinum HD Gel 
Documentation System (UVItec Limited, Cambridge, UK) and the image acquired using the UVIband-
1D gel analysis software. Figure 5.1-2 shows an example of DNA of acceptable quality. The purified 
DNA was also quantitated using the NanoDrop® ND-100 (ThermoFisher Scientific). The concentration 
and purity of the nucleic acid were automatically calculated with the “Nucleic Acid” Application 
module of the NanoDrop Software Version 3.1.0. Optical density (OD) ratios A260/A280 ≥ 1.8 and 
A230/A280 ≥ 1.9 were considered acceptable for WES. 
5.1.5.1.4 Ethanol precipitation 
DNA extracts with OD ratios outside of the desired ranges were purified by ethanol precipitation. 
0.1 volume of 3 M sodium acetate pH 5.2 and 2.5 volumes of ice-cold 100% ethanol were added to 
DNA extracts, mixed, and stored at -20°C overnight to precipitate the DNA. The precipitated DNA was 
recovered by centrifugation at full speed in a microcentrifuge for 20 minutes. The ethanol was then 
poured off and the DNA pellet washed twice with 600 µl room temperature 70% ethanol, centrifuged 
at full speed for 10 minutes, and the supernatant discarded. The DNA pellet was allowed to air-dry for 
15 minutes and resuspended in 25 µl of an elution buffer containing 10 mM Tris-Cl and 0.5 mM EDTA 
pH 9.0. 
5.1.5.2 Whole exome sequencing 
The exome is the protein-coding region of the human genome and although it represents less than 2% 
of the whole genome, it contains more than 85% of disease-causing variants. Since this study aimed to 
detect novel variants potentially causing early-onset HBV-related HCC development, whole exome 
sequencing was the most efficient approach as it focused on the genes most likely to affect phenotype. 
WES covers a relatively small area of the human genome (< 2%) but this corresponds to a region that 
has been extensively characterised making it easier to interpret identified variants in a more meaningful 
manner. Moreover, whole exome sequencing allowed a shorter turnaround time and produced a smaller 
data set allowing more manageable, faster, and easier analysis (Biesecker, Shianna & Mullikin, 2011). 
Samples were couriered to Otogenetics Corporation (Atlanta, GA, USA) for whole exome sequencing. 
Otogenetics is Clinical Laboratory Improvement Amendments (CLIA) compliant, accredited by three 
American federal agencies (the Food and Drug Administration [FDA], Center for Medicaid Services 
[CMS], and the Center for Disease Control [CDC]) responsible for monitoring quality laboratory 
testing. They perform rigorous quality control checks for every step of the sequencing pipeline to 
guarantee delivery of the best possible sequencing data. Moreover, Otogenetics has experienced 
specialists in the field who have worked on more than 25 000 Next Generation Sequencing projects and 
have developed protocols and workflows to get the best possible sequencing data from challenging 
samples (such as samples containing degraded DNA).  
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The workflow for whole exome sequencing can be described in five basic steps:  
1. library preparation by fragmentation of sample DNA and ligation with specialised adapters on 
both ends of the fragments produced; 
2. exome enrichment using hybridisation probes specific to the exonic regions; 
3. cluster amplification of each labelled fragment bound to a flow cell surface through bridge 
amplification; 
4. sequencing using terminator-based technology detecting emission wavelength and intensity to 
identify the bases as they are incorporated; 
5.1.5.2.1 Library preparation 
The amount of input DNA was between 100 ng and 3000 ng as recommended by Otogenetics. Genomic 
DNA was mechanically sheared with an Adaptive Focused Acoustics™ instrument (Covaris, 
Massachusetts, USA) to create random DNA fragments which were selected for an average size of 
230 bp. Quality control checks to confirm fragment sizes were performed using a 2200 TapeStation 
(Agilent Technologies, California, USA) that detects fluorescently stained double-stranded DNA 
including genomic DNA. 
The next steps of library preparation were performed using the automated SPRIworks HT System 
(Beckman Coulter, California, USA). DNA fragments ends were blunted and 5′ phosphorylated, A-tails 
were added to the 3′ ends to facilitate ligation to sequencing adapters, and Illumina compatible adapters 
and indices were added to the ends of the fragments. This was followed by a PCR reaction to enrich for 
product with adapters at both ends. After each step, the sample was purified using a bead-based 
purification system. 
5.1.5.2.2 Exome enrichment 
The SureSelect Human All Exon v5 plus UTR kit (Agilent Technologies) was used for exome 
enrichment as per manufacturer’s instructions. This kit targets 71 MB of genomic sequence representing 
335 765 exons in 21 058 genes and corresponding untranslated regions (UTRs) and uses an in-solution 
hybridisation capture method which utilises long 120-mer, biotinylated cRNA baits for enriching exome 
regions from genomic DNA fragments. These biotinylated cRNA baits were incubated with the library 
for 16 hours and the targeted regions selected by a pull-down assay using magnetic streptavidin beads. 
All libraries constructed with this kit included an index tag that was added following enrichment and 
that enabled multiplex sequencing. Post-hybridisation and capture, the sample was purified using a 
bead-based purification system and the targeted regions were further amplified by PCR using the 
appropriate indexing primer for each sample to produce a sequence-ready library. The quality and 
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quantity of the indexed library were determined using the 2200 TapeStation (Agilent Technologies) and 
High Sensitivity D1000 ScreenTape before sequencing. 
5.1.5.2.3 Cluster amplification 
This library was then loaded onto a flow cell, which is a glass slide with lanes, where the fragments 
were captured on a lawn of surface-bound oligos complementary to the library adapters. A polymerase 
created a complement of the hybridised fragment. The double-stranded molecule was then denatured 
and the original template washed away. The strands were then isothermally amplified into distinct 
clonal clusters through bridge amplification. In this process, the strand folded over and the adaptor 
hybridised to a second type of oligo present on the flow cell. Polymerases created a complementary 
strand forming a double-stranded bridge. This bridge was denatured forming two single-stranded copies 
of the same molecule that were tethered to the flow cell. The process was then repeated over and over 
and was repeated simultaneously for millions of clusters resulting in clonal amplification of all the 
fragments. After clonal amplification, the reverse strands were cleaved and washed off, leaving only 
the forward strands. The 3′ ends were then blocked to prevent unwanted priming.  
5.1.5.2.4 Sequencing and base calling 
Sequencing was performed on the HiSeq 2500 system (Illumina, Inc., San Diego, CA, USA) with a 
paired-end read length of 100 bp and 50 x coverage. The Illumina platform was chosen as it applies a 
sequencing-by-synthesis approach where only one nucleotide per sequencing cycle is incorporated 
using reversible dye terminators. All four bases are present at the same time and compete for 
incorporation. This natural competition minimises incorporation bias and greatly reduces raw error rates 
compared to other platforms (Liu, Li, Li, Hu, He, et al., 2012).  
During the sequencing process, the sequencing primer was extended to produce the first read. With each 
cycle, fluorescently-tagged nucleotides competed for addition to the growing chain and only one was 
incorporated based on the template sequence. After the addition of each nucleotide, the clusters were 
excited by a light source and a characteristic fluorescent signal was emitted. The emission wavelength 
along with the intensity determined the base call. For a given cluster, all identical strands were read 
simultaneously. Hundreds of millions of clusters were thus sequenced in a massively parallel process. 
After the completion of the first read, the read product was washed away. The index read primer was 
then introduced and hybridised to the template and the read generated similar to the first read. After 
completion of the index read, the read product was washed off and the 3′ ends of the template 
deprotected. The template folded over and bound to the second oligo on the flow cell. Index 2 was read 
in the same manner as index 1 and polymerases extended the second oligo forming a double-stranded 
bridge which was then linearized and the 3′ ends blocked. The original forward strand was cleaved off 
and washed away leaving only the reverse strand. Read 2 began with the introduction of the sequencing 
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primer. As with read 1, the sequencing steps were repeated until the desired read length was achieved. 
The read 2 product was then washed away. This entire process generated millions of reads representing 
all the fragments. 
 Post-testing phase 
5.1.6.1 Sequencing data analysis 
Sequencing data analysis involved the following five steps: 
1. Assessment of raw data and read quality 
2. Alignment of sequences to a reference genome 
3. Variant identification 
4. Variant annotation 
5. Variant selection 
The sequencing instrument generated BCL basecall files which were converted to standard FASTQ 
format using bcl2fastq Conversion Software. The quality of the raw reads was assessed and reads that 
did not meet the quality standards were trimmed, corrected, or removed using the FASTX-Toolkit. The 
sequence reads were assembled and mapped to the University of Santa Cruz (UCSC) human reference 
genome hg19 [GRCh37.p13 (GCF_000001405.25)] using the NOVOALIGN short-read aligner 
(www.novocraft.com), producing Sequence Alignment/Map files. The average coverage of each sample 
was then assessed using the software Mosdepth (Pedersen & Quinlan, 2018). Post-processing of the 
reads was then done to remove PCR duplicates using Picard (http://sourceforge.net/projects/picard/). 
The Genome Analysis Tool Kit (GATK) HaplotypeCaller was used for refining alignments and accurate 
variant calling, producing Variant Call Files (VCF).  
After alignment and creation of the VCF, a second script filtering was performed to remove variants 
that were homozygous recessive in the cases but absent or heterozygous in their respective controls. 
These modified VCF files were uploaded onto wANNOVAR, the online version of the software 
ANNOVAR (wannovar.wglab.org) (Chang & Wang, 2012; Wang, Li & Hakonarson, 2010) for the 
functional annotation of the genetic variants that passed the final quality filter (quality score of > 50) 
with information such as variant location (e.g. exonic), class (e.g. non-synonymous), allele frequencies 
in public databases (e.g. the Genome Aggregation Database [gnomAD]) and for non-synonymous 
variants, functional effect prediction scores (e.g. Functional Analysis through Hidden Markov Models 
[FATHMM]). The generated results were downloaded in csv. format and visualised in Microsoft Excel 
(2010).  
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Variants were subdivided into their respective classes (truncating, splice site, and missense). Truncating 
and splice site variants were further filtered on rarity and variants with a gnomAD score of less than 
1% (< 0.01) or formerly unseen variants (indicated by a “.”) were selected. After the same filters were 
applied for non-synonymous variants, the predicted functional impact of the filtered variants was 
examined using the Combined Annotation Dependent Depletion (CADD), deleterious annotation of 
genetic variants using neural networks (DANN), and FATHMM algorithms. Variants with CADD 
phred quality scores of > 15 (equivalent to a 95% probability that the variant has some effect), or DANN 
scores of ≥ 0.99, or identified as being deleterious by FATHMM were selected. Further filtering was 
done by excluding any variants with a minor variant allele frequency of > 0.01 in the 1000 Genomes 
Project database for the general population and the African population. 
Priority variants were selected from this list based on whether they were flagged by more than one 
algorithm for their known functional effect. This list of potential variants was further narrowed down 
by identifying their functions on Genecards® and DisGenet (www.disgenet.org) and selecting priority 
variants that were most likely to contribute to HCC development. Novel variants not described in HCC 
literature were prioritised in terms of whether they had previously been described to contribute to cancer 
development or been associated with other types of cancers.  
5.1.6.2 Confirmation of genetic variants by Sanger sequencing 
Next-generation-sequencing is prone to low levels of detectable errors making it necessary to confirm 
the results obtained by a different method such as Sanger sequencing. Therefore, following the 
identification of the three most promising potentially cancer-predisposing point mutations per case-
control group, confirmation was performed by Sanger-based capillary electrophoresis.  
5.1.6.2.1 Primer design for identification of variants 
A genomic region of approximately 500 bases upstream and 500 bases downstream of each point 
mutation of interest was obtained from NCBI Gene Viewer and input in Primer 3, an online primer 
designing software. Primers flanking the point mutation were generated according to the following 
criteria: minimum primer size of 18 bp, maximum of 27 bp and optimal of 25 bp; minimum primer 
melting temperature of 50°C, maximum of 60°C, and optimal of 55°C. The specificity of each designed 
primer pair for the target region was verified using NCBI BLAST.  
5.1.6.2.2 Verification of presence of variants in cases and sibling controls 
5.1.6.2.2.1 Amplification using PCR 
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PCRs were performed on DNA previously extracted from each case and control to confirm the presence 
of the identified point mutations using the designed primers and following a standard protocol with 
annealing temperatures dependent on the melting temperatures of the designed primers. 
5.1.6.2.2.2 Gel electrophoresis 
A 2% agarose gel was prepared by melting 1.5 g of agarose powder (SeaKem® LE Agarose, Maine, 
USA) in 75 ml of 1X SB Buffer. Five microlitres of each PCR product was mixed with one microlitre 
of 6X Novel Juice (GeneDireX Inc., Taoyuan, Taiwan) and pipetted into wells on the agarose gel to 
separate any PCR product according to size. The samples were electrophoresed alongside a 1 Kb DNA 
ladder (GeneRuler™ 100 bp DNA Ladder, ThermoFisher Scientific) for 30 minutes at 100 V. The 
agarose gel was then visualised under ultraviolet light at a wavelength of 254 nm using the Platinum 
HD Gel Documentation System (UVItec Limited, Cambridge, UK) and the image acquired using the 
UVIband-1D gel analysis software. PCR products with visible bands of the correct size were selected 
for further testing downstream. 
5.1.6.2.2.3 Purification of PCR products 
PCR products were purified using the MinElute PCR Purification Kit (QIAGEN) by following 
manufacturer’s instructions. A buffer was first added to the PCR products and the mixture applied to 
silica gel membrane spin columns to allow efficient binding of the amplified DNA to the column 
membrane. This was followed by a wash step using an ethanol-containing buffer to ensure the removal 
of primers and other impurities that could inhibit sequencing downstream. A centrifugation step in an 
empty tube then ensured the removal of residual ethanol-containing buffer. The DNA was finally eluted 
in 10 µl of elution buffer containing 10 mM Tris-Cl, pH 8.5. 
5.1.6.2.2.4 Sequencing PCR 
Sequencing PCR reactions were carried out in a 96-well plate using the corresponding PCR primers to 
sequence the region of interest. A master mix consisting of the components listed in Table 5.1-1 was 
prepared and distributed in volumes of 8 µl into the appropriate number of wells. Next, 1 µl of each 
primer and 1 µl of purified template DNA from each sample was added to the appropriate wells. The 
cycling conditions shown in Table 5.1-2 were used. 
 
Table 5.1-1 Sequencing reaction master mix, adapted from manufacturer’s instructions 
(ThermoScientific) 
Reagent Volume/µl 
ABI Sequencing Buffer 3 
Big Dye Terminator 1 
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Table 5.1-2 Cycling parameters for sequencing reaction, adapted from manufacturer’s 
instructions (ThermoScientific) 
Cycling parameter Cycles Temperature Time 
Denaturation 
30 
96°C 20 s 
Annealing 50°C 20 s 
Extension 60°C 4 min 
°C: degrees Celsius; min: minute; s: second 
5.1.6.2.2.5 Sequencing PCR purification 
The sequencing PCR reaction products were purified using the BigDye® Xterminator Purification Kit 
consisting of SAM™ and XTerminator® solutions (ThermoScientific) as per manufacturer’s 
instructions; 45 μl of SAM solution and 10 μl of Xterminator® solution were added to each well before 
the wells were sealed with adhesive film. The 96-well plate was vortexed for 30 minutes at 2000 RCF 
and centrifuged for 1 minute at 1000 RCF. 
5.1.6.2.2.6 Capillary electrophoresis and sequencing data analysis 
Capillary electrophoresis was performed on the samples using the ABI Prism 3130XL Genetic Analyzer 
(ThermoFisher Scientific). The information obtained was converted to raw data files using DNA 
sequencing analysis software (ThermoFisher Scientific). The length of the capillaries allowed sequence 
reads of approximately 1 Kb. 
The raw trace files were further analysed using Geneious R11 (Biomatters Ltd., Auckland, New 
Zealand). The quality of each sequence was improved individually by looking at the chromatograms 
and trimming the ends where necessary. A reference sequence for the amplified fragment containing 
the wild-type allele was created using the corresponding primer sequences and was used to trim the 
sequences beyond the primer region. Mismatches or ambiguities were verified manually. 
It was expected that the cases would carry the mutant alleles identified and that the controls would carry 
the wild-type allele or be heterozygous. 
5.1.6.2.3 Confirmation of variants in population controls 
Individuals with CHB, without HCC, and who were older than 30 years of age were screened for the 
selected variants to act as general population controls to further confirm rarity of the variants identified. 
Primer, 2 µM 1 
Water 3 
Total volume 8 
µl: microlitre; µM: micromolar 
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These individuals were selected from a parent project ongoing at the Division of Medical Virology, 
with prior ethics approval from the Stellenbosch University HREC (N11-09-284) and from the newly 
diagnosed HBV-positive individuals from Study 1 (S15/08/179). DNA was extracted from either the 
PBMCs or plasma collected from the study participants as described in Sections 5.1.4.9 and 3.1.10.2.3.1 
respectively. PCRs followed by Sanger sequencing were performed on the DNA extracts as described 
in Section 5.1.6.2.2. It was expected that the frequency of the SNPs in the general population controls 
would be low, thus confirming that they were rare variants. 
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5.2 RESULTS 
 Pre-testing phase 
5.2.1.1 Description of selected HBV-related HCC cases 
For this exploratory study, stringent selection criteria were used on the available cohort, which resulted 
in two HCC patients who met the selection criteria. Cases 1 and 2 were both deceased Coloured males 
diagnosed with HBV-related HCC at the age of 21 and 30 years, respectively. They had no other known 
risk factor for HCC; they had no alcohol dependency, were negative for HIV and HCV, and had no 
known family history of liver cancer. 
5.2.1.2 Screening and selection of controls 
First-generation relatives of each case (Figures 5.2-1 and 5.2-2) were screened using serological, 
molecular, and clinical biochemical testing (Tables 5.2-1 to 5.2-4) for potential enrolment in the study 
as controls based on the study inclusion criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2-1 First-generation relatives of Case 1 
Figure 5.2-2 First-generation relatives of Case 2 
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 Table 5.2-1 Serological and virological test results of Case 1 and male siblings  
 
Table 5.2-2 Liver function test results of Case 1 and male siblings 
 
  
 HBsAg anti-HBc 
IgM 
anti-HBc 
IgG 
HBeAg anti-HBe anti-HBs HBV VL 
IU/ml 
Anti-
HCV 
HIV-1 
Case 1 – + Unknown – + Unknown Unknown – – 
Sibling 1 + – – + – – 5 910 000 – – 
Sibling 2 – – + – – + LDL – – 
Sibling 3 + – + – + – < 20 – + 
Sibling 2 had cleared his hepatitis B virus (HBV) infection and therefore had an undetectable level of HB viral DNA (LDL: 
lower than detectable limit). Sibling 3 was co-infected with human immunodeficiency virus-1 (HIV-1) and was on antiretroviral 
therapy including tenofovir, hence his detectable but unquantifiable HB viral load (< 20 IU/ml). HBsAg: hepatitis B surface 
antigen; anti-HBs: antibody to hepatitis B surface antigen; HBeAg: hepatitis B envelope antigen; anti-HBe: antibody to hepatitis 
B envelope antigen; anti-HBc: antibody to hepatitis B core antigen; IgM: Immunoglobulin M; IgG: Immunoglobulin G; HCV: 
hepatitis C virus; VL: viral load; IU/ml: International Units per millilitre; <: less than; +: positive; –: negative. 
 Albumin g/L 
Normal:  
35-52 
Total bilirubin µmol/L 
Normal: 
5-21 
ALT U/L 
Normal: 
10-40 
AST U/L 
Normal: 
15-40 
AFP µg/L 
Normal: 
0.0-8.0 
FibroScan Kpa 
Normal: 
< 7.2 kPa 
Case 1 33 66 407 117 17098 Unknown 
Sibling 1 43 8 63 42 2.2 5.9 
Sibling 2 43 7 14 20 3.3 4.9 
Sibling 3 45 5 27 30 2.6 5.6 
g/L: grams per litre; µmol/L: micromole per litre; U/L: units per litre; µg/L: micrograms per litre; kPa: kilopascal; <: less 
than 
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Table 5.2-3 Serological and virological test results of Case 2 and siblings 
 
Table 5.2-4 Liver function test results of Case 2 and siblings 
 Albumin g/L 
Normal:  
35-52 
Total bilirubin µmol/L 
Normal: 
5-21 
ALT U/L 
Normal: 
10-40 
AST U/L 
Normal: 
15-40 
AFP µg/L 
Normal: 
0.0-8.0 
FibroScan Kpa 
Normal: 
< 7.2 kPa 
Case 2 46 66 139 315 Unknown Unknown 
Sibling 1 44 18 22 Unknown 8.2 5.1 
Sibling 2 Unknown 6 19 20 6.3 6.6 
g/L: grams per litre; µmol/L: micromole per litre; U/L: units per litre; µg/L: micrograms per litre; kPa: kilopascal; 
<: less than 
 
Based on the study selection criteria, only male siblings with current or past HBV infections and no 
other risk factors of HCC development were screened as potential controls. 
Case 1 had three male Coloured siblings who tested positive for markers of present or past HBV 
infection (Table 5.2-1). Sibling 3 was co-infected with HIV-1, which disqualified him as a potential 
control. Siblings 1 and 2 were male and were older than the case at the time of testing. Sibling 1 had no 
history of liver disease besides a newly-diagnosed chronic HBV infection. Sibling 2 also had no history 
of liver disease although he showed past exposure to HBV and had since cleared the infection (negative 
for HBsAg and positive for total anti-HBc and anti-HBs). Both had no other known risk factors of HCC; 
they had no alcohol dependency and were negative for both HIV and HCV. Their FibroScan results 
were within normal range and ultrasound scans were clear and showed no cirrhosis or space-occupying 
lesions. Therefore, siblings 1 and 2 were selected as the best possible controls for Case 1 and code-
labelled Control 1 and Control 2 respectively. 
 HBsAg anti-HBc 
IgM 
anti-HBc 
IgG 
HBeAg anti-HBe anti-HBs HBV VL 
IU/ml 
Anti-
HCV 
HIV-1 
Case 2 + – + + – Unknown 40 000 – – 
Sibling 1 + – + + – – 32 – – 
Sibling 2 + – + – – Unknown < 20 – – 
HBsAg: hepatitis B surface antigen; anti-HBs: antibody to hepatitis B surface antigen; HBeAg: hepatitis B envelope antigen; 
anti-HBe: antibody to hepatitis B envelope antigen; anti-HBc: antibody to hepatitis B core antigen; IgM: Immunoglobulin M; 
IgG: Immunoglobulin G; HCV: hepatitis C virus; HIV-1: human immunodeficiency virus-1; HBV: hepatitis B virus; VL: viral 
load; IU/ml: International Units per millilitre; <: less than; +: positive; –: negative. 
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Case 2 had two male Coloured siblings with known positive HBV status. At the time of testing for the 
present study, both siblings had been on treatment with tenofovir and were regularly followed-up by a 
gastroenterologist for three years. Sibling 1 had no past history of liver disease besides a chronic HBV 
infection. He had no history of alcohol misuse and was negative for both HIV-1 and HCV. His liver 
enzyme levels were normal and his Fibroscan results were within normal range. For these reasons, 
although he was younger than the case at time of testing, he was included in the study as a control and 
code-labelled Control 3. Sibling 2 was older than Case 2 and had a similar profile to Sibling 1. He was 
included in the present study as a second control and code-labelled Control 4. 
5.2.1.3 Management of newly diagnosed HBV-positive individuals and close contacts 
Siblings 1 and 3 of Case 1 were newly diagnosed with HBV through the present study. They were both 
referred to and reviewed by a gastroenterologist at the Liver Clinic of the Division of Gastroenterology 
and Hepatology at Tygerberg Hospital. Sibling 3 was co-infected with HIV and was already on 
antiretroviral therapy including tenofovir and in regular follow up. Sibling 1 reached treatment threshold 
because of his very high viral load (5 910 000 IU/ml) and elevated AST and ALT levels (Table 5.2-2) 
and was placed on treatment with tenofovir. The immediate contacts (children and sexual partners) of 
Siblings 1, 2, and 3 were tested for HBV markers and found to be negative for active HBV infection. 
 Testing phase 
5.2.2.1 Whole exome sequencing 
5.2.2.1.1 DNA quality validation 
The quality of samples shipped for whole exome sequencing is given in Table 5.2-5. 
Table 5.2-5 Nanodrop readings of samples sent for whole exome sequencing 
Sample Amount of DNA, ng/µl 260/280 ratio 230/280 ratio 
Case 1 21.64 2.33 2.20 
Control 1 86.61 1.95 1.89 
Control 2 58.66 1.91 1.90 
Case 2 3.5 2.53 1.11* 
Control 3 56.68 1.90 1.86 
Control 4 37.74 1.98 1.94 
*did not meet quality control of 230/280 ratio > 1.9 but was still sent for sequencing 
following consultations with Mr Brantley Wyatt (senior project technician 
specialising in library preparation and Next Generation Sequencing, Otogenetics 
USA); ng/ul – nanogram per microliter 
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5.2.2.1.2 Quality of reads 
The average coverage of each sample, calculated using the software Mosdepth (Pedersen & Quinlan, 
2018), was > 50X for all samples (Table 5.2-6) making them suitable for further analysis. 
Table 5.2-6 Average coverage of whole exome sequenced samples 
Sample Average coverage 
Case 1 59.41 
Control 1 63.07 
Control 2 61.88 
Case 2 56.73 
Control 3 51.45 
Control 4 61.97 
 Post-testing phase 
5.2.3.1 Sequence analysis 
Variants that were homozygous recessive in the cases, but absent or heterozygous in their respective 
controls were annotated using wANNOVAR and resulted in an initial list of 1826 variants for Case-
Control Group 1 and 1159 variants for Case-Control Group 2. 
5.2.3.2 Preliminary screening of variants using algorithms 
As per protocol, different filters were further applied to the different algorithms within this list, which 
generated an initial list of potential cancer-predisposing variants for each case-control group (Tables 
5.2-7 and 5.2-8). 
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Table 5.2-7 List of preliminary variants for Case-control Group 1 
Genes Point mutation detail dbSNP 
number 
Class 1000G_ALL fathmm-
MKL_coding_pred 
CADD-
phred 
DANN_score 
HLA-DRB5 HLA-DRB5:NM_002125:exon2:c.C112T:p.Q38X rs1071747 stopgain . Neutral 11,33 0,906 
SPANXN2 SPANXN2:NM_001009615:exon1:c.71dupA:p.N24fs rs782333345 frameshift insertion . . . . 
KLHL17 KLHL17:NM_198317:exon8:c.G1234A:p.V412M rs369390543 nonsynonymous . Deleterious 24,1 0,991 
PERM1 PERM1:NM_001291366:exon3:c.G2190C:p.Q730H rs374445170 nonsynonymous . Neutral 24,4 0,994 
TTLL10 TTLL10:NM_001130045:exon16:c.G1711A:p.D571N . nonsynonymous . Neutral 13,76 0,992 
ITIH6 ITIH6:NM_198510:exon8:c.C2030T:p.S677F rs112265894 nonsynonymous 0,0053 Neutral 23,3 0,991 
PTX3 PTX3:NM_002852:exon2:c.C476T:p.T159M rs112277608 nonsynonymous 0,0076 Neutral 21,1 0,948 
CCDC22 CCDC22:NM_014008:exon8:c.C926A:p.A309D rs183877705 nonsynonymous 0,0008 Deleterious 15,99 0,977 
SMARCA1 SMARCA1:NM_001282874:exon3:c.A415C:p.I139L . nonsynonymous . Deleterious 14 0,943 
USP26 USP26:NM_031907:exon1:c.C74A:p.A25E rs867828251 nonsynonymous . Neutral 19,73 0,824 
SAMD11 SAMD11:NM_152486:exon13:c.A1757C:p.N586T rs146548754 nonsynonymous 0,0012 Deleterious 4,235 0,699 
dbSNP: Single Nucleotide Polymorphism database; CADD: Combined Annotation Dependent Depletion, DANN: deleterious annotation of genetic variants using neural networks, and 
FATHMM: Functional Analysis through Hidden Markov Models algorithms. 1000G: 1000 Genomes Project. Variants with CADD phred quality scores of > 13 (equivalent to a 95% probability 
that the variant has some effect), or DANN scores of ≥ 0.99, or identified as being deleterious by FATHMM were selected. Further filtering was done by excluding any variants with a minor 
variant allele frequency of > 0.01 in the 1000 Genomes Project database for the general population. HLA-DRB5: Major Histocompatibility Complex, Class II, DR Beta 5; SPANXN2: Sperm 
Protein Associated with the Nucleus on the X chromosome N2; KLHL17: Kelch Like Family member 17; PERM1: Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 And 
Estrogen-Related Receptor-Induced Regulator In Muscle 1; TTLL10: Tubulin Tyrosine Ligase Like 10; ITIH6: Inter-Alpha-Trypsin Inhibitor Heavy Chain Family Member 6; PTX3: Pentraxin 
3; CCDC22: Coiled-Coil Domain Containing 22; SMARCA1: SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 1; USP26: Ubiquitin 
Specific Peptidase 26; SAMD11: Sterile Alpha Motif Domain Containing 11  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 136 
 
Table 5.2-8 List of preliminary variants for Case-control Group 2 
Gene Point Mutation Detail dbSNP Class 1000G_ALL 
fathmm-
MKL_coding_pred 
CADD-
phred 
DANN_score 
VEGFA VEGFA:NM_001171623:exon6:c.540delC:p.G180fs rs374210528 Frameshift deletion Unknown Unknown Unknown Unknown 
OR11G2 OR11G2:NM_001005503:exon1:c.682dupA:p.C227fs rs77164062 Frameshift deletion Unknown Unknown Unknown Unknown 
TNN TNN:NM_022093:exon15:c.C3311T:p.T1104M rs113025105 nonsynonymous 0,0022 Deleterious 31 0,999 
CCDC125 CCDC125:NM_001297696:exon2:c.G143C:p.S48C rs111417600 nonsynonymous 0,0012 Deleterious 25,4 0,992 
C6orf132 C6orf132:NM_001164446:exon4:c.G3149A:p.G1050D rs113527767 nonsynonymous 0,0012 Neutral 25 0,996 
RAB19 RAB19:NM_001008749:exon3:c.C232T:p.R78C . nonsynonymous . Deleterious 35 0,999 
HGH1 HGH1:NM_016458:exon3:c.G778A:p.E260K rs370307214 nonsynonymous . Deleterious 33 0,999 
BRCA2 BRCA2:NM_000059:exon27:c.C9875T:p.P3292L rs56121817 nonsynonymous 0,0002 Deleterious 33 0,999 
MYLK3 MYLK3:NM_182493:exon12:c.A2303C:p.E768A rs113145242 nonsynonymous 0,001 Deleterious 24,2 0,996 
ASPHD2 ASPHD2:NM_020437:exon2:c.G214A:p.V72M rs374177116 nonsynonymous 0,0006 Deleterious 17,48 0,993 
ZNRF3 ZNRF3:NM_032173:exon8:c.T1898C:p.L633S rs201483333 nonsynonymous 0,001 Deleterious 6,038 0,993 
C22orf31 C22orf31:NM_015370:exon3:c.C739T:p.L247F rs374421493 nonsynonymous . Deleterious 27,9 0,999 
SEC14L6 SEC14L6:NM_001193336:exon7:c.A542C:p.N181T rs112068496 nonsynonymous . Deleterious 25,2 0,995 
BAIAP2L2 BAIAP2L2:NM_025045:exon7:c.G529C:p.E177Q rs540408118 nonsynonymous Novel Deleterious 23,6 0,997 
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MARVELD2 MARVELD2:NM_001244734:exon2:c.C215G:p.A72G rs112938244 nonsynonymous Novel Deleterious 12,58 0,816 
TMEM14A TMEM14A:NM_014051:exon3:c.T172C:p.F58L rs112397916 nonsynonymous . Deleterious 15,1 0,895 
KDM7A KDM7A:NM_030647:exon17:c.C2306T:p.P769L rs113398071 nonsynonymous 0,0024 Deleterious 18,89 0,977 
CHST7 CHST7:NM_019886:exon1:c.C934T:p.H312Y rs750851012 nonsynonymous 0,0019 Deleterious 16,69 0,982 
ABCB7 ABCB7:NM_001271696:exon12:c.A1589G:p.Y530C rs199687417 nonsynonymous 0,0011 Deleterious 19,04 0,989 
HLA-DRB1 HLA-DRB1:NM_002124:exon2:c.G125T:p.R42M rs1136759 nonsynonymous Unknown Neutral 0.001 0.4 
dbSNP: Single Nucleotide Polymorphism database; CADD: Combined Annotation Dependent Depletion, DANN: deleterious annotation of genetic variants using neural networks, and FATHMM: 
Functional Analysis through Hidden Markov Models algorithms. 1000G: 1000 Genomes Project. Variants with CADD phred quality scores of > 13 (equivalent to a 95% probability that the variant has 
some effect), or DANN scores of ≥ 0.99, or identified as being deleterious by FATHMM were selected. Further filtering was done by excluding any variants with a minor variant allele frequency of > 0.01 
in the 1000 Genomes Project database for the general population. VEGFA: Vascular Endothelial Growth Factor A; OR11G2: Olfactory Receptor Family 11 Subfamily G Member 2; TNN: Tenascin N; 
CCDC125: Coiled-Coil Domain Containing 125; C6orf132: Chromosome 6 Open Reading Frame 132; RAB19: Member RAS Oncogene Family; HGH1: HGH1 homolog; BRCA2: Breast And Ovarian 
Cancer Susceptibility Protein 2; MYLK3: Myosin Light Chain Kinase 3; ASPHD2: Aspartate Beta-Hydroxylase Domain Containing 2; ZNRF3: Zinc And Ring Finger 3; C22orf31: Chromosome 22 Open 
Reading Frame 31; SEC14L6: SEC14 Like Lipid Binding 6; BAIAP2L2: Brain-Specific Angiogenesis Inhibitor 1-Associated Protein 2-Like Protein 2; MARVELD2: MARVEL domain-containing protein 
2; TMEM14A: Transmembrane Protein 14A; KDM7A: Lysine Demethylase 7A; CHST7: Carbohydrate Sulfotransferase 7; ABCB7: ATP Binding Cassette Subfamily B Member 7; HLA-DRB1: Major 
Histocompatibility Complex, Class II, DR Beta 1
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5.2.3.3 Final selection of variants  
The function and disease-association of each gene on the two lists was determined and from these data, 
three priority variants were selected per case-control group. For Case-Control Group 1, the CCDC22, 
SMARCA1, and PTX3 variants were selected and for case-control Group 2, the TNN, RAB19, and 
ZNRF3 variants were selected. 
Primers were designed (Table 5.2-9) and used to confirm the presence of these point mutations by 
Sanger sequencing. 
Table 5.2-9 List of primers used to confirm WES variants 
Name of primer Sequence Amplicon size 
CCDC22-F 5′-tacccacatagtcacagtct-3′ 
222 bp 
CCDC22-R 5′-cactctgctcacctgttc-3′ 
SMARCA1-F 5′-gaaatcagtagaaccagcct-3′ 
283 bp 
SMARCA1-R 5′-gaacatgaaattgggacgtc-3′ 
PTX3-F 5′-cttcatcatgctggagaact-3′ 
369 bp 
PTX3-R 5′-cttgcctccttacctgcc-3′ 
TNN-F 5′-gtctgtacaccatctacctg-3′ 
182 bp 
TNN-R 5′-tagggctccaaacactctat-3′ 
RAB19-F 5′-gatgtaggtgaaggagttcc-3′ 
234 bp 
RAB19-R 5′-ttgcagctccatatttctct-3′ 
ZNRF3-F 5′-cccaatagctctacctcaga-3′ 
248 bp 
ZNRF3-R 5′-ccgtacaagccctgggag-3′ 
5′: 5 prime; 3′: 3 prime; bp: base pair. 
 
5.2.3.4  Sanger sequencing confirmation results 
5.2.3.4.1 Case-control Group 1 
Sanger sequencing confirmed the presence of the CCDC22 non-synonymous C>A transversion 
(rs183877705, Refseq mRNA accession NM_014008), which causes an alanine to aspartic acid amino 
acid change at codon 309 (A309D), in Case 1 (Figure 5.2-3). The two sibling controls were homozygous 
for the wild-type C-allele (Figure 5.2-3). 
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Figure 5.2-3 Representative chromatograms for Case-control Group 1. The chromatograms 
observed for CCDC22 A309D confirming the C>A transversion in Case 1. Sanger sequencing analyses 
similarly confirmed the absence/presence of sequence changes for SMARCA1 and PTX3 (not shown). 
Similarly, the novel SMARCA1 non-synonymous C>A transversion at nucleotide position 415, which 
causes an isoleucine to lysine amino acid change at codon 139 (I139L) (Refseq mRNA accession 
NM_001282874), was present in Case 1. The two sibling controls were homozygous for the wild-type 
C-allele. 
Lastly, the PTX3 non-synonymous C>T transition at nucleotide 476 (rs183877705, Refseq mRNA 
accession NM_002852), which causes a threonine to methionine amino acid change at codon 159 
(T159M) was present in Case 1. The two sibling controls were homozygous for the wild-type C-allele. 
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5.2.3.4.2 Case-control Group 2 
Sanger sequencing confirmed that the TNN non-synonymous C>T transition at nucleotide position 3311 
(rs113025105, Refseq mRNA accession NM_022093), which causes a threonine to methionine amino 
acid change at codon 1104 (T1104M) was present in Case 1. Sibling control 3 carried the variant T-
allele (heterozygous) and sibling control 4 was homozygous for the wild-type C-allele (Figure 5.2-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The novel RAB19 non-synonymous C>T transition at nucleotide 232 (Refseq mRNA accession 
NM_001008749), which causes an arginine to cysteine amino acid change at codon 78 (R78C) was 
confirmed in Case 1 by Sanger sequencing. The two sibling controls were heterozygous for the SNP. 
Lastly, the ZNRF3 non-synonymous T>C transversion at nucleotide 1898 (rs201483333, Refseq mRNA 
accession NM_032173), which causes a threonine to methionine amino acid change at codon 159 
(T159M) was present in Case 1. The two sibling controls were homozygous for the wild-type T-allele. 
 
Figure 5.2-4 Representative chromatograms for Case-control Group 2. The chromatograms observed 
for TNN T1104M confirming the C>T transition in Case 2. Sanger sequencing analyses similarly 
confirmed  the absence/presence of sequence changes for RAB19 and ZNRF3 (not shown). 
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5.2.3.5 Sanger sequencing confirmation results in population controls 
5.2.3.5.1 Case-control Group 1   
A total of 35 CHB controls were analysed for the CCDC22 non-synonymous SNP rs183877705. The 
variant A-allele was observed at a frequency of 0.129 in the controls (Figure 5.2-5) (rs183877705 A-
allele frequencies in global populations range between 0.00–0.02; 1000 Genomes Project Phase 3). 
A total of 33 CHB controls were analysed for the novel SMARCA1 non-synonymous mutation I139L. 
None of the controls harboured the variant A-allele.  
A total of 15 CHB controls were analysed for the PTX3 non-synonymous SNP rs112277608. The 
variant T-allele was observed at a frequency of 0.167 (rs112277608 T-allele frequencies in global 
populations range between 0.00–0.04; 1000 Genomes Project Phase 3). 
 
Figure 5.2-5 Representative chromatograms for Case-control Group 1. The chromatograms 
observed in population controls for CCDC22 A309D. Sanger sequencing analyses similarly confirmed 
the absence/presence of sequence changes for SMARCA1 and PTX3 in population controls (not shown). 
5.2.3.5.2 Case-control Group 2 
A total of 32 CHB controls were analysed for the TNN non-synonymous SNP rs113025105. The variant 
T-allele was observed at a frequency of 0.047 in the controls (Figure 5.2-6; rs113025105 T-allele 
frequencies in global populations range between 0.00–0.02; 1000 Genomes Project Phase 3). 
Stellenbosch University  https://scholar.sun.ac.za
 142 
 
 
 
 
 
 
 
 
A total of 35 CHB controls were assessed for the novel RAB19 non-synonymous mutation R78C. Of 
these, none harboured the variant allele. 
A total of 20 CHB controls were assessed for the ZNRF3 non-synonymous variant rs201483333 
(T159M). Of these, none harboured the variant allele.  
Figure 5.2-6 Representative chromatograms for Case-control Group 2. The chromatograms 
observed in population controls for TNN T1104M. Sanger sequencing analyses similarly confirmed the 
absence/presence of sequence changes for RAB19 and ZNRF3 in population controls (not shown). 
Stellenbosch University  https://scholar.sun.ac.za
 143 
 
5.3 DISCUSSION 
The present study aimed to use whole exome sequencing and use comparisons between cases and sibling 
controls using recommended cut-offs for three different algorithms, CADD, DANN, and FATHMM, to 
identify driver mutations most likely to be implicated in hepatocarcinogenesis. The list of variants was 
further prioritised to three mutations per group based on gene function and prior reported involvement 
with HCC or cancer in general. These selected SNPs were also shown to be rare variants that were 
present in homozygous form only in the cases, and were either in heterozygous form or absent in the 
sibling controls and general population controls. 
There were no overlapping genes in the two case-control groups indicating that any mutations observed 
could be private mutations restricted to the respective families. This is not surprising as it is known that 
the African genome is so diverse that it shows the highest proportion of private alleles and SNPs when 
compared to non-African genomes (Mayaphi, Martin, Mphahlele, Blackard & Bowyer, 2013). This 
finding also supports the theory that hepatocarcinogenesis is a complex process targeting multiple 
signalling pathways (Chen & Wang, 2015; Hayato & Shin, 2012). 
In case-control Group 1, the SMARCA1 variant identified was a novel non-synonymous point mutation 
annotated as being potentially deleterious by FATHMM and CADD. Since it is a novel variant, there 
was no associated frequency data from various human whole genome databases such as the 1000 
Genomes Project. None of the unaffected siblings and population controls (0/33) had the novel variant 
adding weight to the possibility that this was a causal variant. 
SMARCA1 is a gene producing an ATP-dependent chromatin-remodelling enzyme that is part of the 
SWI/SNF complexes that catalyse chromatin remodelling during cellular events that require 
rearrangements of chromatin structure, such as transcription, DNA repair, and replication (Narlikar, 
Sundaramoorthy & Owen-Hughes, 2013). Chromatin remodelling has been described to be a potential 
major pathway in carcinogenesis with 19.6% of human cancers showing mutations in the different 
SWI/SNF subunits (Kadoch, Hargreaves, Hodges, Elias, Ho, et al., 2013) including hepatocellular 
carcinoma (Zhong, Liu, Tian, Wang, Tian, et al., 2014). The role that chromatin remodelling has in 
maintaining genomic stability could explain the link between the SWI/SNF complexes, and therefore 
SMARCA1, and cancer (Narlikar et al., 2013). Although mutations in SMARCA1 have been previously 
described in an exome sequencing study conducted on French patients with HCC of varying aetiologies, 
these mutations were not recurrent (Guichard, Amaddeo, Imbeaud, Ladeiro, Pelletier, et al., 2012). The 
genes predominantly mutated in the SWI/SNF complexes in that study and another whole-genome 
sequencing study on Japanese HCC patients (Fujimoto, Totoki, Abe, Boroevich, Hosoda, et al., 2012) 
were ARID1A and ARID2 but this was not observed in the present study indicating that although the 
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chromatin remodelling pathway is targeted in hepatocarcinogenesis, different genes on that pathway 
can be affected in different populations. 
The CCDC22 SNP rs183877705 was a non-synonymous point mutation with a minor allele frequency 
(MAF) of 0.0008 based on the 1000 Genomes Project and was annotated as having a potentially 
deleterious effect by FATHMM and CADD. The unaffected siblings were homozygous for the wild-
type C allele. However, 12.9% of the general population control group investigated in this study carried 
the variant allele indicating that this variant is not a rare variant in the South African population. This 
finding is most likely caused by the underrepresentation of African genomes in online genomic 
databases such as the 1000 Genomes Project and supports the call to increase genomic research on 
African populations because variants that are rare in other populations may be common in this setting 
and vice-versa (Popejoy & Fullerton, 2016). 
CCDC22 codes for a protein involved in the regulation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) signalling by interacting with copper metabolism Murr1 domain-containing 
(COMMD) proteins. CCDC22 is required for NF-κB activation (Starokadomskyy, Gluck, Li, Chen, 
Wallis, et al., 2013) and its silencing leads to the impaired activation of genes targeted by NF-κB. NF-
κB is a pro-inflammatory transcription factor whose signalling pathway is tightly regulated. It has been 
shown to have oncogenic properties as it is involved in some of the classical cancer pathways such as 
angiogenesis (Xia, Shen & Verma, 2014) and its suppression in tumour cells has been shown to 
generally cause tumour regression. However, it would seem that NF-κB also has anti-tumour effects in 
certain parts of the body, such as the liver. In fact, in chemically-induced HCC models, inhibition of 
the NF-κB pathway was shown to increase tumourigenesis (Maeda, Kamata, Luo, Leffert & Karin, 
2005). Extrapolating from these data, it is possible that the deleterious effect of rs183877705 and 
subsequent potential silencing of CCDC22 could have led to the inhibition of the NF-κB pathway. This, 
in turn, could be a potential contributor to the hepatocarcinogenic process and development of HCC in 
HBV-infected individuals. 
The PTX3 SNP rs112277608 was a non-synonymous point mutation with a MAF of 0.0076 based on 
the 1000 Genomes Project and was annotated as having a potentially deleterious effect by CADD. The 
unaffected siblings were homozygous for the wild-type C-allele. However, 16.7% of the general 
population control group investigated in this study carried the variant T-allele indicating that this variant 
is also not a rare variant in the South African population. As only a small number of controls were tested 
for this particular variant, this finding must be interpreted with caution. 
PTX3 is the prototype member of the long-pentraxin subfamily (Breviarios, Aniellos, Golay, Bottazzis, 
Bairochll, et al., 1992) and is mainly involved in innate immunity and inflammation. While it has been 
implicated in the inhibition of angiogenesis (Rusnati, Camozzi, Moroni, Bottazzi, Peri, et al., 2004), 
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which is one of the hallmarks of cancer (Hanahan & Weinberg, 2011), higher levels of PTX3 in-vivo 
have also been described in certain cancers such as HCV-associated HCC (Carmo, Aroucha, 
Vasconcelos, Pereira, Moura, et al., 2016). It is therefore possible that PTX3 has both pro- and anti-
tumour effects that are cancer dependent (Garlanda, Bottazzi, Magrini, Inforzato & Mantovani, 2018; 
Giacomini, Ghedini, Presta & Ronca, 2018). It must be noted that SNP rs112277608 was recently part 
of an in-silico analysis that described it to have a “neutral” effect by several algorithms (Thakur & 
Shankar, 2016) just as two of the algorithms used in the present study, FATHMM and DANN, did. 
When Thakur & Shankar (2016) calculated the difference in folding free energy ΔG (folding) between 
the wild-type protein and the mutant, they found it to be positive (0.43), suggesting this SNP stabilises 
PTX3. In the light of this information, it is therefore possible that PTX3 function is enhanced by SNP 
rs112277608 leading to pro-cancerous behaviour in individuals with HBV. 
In case-control group 2, the TNN SNP rs113025105 was a non-synonymous point mutation with a MAF 
of 0.0022 based on the 1000 Genomes Project, which is marginally higher than the frequency observed 
in global populations, and was annotated as having a potentially deleterious effect by all three 
algorithms. The variant T-allele was observed at a frequency of 4.7% in the control population in this 
study. 
TNN is part of the tenascin family and is therefore an extracellular matrix glycoprotein. TNN has been 
described as being overexpressed in a number of tumours such as breast, colon (Degen, Brellier, Schenk, 
Driscoll, Zaman, et al., 2008; Scherberich, Tucker, Degen, Brown-Luedi, Andres, et al., 2005), 
pancreas, kidney (Brellier, Martina, Degen, Heuzé-Vourc’h, Petit, et al., 2012), and brain cancer 
(Martina, Degen, Rüegg, Merlo, Lino, et al., 2010). No functional or knockout mice studies have looked 
at the potential effect of abrogation of TNN expression making it difficult to comment on potential 
pathways that could be affected. Moreover, although TNN is primarily involved in osteogenesis, it 
remains the least studied member of the tenascin family and as more functions for genes are being 
discovered regularly, it is possible that TNN is involved in a pathway that has yet to be described. 
The RAB19 variant identified was a novel non-synonymous point mutation annotated as being 
potentially deleterious by all three algorithms. Since it is a novel SNP, there was no associated 
frequency data from various human whole genome databases such as the 1000 Genomes Project. The 
unaffected siblings in the present study were heterozygous for this variant whereas it was completely 
absent in the general population controls (0/35). It is therefore possible that this variant is a private 
mutation segregating in this family and that the heterozygous siblings are at risk of transmitting it to 
future generations although they are not affected themselves. 
RAB19 is a member of the small guanosine-5'-triphosphatase (GTPase) superfamily involved in 
membrane trafficking and post-translational modification of proteins. Just as for several of the 70 
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members in the GTPase family, the roles of RAB19 remain ill-defined. However, there are previous 
reports of the involvement of Rab proteins in carcinogenesis; Rab5a, for example, is overexpressed in 
hepatocellular carcinoma (Fukui, Tamura, Wada, Kamada, Igura, et al., 2007) but other Rab proteins 
such as Rab14 and Rab20 are downregulated in bladder cancer (Ho, Chapeaublanc, Kirkwood, Nicolle, 
Benhamou, et al., 2012). Similarly, future studies on RAB19 may yet show the involvement of this gene 
either as an oncogene or tumour suppressor gene and how it could potentially contribute to HBV-related 
HCC. 
The ZNRF3 variant identified (rs201483333) was a non-synonymous point mutation annotated as being 
deleterious by two FATHMM and DANN and has a MAF of 0.001 as reported by the 1000 Genomes 
Project. None of the unaffected siblings and population controls (0/20) had the variant adding weight 
to the possibility that this was a causal variant although the sample size is too small to state this 
conclusively. 
This gene belongs to the E3 ubiquitin ligases family and has been shown to act as a tumour suppressor 
in gastric cancer (Zhou, Lan, Wang, Shi, Lan, et al., 2013) and nasopharyngeal carcinoma cells (Wang, 
Wang, Ren, Jin & Guo, 2017) by regulating the Wnt/beta-catenin/T-cell factor signalling pathway. 
Defects in the latter pathway have been implicated in gastrointestinal carcinogenesis, including HCC, 
(Kolligs, Bommer & Göke, 2002) indicating that SNP rs201483333 could be a potential driver mutation 
of HCC. In fact, ZNRF3 has been described in a previous exome sequencing study as being a recurrent 
target of mutations in HCC (Schulze et al., 2015). 
 Study strengths and limitations 
The strengths of the present study lie in that it is the first African study using WES to identify germline 
driver mutations of HCC. WES has the advantage of focusing on the coding regions of the human 
genome, enabling greater depth of coverage. WES covers a relatively small area of the human genome 
(<2%) but this corresponds to a region that has been extensively characterised making it easier to 
interpret identified variants in a more meaningful manner. Moreover, most high-penetrance variants are 
mediated by non-synonymous, frame-shifting, and splice variants present within the human exome. 
Lastly, WES is a more appropriate technique to use than other types of approaches such as GWAS 
because the African genome is more genetically diverse than the genome of non-African populations, 
or whole genome sequencing because it is more cost-effective. 
However, these results must be considered within the context of the study limitations. Firstly, it was 
impossible to predict whether the controls used in the study would develop HCC in future. However, 
tests such as abdominal ultrasound scans and clinical biochemical tests were performed to ensure that 
they did not have HCC at the time of sampling. Secondly, the study looked at the biological plausibility 
of identified variants to contribute to carcinogenesis and therefore only one possible cancer-
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predisposing mechanism was studied making it highly unlikely that the variants identified alone could 
cause HCC, although they may have predisposed the patient to develop cancer. There are several others 
major cancer-causing pathways that were not considered in the present study such as epigenetics, loss 
of allele heterozygosity, and large structural or copy number variations and chromosomal 
rearrangements. Lastly, although some of the variants were not found in general population controls, 
the sample size was too small to conclusively state that they were rare alleles in a South African setting. 
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5.4 CONCLUSION 
The present study aimed to use whole exome sequencing to identify inheritable driver mutations most 
likely to be implicated in hepatocarcinogenesis. Two novel variants, in SMARCA1 and RAB19, were 
identified and confirmed to be present in cases and absent or present in heterozygous form in the sibling 
and general population controls; while SMARCA1 has previously been implicated in HCC and other 
cancers, RAB19 had no known link to cancer.  
This is the first study to use WES in HCC South African HCC cases and is therefore also the first to 
identify germline mutations that could have potentially predisposed South African men to develop 
early-onset HBV-related HCC. These results show that there are genetic inheritable variants that could 
have potentially predisposed the cases to develop HCC, although their functional impact is unknown.  
Moreover, as no overlapping variants or genes were identified in this study between the two case-control 
groups, it was not possible to pinpoint common pathways that could have been disrupted and 
contributed to early hepatocarcinogenesis. In addition, due to the diversity of the genomes encountered 
in SSA, it may be difficult to identify high penetrance mutations in this population. It is likely that most 
heritable forms of HCC in SSA will present with their own private mutations. 
The present study has contributed to a better understanding of HCC pathogenesis through the 
identification of variants with the potential of posing an inheritable risk of HCC. It is not, however, 
expected that these results can be translated into clinical practice. Future studies should focus on the 
identified variants in the present study and conduct larger epidemiological studies to conclusively 
demonstrate that they were rare variants, as well as in-silico and proteomic studies to identify the 
biological impact of those mutations. This study and its results could also form the basis for future 
larger WES studies in an African setting.   
Stellenbosch University  https://scholar.sun.ac.za
 149 
 
6. FINAL CONCLUSION 
This study has investigated HBV and HCC from an African perspective and tackled these public health 
issues by incorporating three key components for early diagnosis of HBV-related HCC: HBV screening, 
HCC biomarkers, and HBV-related HCC genomics. 
The case for the implementation of HBV screening in South Africa has been presented by providing 
further evidence of the magnitude of the HBV health problem in South Africa and new evidence that 
the POCT test performs well in the field, is accepted by the community and health care providers, and 
that patients diagnosed with the test can be successfully linked to treatment and long-term follow-up. 
Moreover, it has shown that there are biomarkers that may be used to screen for HCC, paving the way 
for future studies looking into developing HCC risk scores for early diagnosis of HCC. Finally, it has 
shown that there are germline mutations that, in the absence of other risk factors besides HBV infection, 
may contribute to early-onset HBV-related HCC although further studies need to be conducted in larger 
studies to determine the functional impact of the variants identified in the present study.  
These data provide evidence that early diagnosis of HBV-related HCC in SSA is possible particularly 
if a multi-targeted approach is taken. The easiest approach to minimise the incidence of HCC in SSA 
would be to implement HBV screening, at the very least in pregnant women, to break the transmission 
cycle of HBV. The screening programmes could be implemented within antenatal programmes or HIV-
1 clinics that are already in place in most of SubSaharan African countries. Prior to the implementation 
of any screening programme, HBV information campaigns should be extensively conducted to 
familiarise SubSaharan Africans with HBV and its long-term consequences. 
The newly diagnosed HBV-infected individuals will require lifelong follow-up and management and 
therefore future HCC risk scores could be useful in stratifying HCC risk, thus narrowing down the 
number of people who need to be stringently followed-up and therefore alleviating the financial burden 
on the local healthcare system. Therefore, the use of biomarkers identified in the present study, such as 
genotype A and RASSF1A methylation levels, should be investigated further in larger studies in SSA to 
determine their potential for use within risk scores to identify those at highest risk of developing HCC 
among those who have HBV. Furthermore, these markers should be investigated in non-invasive 
samples that would enable them to be implemented in a clinical setting in a SubSaharan African setting. 
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APPENDIX C: CONSENT FORM FOR PATIENT RECRUITMENT AT OCSA CLINICS 
PARTICIPANT CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: Rapid-test-based screening for hepatitis B virus infection 
in a cohort of workers attending occupational health clinics in the Western Cape, South Africa 
PRINCIPAL INVESTIGATOR: Nafiisah Chotun 
ADDRESS:  Division of Medical Virology  
Stellenbosch University, Tygerberg Campus 
CONTACT NUMBER: 021 938 9360 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the nurse any questions about 
any part that you do not understand. 
This research project has been approved by the Health Research Ethics Committee at Stellenbosch 
University and it will be conducted according to international and locally accepted ethical guidelines for 
research, namely the Declaration of Helsinki, the SA Department of Health’s 2004 Guidelines: Ethics in 
Health Research: Principles, Structures and Processes and the South African Guidelines for Good 
Practice in the Conduct of Clinical Trials with Human Participants in South Africa. 
What is this research project all about? 
We want to test 1000 people to find out how many of them have hepatitis B. Hepatitis B is found in the 
liver. In Africa, hepatitis B is mostly acquired in childhood and results in long-term infection. Long-term 
infection increases the risk of getting liver cancer. You may be infected with hepatitis B and not feel sick 
or show any signs of being sick. 
Why have you been invited to participate? 
Because you currently live in South Africa and are attending an occupational health clinic managed by 
OCSA and because you form part of the population at risk for infection with hepatitis B. 
What will you have to do? 
If you accept to take part in this project, the nurse will prick your finger and use a few drops of your 
blood for a rapid test for hepatitis B. This test is quick and the nurse will inform you of your result after 
20 minutes. 
If your result is negative: you will be informed of your result and your participation in the project will 
be complete. No further actions will be required from your side but your data will be recorded as part of 
the project data for analysis. 
If your result is positive: 
You will have to go to the hospital for more testing. The nurse will make an appointment for you. At the 
hospital, your blood will be taken and some tests (viral load, hepatitis B markers, liver enzyme levels 
and AFP level) will be done using that blood sample. You will also be offered two non-invasive scans 
(ultrasound scan and fibrosis scan). These tests will help the doctor decide if you need treatment or not. 
At the hospital, the same blood sample will also be used for other tests (genetics testing, bilirubin, 
albumin and platelet count) and those results will be used by the researchers of this project to answer 
some scientific questions. You will also be asked some questions so the researchers can understand 
Stellenbosch University  https://scholar.sun.ac.za
 196 
 
the disease (hepatitis B) better. These results will not be communicated to you as they will not affect 
your treatment in any way. 
Will you benefit from taking part in this research? 
The test is free and you will know whether you have hepatitis B or not, therefore giving insight on your 
own health status. Hepatitis B can be transmitted from mother to child, by sexual transmission and also 
through contact with infected blood. You will therefore also receive a letter so that your family and 
partners can go to Tygerberg Hospital to be tested for hepatitis B and get treated if they are positive or 
vaccinated if they are negative. This will be beneficial for them as they will know whether they need 
treatment or whether they need to be vaccinated to protect them. 
Are there any risks involved in your taking part in this research? 
As a result of the prick in your finger for the rapid test, there may be some minor pain or bruising. 
If you need to go to the hospital, a blood sample will be taken for tests (described above) and as a result 
of the prick from the needle, there may be some minor pain or bruising. 
If you do not agree to take part, what will happen? 
Your participation is completely voluntary. If you do not want to participate, it will not affect your care in 
any way. You are also free to withdraw from the project at any point, even if you did agree to take part. 
Who will have access to your medical records? 
Only the researchers who are directly involved with the project or with your clinical care will have access 
to your medical records. 
Will you be paid to take part in this project and are there any costs involved? 
You will not be paid to take part in this project. However, all the tests associated with this project will 
be free. If you are positive for hepatitis B and have to go to the hospital, you will receive a refund in 
cash for your transport costs when you go to the hospital. 
Is there anything else that you should know or do? 
You can contact Miss Nafiisah Chotun at telephone number 021 938 9360 if you have any further 
questions or encounter any problems. 
You can contact the Health Research Ethics Committee at telephone number 021 938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your project nurse. 
You will receive a copy of this information and consent form for your own records. 
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Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research project 
entitled Rapid-test-based screening for hepatitis B virus infection in a cohort of workers 
attending occupational health clinics in the Western Cape, South Africa 
 
I declare that: 
 
 I have read this information and consent form and it is written in a language with which I am 
fluent and comfortable / Someone has read this information to me in a language with which I 
am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
I understand that taking part in this project is voluntary and I have not been pressurised to take part. I 
may choose to leave the project at any time and will not be penalised or prejudiced in any way. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20... 
Signature of participant Signature of witness 
Declaration by investigator 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to ………………………………….. 
 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the 
declaration below) 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 20... 
 
 ............................................................................  ...................................................................  
Signature of investigator Signature of witness 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) 
……………..…………………………….. using the language medium of Afrikaans/Xhosa. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her questions satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……………….. 
 
 
 ............................................................................  ...................................................................  
Signature of interpreter Signature of witness
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APPENDIX D: STANDARDISED QUESTIONNAIRE FOR STUDY NURSES 
CLINIC:                NURSE:                   AGE:                   GENDER:   M      F  
Please mark your answers with a cross (☒). You may choose only one answer, unless specified otherwise. 
1.1 HBV rapid testing (the rapid test) 
1. On a scale of 1-5, how difficult (1) or easy (5) was it to perform the test?    1      2      3      4      5  
2. Did you find any of the steps of the rapid test difficult? Yes      No      I don’t know  
3. If you answered yes to question 2, which steps did you find difficult when 
performing the test? Tick those that are relevant to you-multiple answers are 
possible. 
 
If you answered no to question 2, please proceed to question 4. 
 Setting up the test and materials 
 Opening the test strip 
 Performing the finger prick 
 Collecting the blood sample  
 Adding the buffer 
 Knowing when to read the result 
 Reading the result 
 None of the above 
  Other (briefly describe below) 
…………………………………………………...........................................................................................................................................
4. On a scale of 1-5, how confident were you that you read the test results 
correctly: not confident at all (1) - very confident (5)? 
   1     2      3      4      5  
5. Do you think you received sufficient training to perform the HBV rapid test? Yes      No      I don’t know   
6. Did you trust the result of the HBV rapid test? Yes      No      I don’t know   
1.2 HBV rapid testing (general) 
1. Other than the HBV rapid test, have you previously performed a rapid test 
(e.g. HIV-1 rapid test)? 
Yes      No      I don’t know  
2. Did you have enough materials (lancets, cotton swabs, etc.) to carry out HBV 
rapid testing in your clinic? 
Yes      No      I don’t know   
3. Did HBV rapid testing interfere with providing other healthcare services? Yes      No      I don’t know   
4. On a scale of 1-5, how unimportant (1) or important (5) do you think it is to 
have a patient know their result after 20 minutes? 
   1     2      3      4      5  
1.3 Adequacy of patient information testing 
1. Were you able to provide adequate pre-test information to the patient on 
HBV? 
Yes      No      I don’t know   
Elaborate if possible on your reasons why: 
 
2. Were you able to provide adequate post-test information to the patient on 
HBV? 
Yes      No      I don’t know  
Elaborate if possible on your reasons why: 
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3. Were you able to provide adequate counselling to patients identified as 
being HBV positive? 
Yes      No      I don’t know   
Not applicable  
Elaborate if possible on your reasons why: 
 
4. On a scale of 1-5, how low (1) or how high (5) was the level of knowledge of 
the study participants on HBV? 
   1      2      3      4      5  
5. On a scale of 1-5, how little (1) or how much (5) do you think patients 
understood the information they received about HBV? 
   1      2      3      4      5  
Barriers to HBV rapid testing 
1. Were patients offended when offered HBV testing? Yes      No      I don’t know   
3. Were you comfortable discussing HBV rapid testing with patients? Yes      No      I don’t know   
4. Do you think HBV rapid testing may have had a negative effect on patients’ 
opinion about your clinic? 
Yes      No      I don’t know   
5. On a scale of 1-5, how uninterested (1) or interested (5) were patients when 
offered the HBV rapid test? 
   1      2      3      4      5  
6. Have a look at the potential barriers to HBV rapid testing listed.  
Were there any that were relevant to you? Multiple answers are possible. 
a. If yes, please tick all those that you think were relevant to you.  
b. If none were relevant to you, please tick “none of the above”.  
c. If you experienced a barrier to HBV rapid testing not listed, please tick 
“Other” and specify your answer in the space provided. 
 Lack of patient awareness on HBV 
 Time taken for counselling 
 Lack of patient interest in the test 
 Language barriers 
 Complexity of test (multiple steps) 
 Time taken to read test 
 Difficulty reading results 
 Test interrupted routine workflow 
 Test was unreliable 
 Test was invasive 
 None of the above 
  Other (please specify below) 
……………………………………………………………………………………………………………………………….……………………………………………………….
Confidentiality of HBV rapid testing 
1. Were patients concerned about the confidentiality of their result? Yes      No      I don’t know   
2. Were you able to convey the patient’s result in a confidential manner? Yes      No      I don’t know   
Recommendations  
1. Do you think routine HBV testing is an important part of healthcare? Yes      No      I don’t know   
2. Would you recommend the use of this test at the clinic? Yes      No      I don’t know   
Elaborate on your reasons why: 
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APPENDIX E: ETHICS APPROVAL LETTERS FOR BIOMARKER STUDY 
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APPENDIX F: TABLE OF UNIVARIATE AND MULTIVARIATE LOGISTIC REGRESSION ANALYSES FOR RASSF1A PROMOTER 
HYPERMETHYLATION 
Table Appendix-1 Univariate and multivariate logistic regression analyses for RASSF1A promoter hypermethylation status in HBsAg positive cases and controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Cases n = 23 Controls n = 10     
Hypermethylation status   Crude OR (95% CI) Significance OR (95% CI)* Significance 
RASSF1A CpG site 1       
Negative  17 10 1.0 
- 
1.0 
- 
Positive 6 0 - - 
RASSF1A  CpG site 2       
Negative 18 10 1.0 
- 
1.0 
- 
Positive 5 0 - - 
RASSF1A  CpG site 3       
Negative 14 10 1.0 
- 
1.0 
- 
Positive 9 0 - - 
RASSF1A  CpG site 4       
Negative 12 10 1.0 
- 
1.0 
- 
Positive 11 0 - - 
RASSF1A  CpG site 5   1.0  1.0  
Negative 14 10 - 
- 
- 
- 
Positive 9 0 1.0 1.0 
RASSF1A  CpG site 6   -  -  
Negative 15 10 1.0 
- 
1.0 
- 
Positive 8 0 - - 
RASSF1A  overall methylation   1.0  1.0  
Negative 12 10 - 
- 
- 
- 
Positive 11 0 1.0 1.0 
RASSF1A: Ras association domain family 1 isoform A; CpG: CpG: deoxycytidylyl-deoxyguanosine dinucleotides. *adjusted for HBV genotype 
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APPENDIX G: ETHICS APPROVAL LETTER FOR WHOLE EXOME SEQUENCING 
STUDY 
 
 
APPENDIX H: HCC RISK FACTORS CASE RECORD FORM 
HCC RISK CASE RECORD FORM 
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Informed consent completed?  Yes                   If no, please consent before proceeding 
Patient folder number (please place sticker here): 
DEMOGRAPHIC DATA 
Race (please circle): B    W     C    I   Other ________________ 
Gender:       Male               Female  
Weight (in kilograms):___________          height (in metres):________ 
Place of birth:__________________________________ 
Area Born:  Urban                   Rural                    
Monthly income: ___________________         
RISK FACTORS 
1. Family history of liver disease YES NO 
2. If yes to family history of liver disease, please provide details 
3. Consumption of groundnuts 
4. Diagnosis of diabetes YES NO 
5. Diagnosis of hyperlipidaemia YES NO 
6. History of liver biopsy 
If yes, please provide details (why was it performed?) YES NO 
7. Known diagnosis of any known cancer YES NO 
8. HIV status (please tick appropriate response) 
If response is negative or unknown, skip to 17 
POS NEG 
9. If positive, state date of diagnosis 
10. Current CD4  
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11. Nadir CD4 
12. HIV viral load 
13. HAART (please tick appropriate response)                              
If response is no, please skip to 17 
YES NO 
14. Period of time on HAART 
 
15. If on HAART, please tick applicable below   
Tenofovir                                
Lamivudine 
Efavirenz 
Nevirapine 
AZT 
Stavudine 
DdI 
Lopinivir/ritonavir 
Azatanavir 
Other (please state) 
16. If on previous HAART, please tick applicable below     
Tenofovir                                
Lamivudine 
Efavirenz 
Nevirapine 
AZT 
Stavudine 
DdI 
Lopinivir/ritonavir 
Azatanavir 
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Other (please state) 
 
17. HBV status HBsAg  POS  NEG   UNKNOWN 
Anti-HBc POS  NEG   UNKNOWN 
HBeAg  POS  NEG   UNKNOWN 
Anti-HBe  POS  NEG   UNKNOWN 
 
Date HBV diagnosed: ______________________________________ 
If HIV Negative: 
Treatment for HBV:   YES   NO 
Treatment regimen: ____________________________________________________ 
Length of treatment:____________________________________________________ 
Names of household and sexual contacts ________________________________ 
  ________________________________ 
Please thank participant and collect blood in 1 SST tube (yellow top) and one EDTA tube (purple top). 
Interviewer name: 
 
Signature:      Date:  
Blood collected by: 
 
Signature: 
 
 
Stellenbosch University  https://scholar.sun.ac.za
